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1 Cohen's Kappa (often simply called Kappa) is a measure of agreement between two individuals or groups of 
individuals. Kappa is always less than or equal to 1 and a value of 1 would imply perfect agreement and values 
less than 1 imply less than perfect agreement. Different people have different interpretations as to what is a good 
level of agreement. However a generally accepted view would propose that; Kappa < .2 = poor agreement; 
between .2 - .4 = fair agreement; between .4 - .6 moderate agreement;  between .6 - .8 = good agreement; and 






































































































































































































































































































































































































































































































































































































































































































Authors  Trial Type  N  Duration  Intervention  Measure  Results 
Barkley et al.  
(1990b) 
RCT  83  1 week  MPH vs. Placebo  BSEQ  Lappetite, insomnia, stomach ache and headache. 
Most in the ‘mild’ range. 3.6% discontinuation rate.  
Note high incidence of baseline ratings, e.g. 
insomnia in 40% and irritability in 72%.   
Ahmann et al.  
(1993) 






RCT (cross over)  125  2 weeks  MPH vs. Dex  BSEQ  MPH vs. baseline:Lappetite only. Dex vs. baseline: Lappetite and insomnia.  
MPH vs. Dex: insomnia, irritability, prone to crying, 
anxiousness, sadness and nightmares in Dex relative 
to MPH. 
1.6% discontinuation rate on each stimulant 
Schachar et al. 
(1997) 
RCT  91  16 weeks  MPH vs. Placebo  BSEQ  Lappetite, stomach ache, reduced weight gain rate, 
affective symptoms. Adverse effects generally 
persisted over 4 month period 













RCT  580  14 months  MPH vs. 
behavioural 
intervention 
PSES  Mild, moderate or severe side effects were reported 
by approximately 50%, 10% and 3% respectively at 
the end of the trial.  Effect type not specified 
 
 
RCT = Randomised controlled trial, MPH = Methylphenidate, Dex = Dexamfetamine, BSEQ= Barkley side effect questionnaire (derived from a review of prior anecdotal studies in which adverse 








































































































































































































































































































































































2 The transmission disequilibrium test (TDT) provides a mechanism for avoiding population stratification biases 
that can occur in cases control genetic studies. In the TDT parents are used as the controls. Data is examined to 
see whether a particular allele is transmitted together with the disorder/trait more frequently than would be 
expected by chance. As it is guaranteed that cases and controls have originated from the same populations the 























Gene  Study Design  Pooled OR  95% CI 
Dopamine D4 Receptor (exon III VNTR, 7 repeat)  Family  1.16  1.03‐1.31 
Dopamine D4 Receptor (exon III VNTR, 7 repeat)  Case‐control  1.45  1.27‐1.65 
Dopamine D5 Receptor (CA repeat, 148bp)  Family  1.24  1.12‐1.38 
Dopamine Transporter (VNTR, 10‐repeat)  Family  1.13  1.03‐1.24 
Dopamine β‐Hydroxylase (Taql A)  Case‐control  1.33  1.11‐1.59 
SNAP‐25 (T1065G)  Family  1.19  1.03‐1.38 
Serotonin Transporter (5‐HTTLPRlong)  Case‐control  1.31  1.09‐1.59 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Entered Chronic Phase (n = 24) 
 
Tested at T3 (placebo)  
(n = 24/24) 
 
 
Tested at T4 (0.3mg/kg, MPH)  
(n = 23/24) 




Tested at T5 (0.6 mg/kg)  
(n = 22/23) 
1 missed testing session 
1 withdrew due to adverse events 
Entered Chronic Phase (n = 25) 
 
Tested at T3 (0.3 mg/kg)  
(n = 24/25) 
1 withdrew due to adverse events 
 
Tested at T4 (0.6mg/kg)  
(n = 20/24) 
3 missed testing session but 
remained in study 
1 withdrew due to adverse events 
 
Tested at T5 (placebo)  
(n = 22/23) 
1 withdrew due to lack of efficacy 
Analysed at chronic Phase; Placebo n = 69, MPH (0.3 mg/kg) n = 68, MPH (0.6 mg/kg) n = 65  





(n = 195) Excluded 
 
Declined to participate (n = 21) 
 
Not meeting inclusion criteria  
(Conners’ scores < 1.5 SD from mean)  
(n = 69) 
 
Not meeting inclusion criteria (No DSM IV 
diagnosis of ADHD or ICD 10 diagnosis of 
Hyperkinetic Disorder) (n = 18) 
 
Met exclusion criteria (n = 12) 
 9 Previous stimulant treatment 
 2 Epilepsy 
 1 IQ < 80   
 
Randomised (n = 75) 
Allocated to Placebo at acute 
session (n = 25/25) 
 
Tested at baseline T1 (n = 25/25) 
 
Tested under acute condition T2  
(n = 24/25) 
1 withdrew consent
Allocated to MPH 0.3 mg/kg 
at acute session (n=25/25) 
 
Tested at baseline T1 (n = 25/25) 
 
Tested under acute condition T2  
(n = 25/25) 
Allocated to 0.6 mg/kg at 
acute session (n = 25/25) 
 
Tested at baseline T1 (n = 25/25) 
 
Tested under acute condition T2  
(n = 24/25) 
1 withdrew consent
Entered Chronic Phase (n = 24) 
 
Tested at T3 (0.6 mg/kg)  
(n = 23/24)  
1 withdrew due to adverse events 
 
Tested at T4 (placebo)  





Tested at T5 (0.3 mg/kg)  
(n = 21/23) 
1 missed testing session 

































































































































































































































































































































































































































































Testing   1    2  3  4  5 
Session  Baseline    Acute  Chronic 
        4 weeks  4 weeks  4 weeks 
Group   
Hyperkinetic  Baseline  Î placebo  placebo  0.3 mg/kg  0.6 mg/kg 
Disorder    Î 0.3 mg/kg  0.3 mg/kg  0.6 mg/kg  placebo 
    Î 0.6 mg/kg  0.6 mg/kg  placebo  0.3 mg/kg 














































































































































































































































































































   Oppositional defiant disorder (no CD)  31  41.3 
  Conduct disorder (CD)  21  28 
  Depressive disorder  3  4 
  Generalized anxiety disorder  2  2.7 
  Separation anxiety disorder  3  4 
  Tic disorder  2  2.7 





























  HKD Boys  Control Boys     





Age  10.85 (2.46)  10.74 (2.47)             >.05   
BPVS Percentile Rank 
 
35.43 (27.93)  58.94 (26.25)  <0.001*  0.86 
Conners’:  
Parents (T scores) 
       
  Oppositionality  75.57 (11.38)  45.25 (6.42)  <0.001*  3.3 
  Cognitive  72.94 (7.07)  44.16 (3.47)  <0.001*  5.2 
  Hyperactive  83.08 (8.88)  46.12 (3.43)  <0.001*  5.5 
  ADHD Index 
 
77.01 (6.09)  43.96 (3.37)   <0.001*  6.7 
Conners’:  
Teachers (T scores) 
       
  Oppositionality  65.05 (19.52)  49.15 (9.49)  <0.001*  1.0 
  Cognitive  62.77 (12.78)  47.66 (7.95)  <0.001*  1.4 
  Hyperactive  71.00 (14.34)  47.36 (7.42)  <0.001*  2.1 







































2.3 (1.5)  2.4 (1.4)  2.2 (1.4)  2.13 (1.6)  NS     
Errors for Distractors 
(Block1) 
2.2 (1.7)  2.3 (1.6)  1.9 (1.5)  1.9 (1.7)  NS     
Reaction Time to  
Targets B1  (log10) 
2.7 (0.1)  2.7 (.1)  2.6 (.1)  2.6 (.1)  NS     
Reaction Time to  
Targets B2  (log10) 
2.7 (0.1)  2.7 (.08)  2.6 (0.1)  2.6 (0.1)  NS     
Spatial Span 




50.7 (19.5) 50.8 (21.0)  35.1 (20.7) 35.0 (21.8)  ***  0.77  0.75 
Strategy Score  36.3 (4.5)  36.3 (5.1)  32.7 (5.2)  32.7 (5.3)  ***  0.73  0.70 
Stockings of Cambridge 
No. Solved in Min. Moves  7.1 (2.0)  7.2 (2.1)  8.07 (2.0)  8.0 (2.2)  *  0.46  0.38 
Pattern Recognition 
% correct  80.8 (11.1) 81.3 (11.7)  91.0 (8.4)  90.4 (12.1)  ***  0.92  0.89 
Spatial Recognition 
% correct  67.3 (13.6) 68.2 (13.9)  77.6 (13.7) 78.2 (13.8)  ***  0.89  0.72 
Delayed Matching to Sample 
Simultaneous  90.9 (15.5) 90.8 (12.4)  97.1 (7.03) 97.3 (1.5)  **  0.53  0.52 
Delay (0, 4 +12)  59.4 (18.8) 59.5 (17.8)  75.8 (17.7) 75.7 (17.9)  ***  0.91  0.90 
Paired Associates Learning 
Stage Reached  7.9 (0.3)  7.9 (0.3)  7.9 (0.3)  7.9 (0.3)  N.S.     
Total Errors  11.6 (11.5) 11.1 (9.7)  6.7 (7.1)  7.2 (10.4)  **  0.51  0.47 
Total Trials  12.8 (4.09) 12.6 (4.1)  10.7 (2.9)  10.9 (3.9)  ***  0.57  0.58 
ID/ED 




2.61 (0.13) 2.62 (0.09)  2.58 (0.11) 2.57 (0.17)  *  0.24  0.71 
Movement Time Latency  
(5 Choice) log10 
















































































































Age (mean, s.d.)  11.1 (2.5)  10.4 (2.4)  10.9 (2.6) 
BPVS percentile rank (mean, s.d.)  37 (30.4)  32.4 (25.2)  38.63 (29.0) 
Social Deprivation (DepCat score)  4.2 (1.9)  4.0 (1.4)  3.8 (1.9) 
Conners’: Parents (T scores)       
  Oppositionality  74.4 (9.8) 74.6 (13.7)  78.4 (9.0)
  Cognitive  73.7 (5.6) 72.0 (8.3)  72.9 (7.4)
  Hyperactive 81.5 (9.0) 82.2 (9.2)  85.2 (8.5)
  ADHD Index 77.1 (5.4) 76.0 (7.1)  77.5 (5.7)
Conners’: Teachers (T scores)       
  Oppositionality  63.0 (20.1)  61.5 (21.4)  71.1 (16.4)
  Cognitive  63.5 (11.3) 61.2 (16.3)  63.7 (9.9)
  Hyperactive 76.0 (9.8) 66.1 (17.8)  71.1 (12.2)
  ADHD Index 72.0 (18.8) 71.1 (16.6)  73.8 (8.3)
Comorbid Conditions (n)       
  Oppositional defiant disorder (No CD) 11 12 8 
  Conduct disorder (CD)  7 6 7 
  Depressive disorder  1 1 1 
  Generalised anxiety disorder  2 0 1 
  Separation anxiety disorder  3 0 0 
  Tic disorder 1 1 1 







































Go/NoGo             
Errors for Distractors Block 1   2.4 (1.5)  1.9 (1.6)  1.8 (1.5)  1.8 (1.9)  F<1  NS 
Errors for Distractors Block 2  2.3 (1.7)  1.4 (1.6)  1.8 (1.7)  2.0 (2)  F<1  NS 
Reaction Time to targets Block 1 
(log10) 
2.66 (.09)  2.69 (.06)  2.66 (.10)  2.66 (.08)  F=2.7  NS 
Reaction Time to targets Block 2 
(log10) 
2.67 (.09)  2.69 (.07) 2.65 (.13)  2.67 (.09)  F=1.3  NS 
Spatial Span             
Span Score  5.1 (1.5) †  4.8 (1.4)  5.5 (1.3)  5.5 (1.3)  F = 2.6  NS 
Spatial Working Memory             
Total Between‐search Errors  50.8 (21.0) † 47.1 (22.9) 40.8 (19.9)  38.8 (19.9)  F<1  NS 
Strategy Score  36.3 (5.1) †  35.7 (5.3)  35.6 (4.2)  35.5 (4.3)  F<1  NS 
Stockings of Cambridge             
No. Solved in Minimum Moves  7.2 (2.1)  8.0 (1.5)  8.0 (2.0)  8.5 (1.8)  F<1  NS 
Average Moves (5 move 
problems)  7.6 (1.5)  6.9 (1.3)  7.0 (1.6)  6.8 (1.6)  F<1  N.S. 
Initial Thinking Times (5 move 
problems) (log10)
3.59 (.34)  3.47 (0.31) 3.69 (0.37)  3.73 (0.3)  F<1  NS 
Pattern Recognition             
% Correct  80.8 (13.1) † 84.4 (11.1) 86.3(10.9)  91.1 (7.4)  F=1.4  NS 
Latency Correct (log10)  3.31 (0.10)  3.34 (0.13) 3.33 (0.10)  3.29 (0.12)  F<1  NS 
Latency Incorrect (log10)  3.37 (0.16)  3.51 (0.30) 3.44 (0.19)  3.43 (0.23)  F<1  NS 
Spatial Recognition             
% Correct  68.2 (13.9) † 57.7 (13.3) 61.4 (16.7)  65.2 (16.8)  F<1  NS 
Latency Correct (log10)  3.32 (.15)  3.26 (.13)  3.32 (.12)  3.44 (.24)  F = 3.4  * 
Latency Incorrect (log10)  3.27 (.14) † 3.3 (.16) 3.39 (.15) 3.55 (.32)  F = 7.3  ** 
Delayed Matching to Sample             
Simultaneous (% Correct)  90.93 (15.5) † 90 (15.6)  91.2 (19.2)  98.26 (5.8)  F=1.4  NS 
0 s delay (% Correct)  70.0 (25.6) † 59.2 (20.8) 62.4 (24.7)  78.3 (18.0)  F=7.1  ** 
4s delay (% Correct)  56.5 (24.0) † 55.0 (21.5) 62.4 (23.3)  83.5 (16.7)  F=11.84 *** 
12 s delay (% Correct)  50.9 (27.2)† 51.7 (22.0) 60.0 (27.7) 74.8 (20.2)  F=5.75  **
Paired Associates Learning             
Stage Reached  7.96 (0.3)  8 (0.0)  8 (0.0)  8 (0.0)  F<1  NS 
Total Errors  11.6(11.5) †  11.7 (7.9)  13.0 (12.4)  6.5 (5.0)  F=2.8  NS 
Total Trials  12.8 (4.1) † 9.3 (2.7) 8.8 (2.1) 7.2 (2.4)  F=1.5  NS 
ID/ED             
Stage Reached Score  7.5 (1.0) †  7.8 (1.0)  8.2 (1.0)  8.0 (1.0)  F=1.1  NS 
Total Errors  9.3 (6.2)  8.2 (3.5)  7.0 (3.8)  7.6 (3.3)  F<1  NS 
Total Trials  21. 4 (9.74)  18.8 (10.0) 15.8(11.05) 16.2(10.68)  F<1  NS 
Reaction Time (all log10)             
Reaction Time Latency: Simple  2.60 (0.10)  3.10 (0.17) 3.06 (0.6)  2.57 (0.11)  F=1.2  NS 
Movement Time Latency: Simple  2.60 (0.16)  2.73 (0.47) 2.71 (0.36)  2.61 (0.15)  F<1  NS 
Reaction Time Latency: 5 choice  2.62 (0.09)  2.89 (0.12) 2.62 (0.09)  2.60   (0.10)  F=3.3  * 
Movement Time Latency: 5 
Choice 


































































































































       
Errors for Distractors b1  2.4 (1.5)  1.6 (1.5) 1.4 (1.4) 1.2 (1.4) NS 0.01    0.27 0.54
Errors for Distractors b2  2.3 (1.7)  1.6 (1.6) 1.3 (1.4) 1.1 (1.3) 0.03 0.004    0.33 0.4
Reaction Time to targets b1 
(log 10)  
2.66 (0.09)  2.70 (0.07) 2.68 (0.09) 2.67 (0.09) NS 0.005    0.37 0.5
Reaction Time to targets b2 
(log 10) 
2.67 (0.09)  2.69 (0.07) 2.68 (0.09) 2.69 (0.08) 0.02 NS  0.12  0.25
Spatial Span 
       
Span Score*  5.1 (1.5)  5.5 (1.7) 5.7 (1.6) 5.7 (1.5) NS NS    0.26
Spatial Working Memory 
       
Total Between‐search Errors*  50.8 (21.0)  39.9 (20.6) 38.7 (23.0) 35.9 (19.8) NS NS    0.53
Strategy Score*  36.3 (5.1)  35.2 (4.0) 34.4 (5.0) 34.4 (5.2) NS NS    0.26
Stockings of Cambridge 
       
No. Solved in Minimum Moves  7.2 (2.1)  8.3 (1.9) 8.8 (2.2) 8.8 (2.1) NS NS    0.57
Initial Thinking 5 move 
(log 10) 
3.59 (0.34)  3.54 (0.40) 3.63 (0.38) 3.64 (0.35) NS NS    0.14
Subsequent Thinking 5 move 
(log 10) 
2.83 (0.58)  1.88 (1.16) 2.08 (1.06) 2.28 (0.97) NS NS    1.04
Pattern Recognition 
       
% Correct*  80.8 (13.1)  81.8 (13.3) 86.0(12.9) 87.8 (12.5) <0.001 <0.001  0.32  0.47 0.07
Latency Correct (log 10)  3.32 (0.15)  3.30 (0.11) 3.30 (0.11) 3.32 (0.09) NS NS   
Latency Incorrect (log 10)*  3.27 (0.14) 
† 
3.38 (0.17) 3.39 (0.17) 3.42 (0.16) NS NS   
Spatial Recognition 
       
% Correct*  68.2 (13.9)  57.8 (14.0) 67.2 (14.4) 68.9 (13.4) <0.001 <0.001  0.66  0.81 ‐0.75
Latency Correct (log 10)  3.32 (0.15)  3.27 (0.16) 3.3 (0.15) 3.37 (0.15) NS <0.001    0.64 0.32
Latency Incorrect (log 10)*  3.27 (0.14)  3.32 (0.17) 3.34 (0.2) 3.40 (0.15) NS 0.01    0.50 0.32
Delayed Matching to Sample 
       
Simultaneous( % Correct)*  90.9 (15.5)  85.2 (18.0) 91.3 (13.6) 95.4 (9.2) <0.001 <0.001  0.38  0.71 0.34
Delay (0, 4 & 12 sec combined) 
(% correct)* 
59.5 (17.8)  56.0 (19.2) 65.8(21.2) 68.8 (16.3) <0.001 <0.001  0.48  0.72 0.19
Paired Associates Learning 
     
Stage Reached  7.96 (0.3)  8 (0) 8 (0) 8 (0) NS NS  Ceiling effect
Total Errors*  11.6(11.5)  6.7 (6.6) 5.7 (5.7) 5.5 (5.6) NS NS    0.53
Total Trials*  12.8 (4.1)  7.7 (2.2) 7.3 (2.03) 7.2 (1.9) NS NS    1.61
ID/ED 
       
Stage Reached Score*  7.5 (1)  8.0 (.99) 8.2 (.95) 8.0 (.97) NS NS    0.45
Reaction Time 
















































































































































































































































































































































































































































  Effect Size    Proportion of 
HKD cases with 
“deficit” (%)1 Task  d  η2p  p 
Spatial Span         
Span Score  0.52  0.065  <.005  11 
Spatial Working Memory          
Between‐search Errors  0.73  0.117  <.001  24 
Strategy Score  0.58  0.078  <.001  15 
Stockings of Cambridge         
Solved in Minimum Moves  0.25  0.013  >0.05  13 
Pattern Recognition          
Percent Correct  0.65  0.094  <.001  30 
Spatial Recognition          
Percent Correct  0.61  0.085  <.001  28 
Delayed Matching to Sample          
Percent Correct (all delays)  0.84  0.149  <.001  39 
Paired Associates Learning         
Tot Trials  0.46  0.050  <.01  19 
Tot Errors  0.33  0.050  <.05  21 
Intradimensional‐
Extrdimensional Shift  
       
Total Trials  0.26  0.000  >.05  11 
Reaction  Time         
5 choice reaction Time   0.12  0.005  >0.5  8 






































0  1  2  3  4  5  6  7  8 
Hyperkinetic Disorder (%)  18.7  29.3  18.7  9.3  14.7  1.3  1.3  4  2.7 














































Hyperkinetic Disorder  18.7  14.7  40.0  26.7 













































































.282*                   
PAL 
Total Errors 
.231  .854**                 
Pattern 
Recognition 
‐.180  ‐.415**  ‐.519**               
Spatial  
Recognition 
.038  ‐.157  ‐.154  .336**             




‐.045  .324**  .078  .015  .008  ‐.008         
SWM BSE  .166  .074  .097  ‐.107  ‐.191  ‐.317*  ‐.036       
SWM Strategy 
Score 
.095  .210  .237*  ‐.145  ‐.086  ‐.102  .029  .482**     
Stockings of 
Cambridge  
















































.232*                   
PAL 
Total Errors 
.197  .943**                 
Pattern 
Recognition 
‐.232*  ‐.454**  ‐.385**               
Spatial  
Recognition 
.038  ‐.232*  ‐.225  .283*             




.267*  .175  .141  ‐.473**  ‐.058  ‐.303**         
SWM BSE  .210  .273*  .182  ‐.241*  ‐.175  ‐.246*  .170       
SWM Strategy 
Score 
.026  .292*  .260*  ‐.130  ‐.204  ‐.221  ‐.085  .447**     
Stockings of 
Cambridge  

































































































































































.943       
5‐Choice Reaction 
Time 
  ‐.737     
ID/ED Shift 
Total Trials 
  ‐.675     
















      .780 
Pattern Recognition,  
Percent Correct 
      .619 
Spatial Recognition,  
Percent correct 























































































































































Spatial Span  62.7  62.9  62.8 




Stockings of Cambridge  57.3  48.6  53.1 
Pattern Recognition  58.7  71.4  64.8 
Spatial Recognition  61.3  71.4  66.2 



















































































0  1  2  3  4  ≥5 
Current Sample HKD 
(%) 
18.7  29.3  18.7  9.3  14.7  7.3 
Nigg et al (2005) ADHD 
(%) 




















































































































































































































































































































































































































































































BPVS (% Correct)  49.1 (25.0) 37.3 (27.9) 33.3 (29.0) 27.8 (26.9) 66.7 (24.4) 59.4 (22.9) 64.8 (18.0) 54.3 (32.2)
Go/NoGo                 
Errors for Distractors Block 1   3.50 (1.50) 2.16 (1.29) 2.42 (1.31) 1.58 (1.18) 3.32 (1.63) 1.98 (1.01) 1.96 (1.21) 1.68 (0.91)
Errors for Distractors Block 2  3.55 (1.89) 1.91 (1.52) 1.98 (1.02) 1.59 (1.31) 3.06 (2.12) 1.92 (0.72) 1.71 (1.21) 1.19 (0.62)
Reaction Time to targets Block 1  516 (108) 487 (70) 416 (101) 429 (46.6) 505 (96.7)  472 (63.0)  408 (53.4) 404 (45.1)
Reaction Time to targets Block 2   526 (117) 486 (48) 445 (73.2) 419 (50.3) 496 (91.0)  484 (71.3)  414 (58.8) 411 (38.9)
Spatial Span                 
Span Score  4.11 (1.24) 4.94 (0.54) 5.42 (1.38) 5.70 (1.14) 4.72 (1.36) 5.75 (1.00) 6.79 (1.12) 6.43 (1.57)
Spatial Working Memory                 
Total Between‐search Errors  66.0 (9.77) 56.0 (12.8) 46.3 (19.6) 40.2 (19.8) 52.1 (18.9) 37.8 (18.1) 27.9 (17.9) 23.3 (16.1)
Strategy Score  38.3 (3.96) 37.3 (3.24) 35.0 (5.10) 35.1 (4.89) 34.3 (5.16) 34.9 (3.79) 32.0 (4.13) 30.1 (5.80)
Stockings of Cambridge                 
No. Solved in Minimum Moves  5.63 (1.34) 7.06 (2.32) 7.92 (1.31) 7.81 (2.04) 6.83 (2.18) 7.94 1.73)  8.71 (1.64) 8.90 (2.02)
Average Moves (5 move problems)  8.44 (1.27) 7.72 (1.58) 7.81 (1.31) 6.84 (1.28) 7.63 (1.29) 7.28 (1.29) 6.82 (1.07) 6.66 (1.55)
Pattern Recognition                 
% Correct  79.9 (15.6) 81.9 (12.7) 79.5 (8.96) 82.8 (10.5) 91.4 (11.3) 88.0 (7.28) 90.2 (8.74) 93.0 (8.67)
Spatial Recognition                 
% Correct  64.2 (13.6) 68.4 (11.2) 66.3 (16.7) 73.5 (14.0) 70.8 (13.3) 76.6 (13.0) 83.9 (6.56) 78.1 (14.4)
Delayed Matching to Sample 
% Correct 
               
Simultaneous  80.0 (18.9) 95.0 (13.7) 95.0 (12.4) 94.1 (12.2) 95.6 (8.56)96.25 (8.06)98.57 (5.35)99.05 (4.36)
0 s delay  58.8 (23.3) 67.5 (26.2) 70.8 (20.7) 80.0 (26.0) 65.6 (25.5) 76.2 (13.0) 75.1 (25.5) 89.5 (13.6)
4 s delay  48.4 (26.1)51.25 (19.3)60.0 (17.1) 64.4 (26.2) 67.8 19.6)  65.6 (27.3) 88.6 (12.9) 81.0 (16.1)
12 s delay  35.8 (21.7) 48.8 (29.2) 51.7 (26.2) 62.2 (26.2) 63.3 (28.5) 73.8 (22.8) 80.0 (15.7) 77.1 (15.9)
Paired Associates Learning                 
Stage Reached  7.95 (0.23) 8 (0) 8 (0) 7.93 (0.39) 8 (0)  7.87 (0.52) 8 (0) 8 (0)
Total Errors  18.7 (14.8) 14.2 (11.0) 6.50 (3.75) 6.70 (7.53) 9.29 (14.2) 9.27 (11.9) 5.77 (5.05) 5.86 (5.41)
Total Trials  15.0 (4.36) 13.6 (3.48) 10.8 (1.40) 11.1 (4.08) 11.2 (3.58) 12.1 (5.50) 10.2 (1.79) 10.3 (1.71)
ID/ED                 
Stage Reached Score 7.0 (1.33) 7.63 (0.89) 7.58 (0.90) 7.85 (0.99) 7.50 (0.79) 7.81 (0.98) 7.57 (0.94) 8.62 (0.81)
Pre‐ED errors  11.3 (7.71) 9.0 (2.88) 10.6 (7.88) 7.67 (5.53) 8.61 (5.47) 6.50 (2.22) 5.07 (1.07) 5.81 (2.79)
Errors at ED shift  25.2 (4.52) 19.3(9.58) 20.3 (8.90) 17.0 (11.7) 22.3 (9.07) 18.6 (9.82) 22.5 (9.94) 11.7 (10.3)
Reaction Time                  
Reaction Time Latency: Simple  495 (178) 412 (152) 387 (150) 369 (168) 425 (141)  358 (78.3)  324 (56.9) 311 (41.2)
Movement Time Latency: Simple  408 (174) 414 (152) 439 (154) 444 (135) 479 (216)  423 (147)  366 (122) 371 (121)
Reaction Time Latency: 5 choice  550 (274) 397 (76.6) 442 (211) 372 (78.9) 522 (177)  378 (62.7)  332 (46.8) 336 (47.2)





































































7 – 8 years 9 ‐ 10 years 11 ‐ 12 years 13 – 14years 




































































































































































































































































































































































































































































































































































































































































































































































1 % Pattern Correct = 78.47 + 0.25 * age_dec
R-Square = 0.00













































































































































































































































































































































































































1 Total Trials Score = 19.60 + -0.60 * age_dec
R-Square = 0.14
1 Total Trials Score = 13.54 + -0.23 * age_dec
R-Square = 0.03


























































































































































































1 Total Errors = 33.76 + -1.97 * age_dec
R-Square = 0.18
1 Total Errors = 14.87 + -0.64 * age_dec
R-Square = 0.03




































































Intra-Dimensional/Extra-Dimensional Set Shifting -





















7 – 8 years 9 ‐ 10 years 11 ‐ 12 years 13 – 14years 












































































7 – 8 years  9 ‐ 10 years 11 ‐ 12 years 13 – 14years 






























































































































































































































































































































































greater  than would  be  predicted  to  occur  by  chance  (Waschbusch  2002).  The  reported 
rates of ODD in all children with DSM‐IV ADHD are between 50 and 60% with even higher 
rates being  reported  for  those with  combined  type ADHD  (Gillberg, Gillberg, Rasmussen, 
Kadesjo,  Soderstrom,  Rastam,  Johnson,  Rothenberger,  &  Niklasson  2004).  The  rates  of 
coexisting CD are less well studied but appear to be around 14% (MTA Cooperative Group 
1999).  The  essential  features  of  ODD  are  a  recurrent  pattern  of  negativistic,  defiant, 
disobedient,  and  hostile  behaviour  towards  authority  figures, which  leads  to  impairment 
and  those  of  CD  are  a  repetitive  and  persistent  pattern  of  behaviour  in which  the  basic 
rights of others and major age‐appropriate societal norms or rules are violated (American 
Psychiatric Association 1994). The  symptom definitions  for CD and ODD are  identical  for 
ICD‐10 and DSM‐IV and, whilst each system combines them  in slightly different ways, the 
two diagnostic systems are very similar. This makes  it easier to compare research data on 
CD and ODD than  is the case  for ADHD and HKD. The data presented  in this chapter was 











(1) Unusually frequent or severe temper tantrums for the child's developmental level.  
(2) Often argues with adults.  
(3) Often actively defies or refuses adults' requests or rules.  
(4) Often, apparently deliberately, does things that annoy other people.  
(5) Often blames others for one's own mistakes or misbehaviour.  
(6) Often touchy or easily annoyed by others.  
(7) Often angry or resentful.  
(8) Often spiteful or vindictive.  
(9) Frequent and marked lying (except to avoid abusive treatment).  
(10) Excessive fighting with other children, with frequent initiation of fights (not including fights with 
siblings).  
(11) Uses a weapon that can cause serious physical harm to others (e.g. a bat, brick, broken bottle, knife, gun).  
(12) Often stays out after dark without permission (beginning before 13 years of age).  
(13) Physical cruelty to other people (e.g. ties up, cuts or burns a victim).  
(14) Physical cruelty to animals.  
(15) Deliberate destruction of others' property (other than by fire-setting).  
(16) Deliberate fire-setting with a risk or intention of causing serious damage.  
(17) At least two episodes of stealing of objects of value (e.g. money) from home (excluding taking of food).  
(18) At least two episodes of stealing outside the home without confrontation with the victim (e.g. 
shoplifting, burglary or forgery).  
(19) Frequent truancy from school beginning before 13 years of age.  
(20) Running away from home (unless this was to avoid physical or sexual abuse).  
(21) Any episode of crime involving confrontation with a victim (including purse snatching, extortion, 
mugging).  
(22) Forcing another person into sexual activity against their wishes.  
(23) Frequent bullying of others (i.e. deliberate infliction of pain or hurt including persistent intimidation, 
tormenting, or molestation).  
(24) Breaks into someone else's house, building or car.  
  
Conduct Disorder requires 
The Presence of three or more symptoms from those listed above, of which at least three must be from  items 9 – 24 
At least one of the symptoms from items 9 -  24 must have been present for at least six months 
  
Oppositional defiant disorder requires 
The presence of four or more symptoms from those listed above, of which no more than two from items 9 – 24 
These  symptoms must be maladaptive and  inconsistent with the developmental level 































































































































































































































































































































































































































































































































































RTT (block type 1, msec)  468 (110) 460 (78) 443 (84)  460 (95)
 RTT (block type 2, msec)  490 (113) 454 (76) 442 (64)  463 (85)
ERD (block type 1)  2.01(1.52) 2.79 (1.86) 2.48 (1.11)  1.93 (1.22)
ERD (block type 2)  1.96 (1.56) 2.54 (2.05) 2.51 (1.21)  1.56 (1.39)





















    % Correct  68.85 (15.31) 66.99 (14.25) 67.37 (16.11)  77.55 (13.84)
Pattern Recognition   




    % Correct (Sim)  82.46 (19.33) 92.50 (10.03) 96.51 (10.29)  95.34 (7.67)




Total Trials  11.63 (3.87) 12.95 (3.40) 12.84 (5.13)  12.4 (4.17)
 Total Errors   9.04 (13.53) 11.38 (9.19) 10.90 (10.24)  12.89 (14.96)
ID/ED   
Pre ED errors  7.40 (3.20) 11.48 (8.75) 8.44 (6.30)  5.98 (1.41)
Errors at ED shift 21.25 (8.05) 22.63 (8.52) 18.87 (10.70)  13.10 (10.51)
Reaction Time   
    Simple  405 (180)  422 (134) 435 (229)  345 (68)





































































































































































































































































































































































































































































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.08 (0.33)  0.00 (0.33)  0.19 (0.33)  Control 
  0.08 (0.33)  0.25 (0.33)  Pure HKD 





Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.26 (0.33)  0.11 (0.33)  0.27 (0.33)  Control 
  0.37 (0.34)  0.51 (0.34)  Pure HKD 





Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.06 (0.33)  0.53 (0.34)  0.46 (0.34)  Control 
  0.45 (0.34)  0.35 (0.34)  Pure HKD 





Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.27 (0.33)  0.55 (0.34)  0.71 (0.34)  Control 
  0.31 (0.34)  0.39 (0.34)  Pure HKD 




































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.92 (0.35)  0.79 (0.35)  0.61 (0.34)  Control 
  0.07 (0.33)  0.27 (0.33)  Pure HKD 

































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.19 (.33)  0.32 (0.34)  0.88 (0.35)  Control 
  0.15 (0.33)  0.73 (0.34)  Pure HKD 











Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.34 (0.34)  0.67 (0.34)  1.03 (0.35)  Control 
  0.40 (0.34)  0.71 (0.34)  Pure HKD 

























































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.34 (0.34)  0.44 (0.34)  1.05 (0.36)  Control 
  0.14 (0.33)  0.56 (0.34)  Pure HKD 





























































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.58 (0.35)  0.74 (0.34)  0.66 (0.34)  Control 
  0.12 (0.33)  0.09 (0.33)  Pure HKD 






Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.84 (0.35)  1.24 (0.36)  0.81 (0.35)  Control 
  0.28 (0.33)  0.01 (0.33)  Pure HKD 
































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.86 (0.35)  0.31 (0.34)  0.13 (0.33)  Control 
  0.64 (0.34)  0.89 (0.35)  Pure HKD 





Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.78 (0.35)  0.95 (0.35)  0.87 (0.35)  Control 
  0.22 (0.33)  0.04 (0.33)  Pure HKD 














































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.19 (0.33)  0.14 (0.33)  0.09 (0.33)  Control 
  0.35 (0.34)  0.26 (0.33)  Pure HKD 






Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.26 (0.33)  0.09 (0.33)  0.15 (0.33)  Control 
  0.14 (0.33)  0.15 (0.33)  Pure HKD 








Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.56(0.34)  0.86 (0.35)  0.53 (0.34)  Control 
  0.61 (0.34)  0.20 (0.33)  Pure HKD 





Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.85 (0.35)  0.97 (0.35)  0.53 (0.34)  Control 
  0.16 (0.33)  0.25 (0.33)  Pure HKD 


































Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.43 (0.34)  0.71 (0.34)  0.52 (0.34)  Control 
  0.10 (0.33)  0.14 (0.33)  Pure HKD 






Pure HKD  HKD + ODD  HKD + CD  Effect size d (se) 
0.30 (0.34)  0.25 (0.33)  0.16 (0.33)  Control 
  0.15 (0.33)  0.24 (0.33)  Pure HKD 









































































































































































































































































































































































































































































































































































































             








71.6 (13.6)  65.2 (14.2)  65.6 (15.0)  4.0  0.02  0.46  0.42 




             
Total subscale (T score) 
 












































































       
10 item Connors Parent Total  46.8  10.6  6.2  36.4 
10 item Connors Parent 
Restless Impulsive scale 
41.8  18.2  5.5  34.5 
10 item Connors Parent 
Emotional Lability  Scale 
45.5  7.2  10.9  36.4 
High dose (0.6 mg/kg)         
10 item Connors Parent Total  53.2  10.2  4.2  32.4 
10 item Connors Parent 
Restless Impulsive scale 
54.5  16.4  3.7  25.4 
10 item Connors Parent 
Emotional Lability  Scale 































































Total Subscale  29.8 17.0 23.4 29.8  70.2
Restless Impulsive subscale  29.1 16.4 29.1 25.5  70.9
Emotional Lability  Scale  38.2 20.0 16.4 25.5  61.8






Total Subscale  25.5 10.6 17.0 46.8  74.5
Restless Impulsive subscale  21.8 7.3 18.2 52.7  78.2
Emotional Lability  Scale  30.9 14.5 16.4 38.2  69.1





Total Subscale  28.8 17.3 19.2 34.6  71.2
Restless Impulsive subscale  27.1 16.9 27.1 28.8  72.9
Emotional Lability  Scale 
 
















































































































































































































“Full Response”  None  None  None 
“Reliable Change”  CPRS ADHD Subscale  None  None 
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In this paper we examine the current status of the science of ADHD from a theoretical point of view. While the field has reached
the point at which a number of causal models have been proposed, it remains some distance away from demonstrating the viability
of such models empirically. We identify a number of existing barriers and make proposals as to the best way for these to be
overcome in future studies. These include the need to work across multiple levels of analysis in multidisciplinary teams; the need
to recognize the existence of, and then model, causal heterogeneity; the need to integrate environmental and social processes
into models of genetic and neurobiological influence; and the need to model developmental processes in a dynamic fashion. Such
a model of science, although difficult to achieve, has the potential to provide the sort of framework for programmatic model-based




The clinical construct of Attention Deficit Hyperactivity
Disorder (ADHD) remains controversial. Those who
doubt its validity frequently cite statements such as that




, 2000) that ‘after years of clinical research and
experience with ADHD, our knowledge about the
cause or causes of  ADHD remains largely speculative’
(p. 3). In countering this position, clinical specialists and
researchers in ADHD point out that these comments
are being used out of context and cite the many genetic,
neuroimaging, neurophysiological and neuropsycho-
logical studies that not only support the validity of the
disorder, but also provide evidence for it having a biolog-




, 2002). Thus while the field has
reached a point at which relatively sophisticated causal
theories are proposed (Barkley, 1998; Sonuga-Barke,
2002), we still remain some distance from demonstrating
a full causal model of ADHD, or its component symptom
dimensions, in a way that incorporates multiple levels
of  analysis. That this is the case should come as no
surprise. The brain is the most complex of biochemical
‘machines’ and this, linked with the complex polygenic





issue, 2005), would mean that a full causal model would
need to ‘predict a ballet choreographed interactively over
time among genotype, environment, and epigenetic factors,
which gives rise to a particular phenotype’ (Gottesman
& Gould, 2003).
This paper explores some of the important barriers
that we believe must be overcome if  we are to shift from
positing causal theories to demonstrating formal causal
effects. To aid clarity we will utilize the developmental
causal modelling framework proposed by Morton and
Frith (1995). This framework provides a useful notation
with which to describe the interplay between the various
levels of analysis required to fully describe conditions
like ADHD or its component dimensions. Three within-
person levels of analysis are defined – biological, cognitive
and behavioural – with a separate domain for environmental
influences, which can interact at any of the three levels.
Causal models are built by linking elements within the
same or different levels into causal chains (Figure 1).
Morton and Frith have proposed several important
ground rules for guiding the construction and use of
causal models (see Figure 2; Morton & Frith, 1995).
Such models embrace the concept of change over time
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and encourage integration across multiple levels of ana-
lysis, providing the structure for an explanation of the
disorder that is as complete as possible.
The theoretical neutrality of this framework also allows
for the comparison, and integration, of very different the-
oretical approaches. A similar causal modelling approach
has been used successfully with several developmental
disorders including autism (Frith, Morton & Leslie,
1991), dyslexia (Morton & Frith, 1993) and conduct
disorder (Krol, Morton & De Bruyn, 2004). Several
authors have utilized a causal modelling framework to
structure discussions on the pathophysiology of ADHD
(Sonuga-Barke, in press) and to propose possible endo-
phenotypes for ADHD (Castellanos & Tannock, 2002).
However, for our purposes, the framework suggests a
number of considerations that can guide theoretical work
on ADHD and help move towards the demonstration
or evaluation of causal claims. We enumerate the most
salient of these here.
 
The need to work across multiple levels of 
analysis
 
A complete causal model for ADHD or its symptom
dimensions will require integration of genetic, neural,
cognitive and behavioural mechanisms to describe com-
plete causal chains occurring in development. The com-
plexity inherent within each of these levels requires
specialist knowledge and skills, and requires input from
researchers with a wide range of scientific backgrounds.
As a result, most researchers have, to date, worked at
only one level. Thus, disparate evidence suggests the fol-





abnormalities in both dopaminergic and noradrenergic








the behavioural manifestations of ADHD (Castellanos
& Tannock, 2002). Yet few studies have accepted the
challenge of working across these levels of analysis in
order to define their interrelationships empirically in the
same sample. Exceptions are beginning to emerge. For









, 2003) and electrophysiological













, 2004) have started to describe the
links between brain and cognitive function. Also a hand-
ful of pharmacogenomic (Seeger, Schloss & Schmidt,
2001; Roman, Rohde & Hutz, 2004) and family and














strive to make links between the genetic and neural and
cognitive levels of analysis. However, much more emphasis
will need to be placed on these bridging studies in order
Figure 1 A hypothetical simplified causal model. A1 refers to 
genetic originating causes, E1 refers to environmental 
originating causes, Br1 to the abnormal brain conditions, the 
struck out C1 to a cognitive process which is altered by virtue 
of the brain condition and S1 to the signs and symptoms.
Figure 2 Ground rules for causal modelling (Morton & Frith, 1995).
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that the causal chains linking the genetic and environ-
mental causes of ADHD or its component symptom
dimensions, through the subsequent biological and cognitive
levels to the behavioural phenotype, can be understood.
It would, for example, be informative to integrate neuro-
imaging/electrophysiological, psychopharmacological
and/or neuropsychological protocols within the large scale
molecular and behavioural genetic studies into ADHD
(e.g. Asherson & The IMAGE Consortium, 2004). The
incorporation, for example, of a neuropsychological arm
into such a study would assist in the building of causal
chains by exploring the associations between candidate
genes and neuropsychological endophenotypes and the
mediating/moderating effects of these endophenotypes
on genetic effects in ADHD. Another useful strategy
might be to incorporate cognitive, neuroimaging and
molecular genetic methods into existing prospective
epidemiological studies of the impact of perinatal factors
on developmental outcomes. For example, maternal
smoking during pregnancy independently impacts on
the expression of attention problems, other externalizing
problems and academic problems (Batstra, Hadders-
Algra & Neeleman, 2003). The inclusion of neuroimag-
ing and genetics strategies would permit an assessment
of causal chains between maternal psychopathology,
genetic susceptibility to smoking, the prenatal and peri-
natal environment, and ADHD or attention problems in
the offspring. Similar arguments could be made for a
wide range of other important domains.
 
The need to recognize the existence of and 
then effectively model heterogeneity within 
ADHD samples
 
This need to embrace and address vertical integration
across the different levels of analysis is mirrored by the
need to recognize that the heterogeneity inherent within
ADHD samples will also require there to be multiple
pathways within a causal model and a need for horizon-
tal integration between these pathways at each level, and
probably diagonally across levels. Until recently, simple
single-cause models dominated the ADHD literature. Such
models carry an implicit suggestion that the behavioural
symptoms of ADHD are a consequence of a single under-
lying factor such as deficient inhibitory control (Barkley,
1998), state regulation deficits (Sergeant, 2000), or





, in press). Whereas such theories
have stimulated important findings (and indeed, note
multiple processes that may be involved in ADHD), they
have also tended to lead to a continuation of empirical
designs that implicitly assume all children diagnosed with
a given type of ADHD have the same causal aetiology.
Such an assumption is unlikely to bear out, yet failure
to model multiple pathways may ensure that between-
group designs (ADHD versus control) will continue to
find relatively small, mixed effects. In short, single-cause
models have difficulty accounting for the heterogeneity
which is being increasingly recognized as a key factor in
the understanding of the causes of ADHD (Sonuga-
Barke, 2002; Nigg, Willcutt, Doyle & Sonuga-Barke, in
press). Data from several datasets provide convincing
evidence to suggest considerable heterogeneity within








, in press). While this within-sample heterogeneity
is found across all levels of analysis, the complexities are
well illustrated by focusing on the cognitive level. Hetero-
geneity may be manifest in several ways. First, cognit-
ive dysfunctions may be differentially associated with
the inattention and hyperactivity/impulsivity dimensions.
A growing corpus of research suggests that inattention
but not hyperactivity/impulsivity is associated with defi-
cits in executive functioning and working memory, and
poor academic achievement, even in non-clinical
community samples (Rabiner & Coie, 2000; Chhabildas,
Pennington & Willcutt, 2001; Martinussen & Tannock,




, in press). By contrast,
hyperactivity/impulsivity appears to be more closely




, 2001; Sonuga-Barke, Dalen & Remington, 2003;
Toplak, Jain & Tannock, under review). Second, there is
growing evidence that not all individuals with ADHD
manifest cognitive deficits, suggesting heterogeneity in
underlying neural mechanisms and/or marked hetero-





in press; Coghill, Rhodes & Matthews, unpublished data).
Third, various cognitive deficits within individuals with
ADHD may not be correlated, suggesting that ADHD
may be the developmental outcome of a variety of





2001; Rhodes, Coghill & Matthews, under review;
Toplak, Jain & Tannock, under review).
Thus causal models of ADHD will need to account not
only for those both with and without cognitive deficits but
also for the heterogeneity found within the cognitively
affected group. Such data require us to consider the single-
cause models not as separate entities, but as potentially
complementary approaches which, when viewed together,
can provide a fuller appreciation of a complex multi-
dimensional scenario. More studies are needed in which
researchers investigate these contrasting theoretical models
within the same samples to further the development of
multi-pathway models (Sonuga-Barke, 2003) and to identify
specific causal claims more formally in ADHD. It is
crucial to recognize that multiple pathways may not
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simply represent alternative routes into ADHD. Rather, it
may be the norm for most children to have contributions
from several, but not necessarily all, pathways, in varying
degrees. At least three general patterns of multi-pathway
models could be generated. First, we could posit that
ADHD is the common final behavioural consequence
of any of several relatively independent pathways, such





, 1999) and/or a non-working
memory pathway (Rhodes, Coghill & Matthews, 2004))
and one or more non-cognitive pathways (for example, a
motivational pathway, Sonuga-Barke, 2003) and/or an
adaptation to stress pathway (Johnston & Mash, 2001).
Each of these pathways on its own can result in the
ADHD behavioural phenotype. Second, we could posit
that ADHD is caused by a similar array of dysfunctions
in each of these domains, with at least some dysfunction
in all domains required before the phenotype is expressed.
The extensive overlap in function demonstrated between
ADHD and non-ADHD samples would require that
ADHD arises due to the small but additive and inter-
active effects of each pathophysiological process with the
phenotype only being expressed once a threshold has
been reached. Third, it may be that the correct model is
a combination of the two described above. Thus, while
ADHD could arise as a consequence of one of several
independent pathways, an interaction between several
pathways might be more common, with the detail of the
interactions dictating the precise presentation severity,
and possibly response to treatment. The situation for
ADHD with comorbidity will, of course, be even more
complex.
This analysis points to the fact that it will be important
to look beyond the frequently emphasized fronto-striatal/
executive networks in the brain to account fully for ADHD,
even at the cognitive level of analysis. Thus, structural and
functional neuroimaging studies and electrophysiology,
including transcranial magnetic stimulation, have shown





















, 2002). These studies
have mostly demonstrated the now well-recognized
abnormalities in frontal cortical regions and basal ganglia.
Yet, less often addressed are the morphological and func-
tional differences that are revealed in the motor cortex,















, 2004) cannot be explained by the neuropsy-
chological models described above.
Along the same lines, recent neuropsychological studies
have utilized batteries of neuropsychological tasks meas-
uring a range of abilities dependant on a broader range




 (2003, under review)
reported deficits in ADHD children on several short
duration timing tasks dependant on the cerebellum for





 (2004, under review) described perform-
ance deficits across a wide range of tasks from the CAN-
TAB battery including a pattern of performance on two
tasks, Delayed Matching to Sample and Pattern Recog-
nition, which mirrored those seen in patients with tempo-
ral lobe, parietal lobe or amygdalo-hippocampal damage
and Alzheimer’s dementia more than patients with fron-
tal lobe injury. Importantly, performance on both tasks
was independent of behavioural inhibitory control and
was improved following the administration of methyl-
phenidate. These studies suggest that a conceptualiza-
tion of ADHD largely restricted to fronto-striatal
circuits may require broadening within a multi-pathway
framework. However, further study is required to con-
firm the interrelationships between these and other
cognitive deficits, to evaluate relative effect sizes, and to
examine their relationships with genetic and environ-
mental causal factors and associated neural mediating
mechanisms.
 
The need to integrate environmental/social 
influences within genetic and neurobiological 
mechanisms
 
The causal modelling framework is neutral about the
relative contribution of  genetic and environmental
factors as originating causes. The scientific belief  that
ADHD is best regarded as a biogenetic neuropsychiatric
disorder receives support from the large and growing
literature on the genetics and neurobiology of ADHD as
cited earlier. Indeed, twin, family and adoption studies
suggest a large genetic, but relatively small (mainly





2003), which seems to remain relatively constant across





cular genetic studies implicate a number of potentially
(neurobiologically) functional susceptibility genes in the
pathophysiology of the condition (especially those cod-
ing for the structure of dopamine receptors (e.g. DRD4)
and transporters (e.g. DAT1; DiMaio, Grizenko & Joober,
2003)). While these different lines of evidence clearly
support a role for genetic factors in ADHD, they do not
suggest that this is to the exclusion of environmental
factors. To point out one issue, genetic effects in the case
of ADHD are necessarily expressed within, enabled by,
and in some cases doubtless mediated and/or moder-
ated by, particular biological and social environments
that are at present not well mapped. Current designs are
464
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sensitive to these effects. For example geno-environment
correlations, in which the child’s temperament elicits
particular behavioural sequences in the social environ-
ment that in turn shape child development are expressed
as genetic effects in twin study variance partitioning
(see Ge, Conger, Cadoret & Neiderhiser, 1996). In short,
viewing ADHD as essentially a genetically determined
condition is an oversimplification at best.
The work of Kreppner and colleagues on the impact
of the early severe deprivation experienced by children
adopted out of the Romanian orphanages shows a raised
incidence of ADHD (among other problems), increasing
as a function of length of deprivation experienced
(Kreppner, O’Connor & Rutter, 2001). This is highly
suggestive of an environmental route into ADHD. The
link between deprivation and ADHD is likely to be
mediated by chronic changes in the neurobiology of the
child, exemplifying the distinction between extrinsic
causal mechanisms and intrinsic mediating factors in
causal models. Similarly, neurobiological changes have
been documented in animal models of environmentally
induced stress (Matthews & Robbins, 2003). These studies
highlight the importance of thinking clearly about the
relationships between genetic and environmental influences
and neurobiology: while genetic effects may well be medi-
ated in part by neurobiological changes, they may also
be mediated by psychosocial events due to genotype-
environment correlations. Further, not all neurobiologic-
ally mediated effects will have a genetic origin.
 
The need to properly characterize 
endophenotypes
 
Endophenotypes are those mediating factors, the unseen
components, which sit between the observed manifesta-
tions of a disease or disorder and its originating causes.
With respect to neuropsychiatric conditions, they may
be neuroanatomical, biochemical, neurophysiological or
neuropsychological in nature (e.g. Gottesman & Gould,
2003). They are particularly useful in helping us to
develop our understanding of conditions in which com-
plex genetic and environmental factors must be linked to
a behavioural phenotype, which is difficult to define pre-
cisely and consistently. The endophenotype concept fits
comfortably within the causal modelling framework,
with endophenotypes representing aspects of abnormal
functioning at either the biological or cognitive levels.
Accurate characterization of candidate endophenotypes
for ADHD may suggest simpler clues to the originating
causes of this disorder than the behavioural phenotype
itself. Properly characterized endophenotypes could
further aid genetic research by acting as measurable
markers of genetic risk. Inherent to this argument is the
suggestion that by deconstructing a disorder like ADHD
into its underlying component processes we will not only
simplify genetic analysis but also provide alternative
ways of describing and classifying those with the dis-
order and hopefully reduce the heterogeneity associated
with the current behavioural phenotypes.
Various criteria, which should be met by a valid endo-
phenotype, have been described (Figure 3). Castellanos
and Tannock (2002) suggest that an endophenotype
should not be excluded solely on the basis that existing
data suggests that they are not heritable/familial (i.e.
‘genetic’); a criteria proposed by a number of authors.
However, it is clearly of considerable importance to
know whether or not an endophenotype relates to
genetic causes of a disorder. In such cases, three further
criteria apply: (1) the endophenotype should itself  be
heritable; (2) the endophenotype should co-segregate
with illness within families; and (3) the endophenotypes
found in affected family members should also be found
in non-affected family members at a higher rate than in
the general population (Gottesman & Gould, 2003).
Several potential neuropsychological endophenotypes
for ADHD have been described, including a specific
abnormality in reward-related circuitry that leads to
shortened delay gradients and delay aversion (Sonuga-
Barke, 2002), deficits in temporal processing that result
Figure 3 Criteria for an endophenotype.
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, 2003), deficits in working memory
(Rhodes, Coghill & Matthews, 2004; Bedard, Martinus-
sen, Ickowicz & Tannock, 2004) and non-working
visual memory (Rhodes, Coghill & Matthews, 2004),









, in press). While
each of these proposed neuropsychological endopheno-
types meets several of the expected criteria, none meet
them all. The heritability and co-segregation within fam-
ilies remains unexplored for most endophenotypes. Only
attentional set shifting and stop signal inhibition have
been demonstrated to be familial and more frequent in





While several of  these endophenotypes have been
demonstrated to be relatively sensitive markers for ADHD
their specificity to ADHD is less clear (Banaschewski,
Hollis, Oosterlaan, Roeyers, Rubia, Willcutt & Taylor,
this issue, 2005). As previously suggested, it is unlikely
that all endophenotypes will be present in all cases. It is,
therefore, not surprising that cohort level analyses on
such heterogeneous samples suggest high sensitivity but
low specificity. This is one of the reasons for neuropsy-
chological tests being relatively ineffective tools in the
diagnosis of DSM or ICD defined ADHD. Additionally,
several of the proposed endophenotypes appear to be
common to several neurodevelopmental disorders. For
example, working memory has also been proposed as an
endophenotype for schizophrenia (Gottesman & Gould,
2003), and stop signal inhibition has been implicated in
schizophrenia, language disorders, conduct disorder and
autism. Indeed, the neuropsychological and neurophysi-
ological similarities and dissimilarities between ADHD
and other commonly comorbid conditions, such as conduct
disorder (Schachar & Tannock, 1995; Oosterlaan &




, 2004) and specific
learning difficulties (Tannock, Martinussen & Frijters,
2000), remain contentious and unresolved.
However, this does not imply that we should abandon
our search for and description of endophenotypes. Rather,
it may suggest that we should be investigating potential
neuropsychological rather than behaviourally defined
subtypes of ADHD (see Nigg, Blaskey, Stawicki & Sachek,
2004). The neuropsychological assessment of those with
ADHD could then assist in more fully describing an
individual’s condition and aid clinicians to decide on the
most appropriate pharmacological, psychological and
educational treatment strategies. A more adventurous
but potentially far more profitable strategy would be to
concentrate on mapping out the causal pathways both
to and from cognitive deficits in delay sensitivity, behavi-
oural inhibition, working and non-working memory,






The need to take developmental aspects 
seriously
 
Despite widespread recognition of ADHD as a develop-
mental neuropsychiatric condition, very few causal
explanations have seriously considered the two-way,
interactions between pre-existing abnormal functioning
and biological, cognitive, emotional, motor and social
developmental processes, and their contribution to the
expression of the behavioural phenotype (Olson, Bates,





 (2004) provide an outline of various
temperament-based early precursors to ADHD that warrant
consideration. Sonuga-Barke (in press) has discussed
this issue with respect to the development of delay aver-
sion and associated deficits in self-organizational skills,
suggesting that at least three related developmental













, whereby the develop-
mentally antecedent impulsive response of the child
shapes their social and family environment by eliciting a
punitive or negative response from parents and siblings
to a failure to engage effectively with the delay-rich envir-













, whereby the punitive social environment, partially
created by the behaviour of the child, moderates the
links between underlying and early appearing impulsive-
ness and the emergence of a more generalized delay aver-




 to the child’s underlying pre-
disposition toward impulsiveness and the constraints
this imposes on experience. It is likely that similar pro-
cesses play a role in other causal pathways to ADHD.
Causal models must also take into account the ways
in which a failure of development in one cognitive ability
impacts on the development of successive cognitive abil-
ities. The potential importance of this concept to causal
modelling for ADHD can be illustrated by considering
the role played by working memory deficits in the devel-
opment of ADHD. Working memory deficits, although
relatively understudied, have been considered by many
to be core cognitive risk factors for ADHD requiring
accommodation within a causal model of ADHD (Cas-
tellanos & Tannock, 2002). Deficits in timing (Toplak,
Rucklidge, Hetherington, John & Tannock, 2003) and
non-working visual memory (Rhodes, Coghill & Mat-
thews, 2004), which, while not dependent on working
memory performance, may themselves impact on the
development of working memory, have been recently
identified. Thus, if  the usual development of accurate
working memory performance is contingent upon the
development of cerebellar timing functioning and spatial
recognition memory, then impaired development of
466
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either of these abilities may impact on the development
of  spatial working memory functioning. While such
hypotheses are still speculative, they warrant further
investigation and illustrate the potential importance of
such considerations. Further, the possibility that very
basic sensory and perceptual processes may be impaired
in ADHD, which, over the course of development, may
manifest subsequently as impaired performance on vari-
ous tasks and interpreted as ‘impairments in executive





Lastly, with regard to development, a causal model of
ADHD must also account for changes in phenotypic
expression over time. Future studies will need to differ-
entiate between ‘true’ and ‘apparent’ changes in symp-
toms across the lifespan. For example, is the reduction





, 1995) a true shift towards normality
or simply an apparent change resulting as a consequence
of normative development? That is, does that shift rep-
resent a change over time, mirroring normative develop-
ment, from a more visible motoric hyperactivity to an
inner restlessness and fidgetiness which, while less
noticeable and impacting on others, is still both impair-
ing to the individual and remains as far removed from
the normal distribution of experience as the symptoms
in earlier life (Barkley, 1998)? In each case, a causal
modelling paradigm would make different, testable, pre-
dictions. If  the shift is towards normalization, then this
should be reflected by a similar shift in the underlying
pathophysiology (e.g. Rothenberger, Woerner & Blanz,
1987), which would not be the case in the converse sce-
nario. The accurate developmental description of each
of these levels within causal chains would both aid the
clarity of the resultant causal models and provide a
more objective basis from which descriptions of ADHD
across the lifespan, particularly in adolescence and




The neuroscience of ADHD stands at a watershed. New
brain study and genetic technologies provide us with the
tools to examine the neurobiology of ADHD in an
increasingly sophisticated and powerful way. If  this is to
be harnessed effectively, then research must be guided by
equally sophisticated and powerful models of causes and
causal processes. In this paper we have made a number
of recommendations to overcome existing barriers to the
development of empirically based causal models, and so
facilitate model-guided research programmes in the neuro-
science of ADHD. Such programmes should routinely
use both the causal and developmental contingency
modelling paradigms to promote research, which seeks
to clarify the associations between both the different levels
of analysis within a model and the interrelationships
between various models and causal pathways. Such
approaches will be particularly valuable because of their
ability to model heterogeneity in ADHD at a number of
different levels. For instance, a reduction of phenotypic
heterogeneity is crucial for further progress in the iden-
tification of susceptibility genes for ADHD or its symp-
toms dimensions. On a more practical level, this sort of
analysis may provide the basis for identifying different
psychopathophysiological subtypes of ADHD associ-
ated with different causal pathways, which has the
potential to provide the basis for a new classification
system. Such studies will require a concerted effort to
collaborate across a range of levels; between theorists
with differing perspectives, between researchers with a
wide range of experimental backgrounds, and between
centres to enable the recruitment of the large samples
that will be required to explore the types hypotheses
generated from such an approach. Such a model of sci-
ence, departing as it does from the discipline-specific and
individual laboratory-based nature of current practice,
will not be easy to achieve, but without it, it will not be
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Canners' Parent Rating Scale
b) C. KeithConners.Ph.D.
Revised (S)





• \t..nlh 0.) ---y;;;;--
Instructions: Below area numberof commonproblemsIhal dlildren h~ve.Pleaserateeachilem accordingto your
child's beh~viorin the I~SI month. For e~chill'm. ask yourself. "lIow muchof a problem hasthis beenin the lasl
mOlllh?".andcircle thcbeslanswcrfor eachone. If none.nOIalall. seldom.or veryinfrequcntly.you wouldcircle O.
If verymuch true.or it occursvery oftenor frcquenlly.you would cirdc~. You would circle I or 2 for ratingsin
!1etwecn.Pleaserespondto eachilem."" rR':' H'ST ,\ PflCT'TY VERY"'UCII
,\T .-\Ll. lITT1.l \lLCH TRl:E TRUE
t ••••('''~I. TRtf IOflC'n.QuIIt';I (Vff)Oftcn.
Sc:1J.""1 t(\;1,;.~••.•tlll\;lllyl foiln ~h~1.fUC11(i
~: :~~~I~n:li;(~·~:~;f~list~~t~~.:::::::::::::::::::::::::.::::::::::::::.:::::::.::::::::::::.:::::::: I ~
J. Ditficultydoingorcomplelinghomework 0
4. Is always"on thego" or actsas if driven hy a molor 0
5. Short;tllenlionspan I 0
6. Argueswith adults ; 0
7. Fidgelswith handsor feCIor squirmsin seal 0
~. Fails loconlplelc assignmcllls 0
<J. Hard10 cOlllrol in mallsor while groceryshopping 0
10. Messyor disorganizedathomeor school 0
11. Losestemper 0
12. Needsdose supervision10gC[throughassignments I 0
I~. Only altendsif il is somelhinghe/shcIS veryinlcrcstedin 0
14. RunsaboU!or climbsexce"ivcly in silUalionswherc il is inappropriale.. 0
15. Distractibilityor ath:ntionspana problem 0
16. Irritable 0
17. Avnilb. c>.prt:ssc:srt"llIctal1~:eahour. O[ ha" dillil'lIhil~~eng.agingin la~ks
Ihal require~ustaincdmentaleffort (suchas sd100lworkor homework) 0
IS. R.:stlessin Ih.:"squimlY" sense 0
19.Getsdislractedwhengiveninstruclionstodo som.:thing 0
:!O. Actively defiesor refuscstocomply wilh adults·r.:quesls 0
21. Has troubleconcentratingin class 0
22. Ha~difficulty wailing in linesor awaitinglurn in gamesor groupsilualions ()
2.1. Lcavc:sseatinclassroomor in othersitualionsin whiehremainingsealedis
c"pecled 0
~4.Deliberatelydl>CsIhings[h;1Iannoyothe!pellple ()
~5.Doesnot follow throughon instructionsand fails [0 finish scholllwor~.
chorcsor lhllies in Iheworkplaec(nol dueto Opposilionalbeh;,,·joror
failureto understandinslructions) 0
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Canners' Teacher Rating Scale-Revised (5)
byC. KeithConners,Ph.D.





Teacher'sID: _ Today'sDate:_~_~ __
Munlh Dot) Year
Instructions: Below area numberof commonproblemsthatchildrenhavein school. Pleaserateeachitemaccord·
ingto howmuchof a problemithasbeenin thelastmonth. For eachitem.askyourself."How muchof aproblemhas
thisbeenin thelastmonth?'".andcircle thebestanswerfor eachone. If none.notatall. seldom.or veryinfrequently,
youwouldcircleO. If verymuchtrue.or it occursveryoftenor frequently.you would circle 3. You would circle J or
2 for ratingsin between. Please respondto eachitem. NOTT1WE JUST A PRETTY VERY MUCH
AT ALL UTIl..E MUCH TRUE TRUE
(N('\n. TIWE (Often.Quite. f~ry Of'~.
Sddom) «(A:c~ionaJly) Bit) ~ry F~u('11(1
I. Inattentive.easilydistracted .
2. Defiant .
3. Restlessin the"squirmy" sense .
4. Forgetsthingshe/shehasalreadylearned .
5. Disturbsotherchildren .
6. Actively defiesor refusesto comply with adulls' requests .
7. Is always"on thego" or actsas if driven by a motor .
8. Poori!l spelling .
9. Cannotremainstill .
10. Spitefulorvindictive .
11. Leavesseatin classroomor in othersituationsin which remainingseated
is expected .
12. Fidgetswith handsor feetor squirmsin seat .
13. Not readingup to par .
14. Shon attentionspan .
15. Argueswithadults .
16. Only paysattentionto thingshe/sheis really interestedin .
17. Hasdifficulty waitinghislherturn .
18. Lacks interestin schoolwork .
19. Distractibilityor attentionspanaproblem .
20. Temperoutbursts;explosive,unpredictablebehavior .
21. Runsaboutorclimbs excessivelyin situationswhereit is inappropriate..
22. Poor in arithmetic .
23. InleffiJptsor intrudesonothers(e.g..butlsintoothers'conversationsorgames)
24. Hasdifficultyplayingor engagingin leisureactivitiesquietly .
25. Fails to finishthingshe/shestans .
26. Doesnotfollow throughon instructionsandfails to finish schoolwork
(noldue10oppositionalbehavioror failuretounderstandinstructions) .
27. Excitable.impulsive .












Kiddie Schedule for Affective Disorders and Schizophrenia – 
Present/Lifetime version (Kiddie SADS-PL) -  ADHD Module, 










Difficulty sustaining attention on tasks or play activities 
Has there ever been a time when you had trouble paying attention 
in school?  Did it affect your schoolwork?  Did you get into trouble 
because of this?  When you were working on your homework did 
your mind wander?  What about when you were playing games?  
Did you forget to go when it was your turn? 
0 No information 0 
1 Not present 1 
2 Subthreshold – occasional 
difficulty – minimal effect on 
functioning 
2 
3 Threshold – often has 
difficulty – moderate to severe 




Was there ever a time when little distractions would make it very 
hard for you to keep your mind on what you were doing?  Like if 
another kid in class asked the teacher a question while the class 
was working quietly was it ever hard for you to keep your mind on 
your work?  When there was an interruption, like when the phone 
rang, was it hard to get back to what you were doing before the 
interruption?  Were there times when you could keep your mind on 
what you were doing and little noises and things didn’t bother you?  
How often were they a problem? 
0 No information 0 
1 Not present 1 
2 Subthreshold – occasionally 
distracted – minimal effect on 
functioning 
2 
3 Threshold – attention often 
disrupted by minor 
distractions other kids would 
be able to ignore.  Moderate 
to severe effect on functioning 
3 
 
Difficulty remaining seated 
Was there ever a time when you got out of your seat a lot at 
school?  Did you get into trouble for this?  Was it hard to 
stay in you seat at school?  What about dinner times? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasional 
difficulty staying seated when 
required – minimal effect on 
functioning 
2 
3 Threshold: often has difficulty 
staying seated when required 




Makes a lot of careless mistakes 
Do you make a lot of careless mistakes at school?  Do you 
often get problems wrong on tests because you didn’t read 
the instructions right?  Do you often leave some questions 
blank by accident?  Forget to do the problems on both sides 
of a handout?  How often do these types of things happen?  
Has your teacher ever said you should pay more attention to 
detail? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
makes careless mistakes – 
minimal effect on function 
2 
3 Threshold: often makes 
careless mistakes  - moderate 




Is it hard for you to remember what your parents and 
teachers say?  Do your parents or teachers complain that 
you don’t listen to them when they talk to you?  Do you “tune 
people out”?  Do you get into trouble for not listening? 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
doesn’t listen – minimal effect 
on functioning 
2 
3 Threshold: often doesn’t 
listen.  Moderate to severe 








Difficulty following instructions 
Do your teachers complain that you don’t follow 
instructions?  When your parents or teacher tell you to do 
something, is it sometimes hard to remember what they said 
to do?  Do you lose points on your assignments for not 
following directions? 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasional 
difficulty following instructions 
– minimal effect on 
functioning 
2 
3 Threshold: often difficulty 
following instructions.  




Difficulty organising tasks 
Is your desk or locker at school a mess?  Does it make it 
hard for you to find things you need?  Does your teacher 
complain that your work is messy or disorganised?  When 
you do your worksheets, do you usually start at the 
beginning and do all the problems in order, or do you skip 
about?  Do you often miss problems?  Do you have a hard 
time getting ready for school in the morning? 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
disorganised. Minimal effect 
on functioning 
2 
3 Threshold: often 
disorganised.  Moderate to 
severe effect on functioning 
3 
 
Dislikes/avoids tasks requiring attention 
Are there some kinds of school work that you hate more 
than others?  Which ones?  Why?  Dou you try to get out of 
doing your ______ assignments?  Do you pretend to forget 
about your homework to get out of doing it?  About how 
many times a week do you not do your homework? 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
avoids tasks that need 
sustained attention and/or 
expresses mild dislike for 
these tasks.  Minimal effect 
on functioning. 
2 
3 Threshold: often avoids tasks 
that need sustained attention 
and/or expresses moderate 
dislike for these tasks.  





Do you lose things a lot?  Your pencils at school?  
Homework assignments?  Things around home?  About how 
often does this happen? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold; occasionally 
loses things. Minimal effect on 
functioning 
2 
3 Threshold: often loses things 
(e.g. once a week or more).  





 Forgetful in daily activities 
Do you often leave your homework at home or your books or 
coat on the bus?  Do you leave your things outside by 
accident?  How often do these things happen?  Has anyone 
ever said that you’re too forgetful? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
forgetful. Minimal effect on 
functioning 
2 
3 Threshold: often forgetful.  






Do people often tell you to sit still, to stop moving or stop 
squirming in your seat?  Teachers?  Parents? Do you 
sometimes get into trouble for squirming in your seat or 
playing with little things at your desk?  Do you have a hard 
time keeping your arms and legs still? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
fidgets with hands or feet or 
squirms in seat. Minimal 
effect on functioning 
2 
3 Threshold:  Often fidgets with 
hands or feet or squirms in 
seat (e.g. at least 50% of 
time).  Moderate to severe 
effect on functioning 
3 
 
Runs or climbs excessively 
Do you get into trouble for running down the hall in school?  
Does your mum often have to remind you to walk instead of 
run when you’re out together?  Do your parents or teacher 
complain about you climbing things you shouldn’t?  What 
kinds of things?  How often does this happen? 
 
Adolescents: Do you feel restless a lot?  Feel like you have 
to move around, or that it is very hard to stay in one place? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
runs about or climbs 
excessively.   Minimal effect 
on functioning 
2 
3 Threshold: often runs about or 
climbs excessively.  Moderate 
to severe effect on 
functioning.  (In adolescents 
may be limited to a subjective 
feeling of restlessness). 
3 
 
On the go/acts like driven like a motor 
Is it hard for you to slow down?  Can you stay in one place 
for long, or are you always on the go?  How long can you sit 
and watch TV and play a game?  Do people tell you to slow 
down a lot? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally.  
Minimal effect on functioning 
2 
3 Threshold: often acts as if 
driven by a motor.  Moderate 
to severe effect on functioning 
3 
 
Difficulty playing quietly 
Do your parents or teachers often tell you to quiet down 
when you’re playing?  Do you have a hard time playing 
quietly? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold; occasionally 
has difficulty playing quietly.  
Minimal effect on functioning 
2 
3 Threshold: often has difficulty 
playing quietly.  Moderate to 




Blurts out answers 
At school, do you sometimes call out the answers before 
you’re called on?  Do you talk out of turn at home?  Answer 
questions your parents ask your siblings?  How often? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold; talks out of 
turn.  Minimal effect on 
functioning 
2 
3 Threshold: often talks out of 
turn (e.g. daily or nearly 
daily).  Moderate to severe 




Difficulty waiting turn 
Is it hard for you to wait your turn in games?  What about in 
line in the cafeteria or at the water fountain? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold; occasionally 
has difficulty waiting turn. 
Minimal effect on functioning 
2 
3 Threshold: often has difficulty 
waiting turn.  Moderate to 
severe effect on functioning 
3 
 
Interrupts or intrudes 
Do you get into trouble for talking out of turn in school?  Do 
your parents,  teachers or any of the kids you know 
complain that you cut them off when they’re talking?  Do 
kids complain that you break in on games?  Does this 
happen a lot?   
 
0 No information 0 
1 Not present 1 
2 Subthreshold; occasionally 
interrupts others. 
2 





When you’re playing or doing one thing, do you often stop 
what you’re doing because you think of something else 
you’d rather do?  Do you have trouble sticking with one 
activity?  (Survey multiple items: e.g. setting the table, other 
chores, schoolwork, video games).  Have other people said 
you do?  Your teacher?  Your mum? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold: occasionally 
shifts tasks and doesn’t 
complete activities. 
2 
3 Threshold: shifts tasks and 




Do people say you talk too much?  Do you get into trouble at 
school for talking when you’re not supposed to?  Do people 
in your family say you talk too much? 
 
0 No information 0 
1 Not present 1 
2 Subthreshold; occasionally 
talks excessively 
2 
3 Threshold: often talks out of 
turn (e.g. daily or nearly 
daily).  Moderate to severe 






















 CE MSP Symptom duration  > 6 
months 





Age of onset under 7  
(write in when: -
_____________ years ) 














Impairment – with family 0 1 2 0 1 2 
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PARENTS'USUAL TYPE OF WORK.eyenIfnotworkingnow. (Aease
be specifIC - for example. auto meChantC. tJlgh school leacher. nomemaker.





THIS FORM FILLED OUT BY: (print your full name)
Your genoer 0M31e






Please fil!out thIs form10renectyour Ylew of the
child's behavior even if other people mIght not
agree. Feel free to p"nl addItional comments
besiae each itemand In the space provided on






Be sure you answered all
items. Then seeother side.
Compared to others of the same
age, how well does he/she do
each one?
Compared to others of the same
age, how well does he/she do
each one?
!. Please list the sports your child most likes Compared to others of the same
to take part in. For example:sWimmIng.
age. about how much time does
baseball.skatrng.skateboardIng.bike










11.Please list your child's favorite hobbies.
activities, and games, other than sports.F r x mple:stamps.d lls. books. pia o.
/ i





a.C.Ill. Please list any organizations, clubs, teams,
t
group y ur child elongs to.






b.C.V. j bs atch res your child has.
f
For ex mple:p per ou e aby ilting.making
, h well does he/she carry
bed.wo ki gi stor .etc. (I cludeb thpaId
them out?




























Please print. Be sure to answerall items.
V. 1. About now many close friands does your cnild nave? (00 not include brotners & sisters)oNone 01 02 or 3 o4 or more
2. About now manytimes a week does your cnild do things witn any friends outside of regular scnool nours?
(00 not Include brotners & sisters) 0Less tnan 1 01 or 2 03 or more
VI. Compared to otners ot nis/ner age, how well does your cnlld:



















oHas no brothers or sisters
VII. 1. Performance in academic subjects. oDoes not attend school because _
BelowAbove
Check a box for each subject thatchild takes
FallingAverageAverageAverage
a. Reading.English. or LanguageArts
00
Other acat1emic






0ness. Do not in- dudegym.ShoP. t.driwtr'5 Bd .. or othernonacademicsub}I!CIS.
g.
2. Does your child receive special education or remedial services or attend a special class or special school?
oNo 0Yes-kind of services. class. or school:
3. Has your child repeated any grades? 0No 0Yes-grades and reasons:
4. Has your child had any academic or other problems in school? 0No
When did these problems start? _
Have these problems ended? 0No 0Yes-when?
oYes-please describe:
Does your child have any Illness or disability (either physical or mental)? 0No
What concerns you most about your child?
. Please describe the best things about your child.
PAGE 2
oYes-please describe:
Be sure you answeredall items.
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Pleaseprint. Be sure to answerall Items.
Below is a list of items thatdescribe children and youths. For each item that describes your child now or withinthepast 6 months,
please circle the 2 if the Item is very trueor oftentrueof your child. Circle the 1 if the item is somewhat or sometimes trueof
your child. If the item is not trueof your child, circle the O. Please answer all items as well as you can, even If some do not seem
to apply to your child.
o =Not True (as far as you know) 1 =Somewhat or Sometimes True 2 ••Very True or Often True
I
012 1. Acts too young for hislher age
p
132. Feels he/she has to be perf ct
0
2 Dnnks alc ol withoutpa nts' approval 13 r compl ins that no one loves h,m/her
(describe):
1
4 thers are ou to g t him/he0
0
5. l wort less or inf rior3. rgues a 101
0
4 Fails to finish t ing he1shestarts
0
6 G ts hurt a lot, acc d nt-p one7 in m ny fig ts5 Ther is v yli tlehe1shee j ys6. Bow l m ve ents t ide ile8 t teas d lot9 Ha g r d wit o rs whOget in troubl7 r g g, boastB C 't c n e trat , an't pay attentio for long40 ars s unds or v ic s that aren't there
(describe):0
9 get hish1ermin ff c r in th ug ts;
obs sions (describe):
I 04 Impulsive r c wi ut thi king
0
10 it still,r sUe s, or yp rac i
0Would r ther b al e than with hersLyi r he ti glin to adul s r d d t
0
mp ai s f o li essB s f ng ai s5 N rv us. ighs ung. r n
0
o f d r se ms t be in a fo. ri a l m v m twi chi (desc ibe): __ue ni l6 uel y, bull ing,or m n o h rs 0gh m
0
ydre o t l t i hi l r th ughtso lik y h r k diber l r f o t p Ss i idet p . d ' mov bowelsand l tof t b5 fe f l o nxi2 str y l er w i gsdizzy li he d. e t i g b l nging to i lh r family oro g y
others
Ov2 isob i l
0
ed wit u g o a ont ch lw t4 n't w
56. Physical problems withoutknownmedical
n't et a n ith th r kids cause:e to f el gu lty f e misbehaving1 a h p (n s m c r ad h s
0
27. E j loub Head che1 0
c N , ck0 8 k ul m c ool, o ls w red P bl it y ( ~ c ed by glasses)
0
r a , u i , pl ce , (de cribe):
other than school (describe):
0e R or t ki pr blems
0
f.Stomach ch3 i lg V i i , pl m ink or d om thin adh Ot ( crib ):
PAGE 3 Be sure you answeredall Items. Thensee other side.
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Pleaseprint. Be sure to answerall items.
0= Not True (as far as you know) 1 =Somewhat or Sometimes True 2 =Very True or Often True
0
1257. Physically attacks people 0184Strange behavlor (de cribe):
0
8 icks nose. skin.or other parts of body
(describe):
05 idea (des ribe):
0
59. Pla with own s x parts on public6. Stub om. sulle , o Irntable
0
60 too mu h7 udde ch nges n mood r feelings
0
61 Poor sc ool work8 lks a l t2 oorly c or i t dor clumsy9uspicious
0




as lotR s aw y f om Om9 emp r ta u s h t temp rcreams a lot
0
. hink ab ut s x to muchetive, ke p thi s o lr n pe ple7 s h ng h r ' h e (desc ibe): __mb- uc ing
0
mo , h w . r sniffs tobacco
0




1. uancy, s i c l
0
x l pr bl m (d s ib ):U i e. l w m in , la ks energy
0
3 happy. d, r p ess dh w ng ff or JowOlng 0, u lly udh or t mi
as d u s f r n d ca pu p (don't
a
m t k d include alcohol or tobacco) (describe):
a
e han s i d ing day and/or
night (d scribe):
a
06 V li mB In tt ive r a l r ct7, W f d i day
0
, p c pr bl ( ):t th b d
a
9 ining8 t b ankly a1 ish f p it s xal t h mt dr wn. ' g Inv lv d w th otherst ide th h
2 orn sr u t n t i g he/sh d sn't eed 113. Please write in any problems your child has that
(describe):
were not listed ab ve:
0 0







Appendix 5a: Conners’ Global Index – Parent (Conners 1997) 




CGI-P: Canners' Global Index - Parent Version
by C. Keith Conners, Ph.D.
Child 10: Gender: M F
\CI1'~k~)
Birthdate:__ /__ /__ Al:e:__ School Grade:
Mom'" o .•y Y••••
Parent ID: _ Toda)"s Date:__ /__ /__
Month DiI)' Vur
Instructions:Belowarca numberof commonproblemsthatchildrenhave.Pleaserateeachitemaccordingtoyour
child'sbehaviorin thelastmonth.Foreachitem,askyourself,"How muchof a problemhasthisbeenin thelast
month?",andcirclethebestanswerforeachitem.Ifnone.notatall.seldom.orvert infrequently.youwouldcircleO.
If verymuchtrue.or it occursveryottenor frequently.ouwouldcircle3. YouwouldcircleI or 2 forratingsin
between,Pleaserespondtoalltheitems,






























CGI-T: Canners' Global Index - Teacher
by C.KeithConners,Ph.D.
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Cri~ oft nande sily ..' I
5.
Inat en ive.easilyd stracted ................
6.
Fidg ting .. ........... ..
7
Dis ur he chil ren....... ......................................................
8
m dsmustbem imm diately-easilyfrustrated
9
a ls tofmishthingsh / h star s I
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Abstract Rationale: Dysfunction of executive neuropsy-
chological performance, mediated by the prefrontal cortex,
has been the central focus of recent attention deficit/
hyperkinetic disorder (AD-HKD) research. The role of
other potential neuropsychological “risk factors”, such as
recognition memory, remains understudied. Further, the
impact of methylphenidate (MPH) on key neuropsycho-
logical processes in AD-HKD remains poorly understood.
Objectives: To compare the performance of boys with
AD-HKD on a spatial working memory (SWM) task and
on two non-working memory tasks [a simultaneous and
delayed matching-to-sample task (DMtS) and a pattern-
recognition task] with that of healthy boys, and to inves-
tigate the impact of acute and chronic MPH on perfor-
mance of these tasks. Methods: Baseline performance of
75 stimulant-naive boys with AD-HKD was compared
with that of 70 healthy boys. The AD-HKD boys were
then re-tested following the administration of acute and
chronic challenges with MPH (0.3 mg/kg and 0.6 mg/kg)
under randomised double-blind placebo controlled condi-
tions. Results: Compared with healthy boys, the AD-HKD
boys demonstrated performance deficits on all neuropsy-
chological tasks. A single dose of MPH restored perfor-
mance on the DMtS task but had no impact on the SWM
or pattern-recognition tasks. Chronic MPH administration
did not alter performance on the SWM task but did im-
prove performance on both the pattern-recognition and
DMtS tasks. However, the acute restorative effect of MPH
on DMtS diminished with repeated administration. Con-
clusions: Our results suggest that current conceptualisa-
tions of the neuropsychological basis of AD-HKD and the
proposed therapeutic mechanisms of MPH require broad-
ening.
Keywords ADHD · Methylphenidate · CANTAB ·
Delayed matching to sample · Visual memory · Working
memory · Tolerance
Introduction
Disorders of attention and hyperactivity are common, but
controversial, clinical constructs which present a major
public health challenge (NIMH 2000). In view of con-
tinuing debate surrounding the nosology of these condi-
tions, we have chosen to adopt the convention described
by Schachar and Tannock (2002). Hence, we will refer to
specific diagnostic terms, such as hyperkinetic disorder
(HD) or attention deficit hyperactivity disorder (ADHD)
when addressing a particular diagnostic entity and set of
criteria. We will use the acronym deficit/hyperkinetic
disorder (AD-HKD) when referring to characteristics that
are believed to be shared by ADHD and HD. It is im-
plausible that AD-HKD represents the clinical presenta-
tion of a single neuropsychological or neurophysiological
abnormality (Castellanos and Tannock 2002; Todd 2000;
Sonuga-Barke 2002). Whilst much AD-HKD research has
sought to explain this disorder within a single “grand
theory”, genetic (Nadder et al. 2002; Todd et al. 2001),
neuropsychological (Solanto et al. 2001), pathophysiolog-
ical (Rothenberger et al. 2000) and phenotypic (Bieder-
man et al. 1992) studies have all identified a high degree
of heterogeneity within the AD-HKD population, sug-
gesting a multi-factorial aetiology, which is unlikely to be
accounted for within any such model. More likely, AD-
HKD is a constellation of behavioural features generated
by several relatively independent pathophysiological risk
factors. Putative risk factors, or “endophenotypes”, of as-
sumed major effect, with direct experimental support,
include deficits in executive neuropsychological functions
such as inhibitory control (Barkley 1997) and working
memory (Kempton et al. 1999). Executive neuropsycho-
logical functions are dependent on intact functioning of
the prefrontal cortices and their projections to subcortical
targets such as the caudate nucleus and nucleus accum-
S. M. Rhodes · D. R. Coghill ()) · K. Matthews
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bens (Fuster 1989). Imaging studies have consistently
implicated these brain regions in the pathophysiology of
AD-HKD (Giedd et al. 2001). Accurate performance of
these tasks is dependent on intact dopaminergic and
noradrenergic neurotransmission and can be modified
by even small manipulations in catecholamine release
(Mehta et al. 2001). Hence, the therapeutic effects of
stimulant drugs such as methylphenidate (MPH) and
dexamphetamine in AD-HKD are thought to arise from
actions on these circuits (Volkow et al. 2001b). Delay
aversion is another potential “endophenotype” with ob-
served impulsivity representing a strategy to reduce the
subjective experience of delay (Sonuga-Barke 2002).
Working memory and AD-HKD
Definitions of working memory are contentious and, at
times, confusing. Whilst some authors consider working
memory simply as the process of actively maintaining
relevant information in mind for brief periods of time
(Gleitman et al. 1999), a more comprehensive and influ-
ential view emphasises the importance of computational
processing and states that working memory is best con-
sidered as the capacity to simultaneously store and ma-
nipulate information (Baddeley 2003, 1986). Indeed,
Baddeley (1996) endorses Daneman and Carpenter’s def-
inition of a working memory task as “one that simulta-
neously requires the storage and manipulation of infor-
mation” (Daneman and Carpenter 1980), thus differenti-
ating such tasks from those that require storage but no
manipulation. Whilst deficits on “true” working memory
tasks, with substantial executive demands, have been ac-
cepted as part of the pathophysiology of AD-HKD, rela-
tively little attention has been paid to the possibility that
these children, many of whom are, by definition, disor-
ganised and forgetful, may also demonstrate specific
performance deficits on non-working memory tasks which
place much lower demands on executive functioning.
Studies have reported that children with AD-HKD dem-
onstrate deficits on free recall (Borcherding et al. 1988;
Loge et al. 1990), paired associates learning (Conte et al.
1986; Chang et al. 1999), spatial recognition (Kempton et
al. 1999) and delayed matching-to-sample (Chelonis et al.
2002; Kempton et al. 1999) tasks (DMtS); however, neg-
ative findings have also been reported particularly on
memory tasks in which stimuli are clustered or recall
strategies are presented (August 1987; Benezra and Dou-
glas 1988; Voelker et al. 1989), and also on a pattern-
recognition task (Kempton et al. 1999), suggesting that
when executive demands are reduced, the tasks become
manageable. Unfortunately, much of this work has been
hampered by a range of methodological concerns, in-
cluding the failure to use clearly defined, specific, sensi-
tive measures, small sample sizes, the use of rating scales
rather than clinical interviews in the assessment of sub-
jects and the inclusion of children with AD-HKD who
were either currently taking stimulant medication or who
had been recently withdrawn from stimulant medication.
Thus, we compared the performance of 75 stimulant-
naive boys meeting diagnostic criteria for ICD-10 HD and
DSM-IV ADHD combined subtype, aged between 7 years
and 15 years, with 70 age-matched healthy controls on
three memory tasks selected from the Cambridge neu-
ropsychological test automated battery (CANTAB) neu-
ropsychological test battery (Fray and Robbins 1996).
The CANTAB battery has been extensively validated
in both child (Curtis et al. 2002; Luciana and Nelson
1998; Hughes et al. 1999; Williams et al. 2000) and adult
(Robbins et al. 1994) populations. Tasks within the bat-
tery have been shown to be differentially sensitive to
dysfunction in several brain regions, including frontal,
temporal and amygdalo-hippocampal regions (Owen et al.
1995). Here, we report performance on three memory
tasks selected from the battery—a spatial working mem-
ory (SWM) task and two “non-working” recognition
memory tasks (pattern recognition and both simultaneous
and delayed matching to sample). Performance on further
tasks from the CANTAB battery, including stockings of
Cambridge (Tower of London), intra-dimensional/extra-
dimensional shift, spatial span, spatial recognition, paired
associates learning and reaction time, will be reported
separately. Successful performance on this SWM task has
been shown to be associated with activations of the dor-
solateral and ventrolateral PFC and posterior parietal
cortex in functional neuroimaging studies in children
(Nelson et al. 2000) and adults (Mehta et al. 2000b; Owen
et al. 1996). Performance deficits on this SWM task have
previously been reported in children (Kempton et al.
1999) and adults (Mehta et al. 2000a) with ADHD. Suc-
cessful performance of the pattern recognition and DMtS
“non-working” visual recognition memory tasks requires
intact short-term visual memory processing, imposes
minimal “executive” demands and is sensitive to both
temporal lobe and amygdalo-hippocampal (but not frontal
lobe) damage (Owen et al. 1995). Deficits on this DMtS
task have been reported in children with ADHD (Kemp-
ton et al. 1999). Kempton and colleagues did not, how-
ever, find performance deficits on the pattern-recognition
task.
In the present study, we wished to test subjects under
drug-free baseline conditions and then to re-test the AD-
HKD under randomised, double-blind, placebo-controlled
conditions on the three tasks following acute and chronic
challenges with MPH. The inclusion of a medication con-
dition serves several purposes. From a clinical perspective,
it provides an indication as to which aspects of neu-
ropsychological performance may be enhanced or dimin-
ished by MPH. Knowledge of the effects of MPH, an
indirect dopamine agonist, on neuropsychological perfor-
mance also increases understanding of the complex patho-
physiological processes that underpin AD-HKD. Improved
performance following administration of MPH has been
reported for the SWM task (Mehta et al. 2000a,b) and on a
DMtS task (Chelonis et al. 2002).
On the basis of data published prior to our initiation of
the present study, we made three predictions: (1) at
baseline AD-HKD boys will display performance deficits
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on SWM, DMtS and pattern-recognition tasks; (2) acute
MPH will improve performance on the SWM task but
have no effect on the DMtS and pattern-recognition tasks;
(3) the effects of chronic MPH on these tasks will be the
same as those seen with acute MPH.
Materials and methods
This study was approved by the Tayside Committee on Medical
Ethics. All volunteers provided written informed consent.
Subjects
Subjects in the AD-HKD group were recruited from a group of
boys aged between 7 years and 15 years old who had been referred
to the Tayside Child and Adolescent Psychiatry Service. We used a
two-stage screening procedure. Eligible and consenting subjects
scoring >1.5 standard deviations from the mean on both the Con-
ners’ parent rating scale short version (CPRS-26) and the Conners’
teacher rating scale short version (CTRS-28) were interviewed by
an experienced child and adolescent psychiatrist using the Kiddie-
SADS present and lifetime (K-SADS-PL) (Kaufman et al. 1996)
semi-structured diagnostic interview. Those meeting the diagnostic
criteria for HD (F90)—as defined in the international classification
of diseases version 10 (ICD 10 1992)—and ADHD combined
subtype—as defined in the diagnostic and statistical manual version
IV (DSM IV 1994)—and not meeting exclusion criteria, were in-
vited to participate in the study. Exclusion criteria for subjects
included a history of neurological impairment, previously deter-
mined learning disability (IQ<80), chronic physical illness, sensory
or motor impairment, current or previous exposure to stimulant
medication, and abuse of any illegal drugs. The presence of a range
of commonly occurring co-morbid conditions, including opposi-
tional defiant disorder, conduct disorder and anxiety disorder, did
not result in exclusion from the study (Table 1). The intention was
to ensure recruitment of a group of children representative of those
seen in typical clinical practice within the National Health Service
in the UK. All co-morbid diagnoses were considered secondary to
the primary diagnosis of AD-HKD. Five children met criteria for
multiple co-morbid diagnoses.
Subjects for the age-matched healthy control group were se-
lected from local schools following a similar two-stage screen.
Consenting pupils scoring <1 standard deviation from the mean on
the CPRS-26 and the CTRS-28 and all subscales of the CBCL, with
no current or past psychiatric diagnosis on the K-SADS-PL inter-
view and not meeting exclusion criteria, were invited to participate
in the study. Exclusion criteria were identical to that of the AD-
HKD group
The British picture vocabulary scale (BPVS) (Dunn et al. 1997)
[2nd edn] was used to estimate general intellectual ability for both
the AD-HKD and control subjects. The BPVS assesses verbal in-
telligence and was chosen for its ease of administration and ability
to be used with children aged between 3 years and 15 years. It is an
individually administered, norm-referenced, wide-range test of re-
ceptive vocabulary for Standard English.
Neuropsychological testing
Delayed matching to sample. The DMtS task was selected from the
CANTAB (Owen et al. 1995; Robbins et al. 1997). This task as-
sesses a subject’s ability to remember the visual features of a
complex, abstract, target stimulus. At the beginning of each trial, a
pattern consisting of four quadrants, each differing in colour and
form, appears in the centre of a touch-sensitive screen in a white
box for a presentation period of 4.5 s. Subjects are asked to re-
member the pattern. In the “simultaneous condition”, four choice
patterns then appear in red boxes located under the target pattern.
The subject is required to respond by touching the choice pattern
that corresponds exactly (in both colour and form) to the target
pattern above. Only one of the choice patterns is identical to the
target. Correct and incorrect responses are signalled by differing
auditory tones and visual feedback in the form of green ticks or red
crosses. If subjects’ make an incorrect response, they are required
to continue to choose until the target stimulus has been chosen. The
conditions for the delayed portion of the task are identical to those
of the simultaneous condition with the exception that, after the
initial presentation period, the target pattern disappears from the
screen. The four choice patterns are then presented following one of
three delays; 0, 4, and 12 s. Following three practice trials (one each
of the simultaneous presentation, 0-s and 12-s delay), a total of 20
test trials are presented with each of the four conditions presented
in a pseudorandom order. Data were analysed separately for the
simultaneous and delay conditions.
Spatial working memory. This is a self-ordered searching task
(Petrides and Milner 1982) that assesses working memory for
spatial stimuli and requires a subject to use mnemonic information
to work towards a goal. Subjects are required to “search through” a
spatial array of coloured boxes presented on a screen to collect
“blue tokens” hidden inside the boxes. Returning to a box where a
token has already been found constitutes a “between search” error
(BSE) and returning to a box already opened and shown to be
empty earlier in the same search sequence constitutes a “within
search” error (WSE). A strategy score is calculated based on how
often a searching sequence was initiated from the same box during
a trial (Fray and Robbins 1996).
Pattern recognition. This test measures a subject’s ability to re-
cognise a previously presented abstract pattern from two adjacent
stimuli. The primary measure in this task is the number of correct
patterns chosen across two trials of 12 patterns in each set.
Procedure
The study was conducted in three stages: baseline, acute challenge
and chronic challenge.
We first compared the baseline performance of the drug-naive
AD-HKD group prior to exposure to MPH and control group on
each of the tasks. The control group were not re-tested and exited
the study at this point. The AD-HKD group were randomised under
double-blind conditions into three treatment groups. Two weeks
after the initial baseline test session, the AD-HKD boys were given
a single oral dose acute challenge with MPH at between 0800 hours
and 0900 hours, at one of three doses (group 1=placebo, group
2=0.3 mg/kg, group 3=0.6 mg/kg) and re-tested on the neuropsy-
chological tasks using the first parallel test version 90 min later. For
the chronic challenge, MPH administration was continued for a
further three periods of 28 days immediately following the acute
challenge. This phase of the study was also conducted under ran-
domised, double-blind, placebo-controlled, conditions in a cross-
over design, with each subject taking MPH twice daily (at 0800
hours and 1200 hours) at each of the three doses (placebo, 0.3 mg/
kg and 0.6 mg/kg per dose), starting with the dose given at the acute
Table 1 Co-morbid diagnoses in the AD-HKD group
N % of sample
No co-morbid diagnosis 18 24
Co-morbid diagnoses
Oppositional defiant disorder 31 41.3
Conduct disorder (CD) 21 28
Depressive disorder 3 4
Generalised anxiety disorder 2 2.7
Separation anxiety disorder 3 4
Tic disorder 2 2.7
Social phobia 1 1.3
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challenge and rotating around the other two doses (Fig. 1). Subjects
were re-tested using the second, third and fourth parallel task bat-
teries 90 min after taking their morning medication at the end of
each 28-day block.
Data analysis
All baseline comparisons between AD-HKD and control boys were
analysed using ANCOVA with BPVS percentile rank scores as a
covariate. Performance at the simultaneous condition of the DMtS
task was analysed separately using univariate ANCOVA, whilst
performance at delay conditions of this task and BSE on the SWM
task were analysed using repeated-measures ANCOVA (0, 4, 12-s
delays for DMtS; 3, 4, 6, 8 boxes for BSE in SWM).
Acute challenge data were analysed using repeated-measures
ANOVA for both simultaneous and delay conditions on the DMtS
task and all measures on the SWM task. Percentage correct scores
on the pattern recognition task failed to meet normality and ho-
mogeneity of variance assumptions and hence were analysed using
the non-parametric Wilcoxon Sign test for repeated measures.
For chronic data, a mixed-design ANOVA was used with re-
peated measures on treatment taken (placebo, 0.3 mg/kg or 0.6 mg/
kg MPH) and the order in which it was taken (1st, 2nd or 3rd). No
effects of order in which the drug was taken were found for any
task. Following ANCOVA/ANOVA, further exploration of the data
was conducted by determination of simple effects or interactions.
Alpha for the primary outcome measures of the three tasks were
adjusted using the Bonferroni method in order to keep the alpha-




The AD-HKD group comprised 75 boys (mean age
10.8 years) and the healthy control group comprised 70
boys (mean age 10.7 years). There was no significant age
difference between the AD-HKD and the healthy control
group (t1,113<1). The AD-HKD group had significantly
lower BPVS scores than controls (F=27.2, P<0.001); thus,
BPVS scores were used as a covariate in the baseline
analyses. As would be expected, the AD-HKD group
scored significantly higher than the healthy control
group with respect to ADHD index scores on the parent
(F=1571.4, P<0.001) and teacher (F=103.9, P<0.001)
Conners’ rating scales.
With respect to the acute and chronic challenge anal-
yses, there were no significant differences between the
three AD-HKD treatment groups (placebo, 0.3 mg/kg and
0.6 mg/kg) with respect to age (F<1), BPVS percentile
rank (F<1), parent-rated ADHD composite score (Con-
ners’ scale) (F<1), and teacher-rated ADHD composite
score (Conner’s scale) (F<1). There were also no signif-
icant differences between these groups with respect to the
incidence of most co-morbid diagnoses conduct disorder
(F<1), oppositional defiant disorder (F<1), social phobia
(F<1), generalised anxiety disorder (F=2.1, P>0.05), and
tic disorder (F<1). However, there was a significant dif-
ference between the treatment groups with respect to
separation anxiety disorder (F=3.4, P<0.04). All three
boys diagnosed with this co-morbid condition were in one
treatment group (those taking placebo at the acute and
first chronic session). Separation anxiety disorder is not




Delayed matching to sample. At baseline (Table 3),
the AD-HKD group demonstrated deficits, relative to
controls, at both the simultaneous (F1,142=8.7, P<0.004,
Fig. 1 Flow chart of procedure







Age 10.85 (2.46) 10.74 (2.47) >0.05
BPVS percentile rank 35.43 (27.93) 58.94 (26.25) <0.001*
Conners’ parent (T scores)
Oppositionality 75.57 (11.38) 45.25 (6.42) <0.001*
Cognitive 72.94 (7.07) 44.16 (3.47) <0.001*
Hyperactive 83.08 (8.88) 46.12 (3.43) <0.001*
ADHD index 77.01 (6.09) 43.96 (3.37) <0.001*
Conners’ teachers (T scores)
Oppositionality 65.05 (19.52) 49.15 (9.49) <0.001*
Cognitive 62.77 (12.78) 47.66 (7.95) <0.001*
Hyperactive 71.0 (14.34) 47.36 (7.42) <0.001*
ADHD index 72.23 (14.93) 47.79 (8.12) <0.001*
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d=0.52) and delay (F1,142=26.4, p<0.001, d=0.90) condi-
tions (Fig. 2a). There was a significant interaction be-
tween performance accuracy and duration of task delay
(F=4.7, P<0.01). AD-HKD subjects made fewer correct
responses with increasing delay, showing greatest per-
formance deficits at the 12-s delay condition (F=4.6,
P<0.03), whilst control boys performed equally across all
delays. To investigate the relationship between perfor-
mance under both simultaneous and delay conditions,
performance under the delay conditions was re-analysed
with accuracy at the simultaneous condition as a second
covariate. No significant effect of the simultaneous con-
dition as a covariate was found. There remained a sig-
nificant interaction between performance accuracy and
duration of task delay (F2,282=3.6, P<0.03)] and boys with
AD-HKD still made fewer correct responses with in-
creasing delay, showing greatest performance deficits at
the 12-s delay condition (F=5.6, P<0.02).
Incorrect responses were not associated with shorter
response latencies for either group at the simultaneous
condition (F<1). Under delay conditions, incorrect re-
sponses were associated with significantly shorter re-
sponse latencies in the AD-HKD group (F1,74=9.5,
P<0.003). There were, however, no differences between
response latencies across the three delay conditions for
either group. Regression analysis revealed that latencies
for incorrect responding did not predict accuracy of re-
sponding at the simultaneous, 4-s or 12-s delay condi-
tions for AD-HKD boys. Shorter latencies were associ-
ated with increased error at the 0-s delay condition
([F=9.1, P<0.004]), but this contributed only a small
proportion of the total variance for incorrect responses
(r2=0.145).
Spatial working memory. AD-HKD boys made more BSE
on the SWM task (F1,142=19.43, P<0.001, d=0.75). There
was a significant interaction between group and difficulty
level (F1.6,223=15.1, P<0.001), and post-hoc tests revealed
that AD-HKD boys made more errors at the eight-box
stage than at three-box stages (P<0.001), four-box stages
(P<0.001) or six-box stages (P<0.02). AD-HKD boys also
had higher strategy scores indicating a lower use of
strategy (F2,142=16.52, P<0.001, d=0.70). There was no
group difference in the number of WSE made. Strategy
score was significantly correlated with total BSE for
both AD-HKD (r=0.513, P<0.001) and control (r=0.588,
P<0.001) boys.
Pattern recognition. AD-HKD boys made fewer correct
responses on the pattern-recognition task (z=5.267,
P<0.001, d=0.89). There was no significant difference
between the groups in latencies for correct responses.
AD-HKD boys had shorter response latencies for incor-
rect choices (F1,121=5.8, P<0.02). However, regression
analysis revealed that the latencies for incorrect responses
did not predict overall accuracy of responding for the
AD-HKD boys.
Acute challenge
Delayed matching to sample. Acute oral MPH had no
effect, at either dose, on performance accuracy under si-
multaneous test conditions (Table 4). MPH at a dose of
0.6 mg/kg, restored performance accuracy in AD-HKD
boys, across each of the delay conditions, to the levels
observed in controls (F1,88=1.2, P>0.05) (Fig. 2b). How-






F P ES (d)
Delayed matching to sample
Simultaneous % correct 90.93 (15.5) 97.14 (7.03) 8.7 <0.004* 0.52
Delay % correct (0 s, 4 s,
12 s combined)
59.52 (17.84) 75.66 (17.91) 27.18 <0.001* 0.90
Spatial working memory
Total between-search errors
(3, 4, 6, & 8 boxes com-
bined)
50.84 (21.0) 34.99 (21.1) 18.8 <0.001* 0.75
Strategy score 36.32 (5.11) 32.73 (5.11) 16.52 <0.001* 0.70
Pattern recognition
% correct 80.78 (13.1) 90.95 (8.37) 5.3 (z) <0.001* 0.89
Table 4 Summary of findings: acute responses
Measure Placebo mean (SD) 0.3 mg/kg mean (SD) 0.6 mg/kg mean (SD) F P
Delayed matching to sample
Simultaneous % correct 90.0 (15.6) 91.2 (19.22) 98.26 (5.76) 1.4 >0.05
Delay % correct (0 s, 4 s, 12 s combined) 55.55 (14.67) 61.6 (20.3) 78.84 (12.97) 7.11 <0.001*
Spatial working memory
Total between-search errors (3, 4, 6, & 8
boxes combined)
47.08 (22.92) 40.8 (19.95) 38.83 (19.9) <1 >0.05
Strategy score 35.67 (5.3) 35.56 (4.23) 35.46 (4.29) <1 >0.05
Pattern recognition
% correct 84.38 (11.07) 86.33 (10.93) 91.15 (7.40) 1.4 >0.05
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ever, the AD-HKD group continued to show impaired
functioning across each of the delay conditions under
both placebo (F1,91=29.9, P<0.001) and 0.3 mg/kg MPH
(F1,90=10.8, P<0.001). Enhanced performance under
MPH 0.6 mg/kg was not accompanied by significant
changes in latencies to make correct responses.
Spatial working memory. Acute MPH did not affect per-
formance on any of the key measures from the SWM task.
There was no significant effect of treatment group on
BSE. A significant effect of session (F1,70=19.0, P<0.001)
revealed that, overall, boys showed a reduction in BSE at
the acute challenge session. There was no significant
session  treatment group interaction (F2,70 <1); however,
showing that reduction of errors at the acute challenge
session cannot be attributed to MPH. There were no other
significant interactions between task difficulty, treatment
group and session. MPH had no effect on WSE or strategy
score.
Pattern recognition. MPH did not affect performance or
latencies on the pattern-recognition task. There was no
significant effect of treatment group on percentage of
correct responses (F2,70=1.1, P=0.34). Whilst subjects
demonstrated improved responding at the acute challenge
session (F1,70=18.9, P<0.001), there was no significant
treatment group  session interaction.
Fig. 2 Delayed matching to sample. a Percentage correct responses
under simultaneous and delay conditions at baseline. AD-HKD
group (closed circles) made fewer correct responses under both
simultaneous and delay conditions than control group (open cir-
cles). There was a significant interaction between performance
accuracy and duration of task delay. AD-HKD group made fewer
correct responses with increasing delay, showing greatest perfor-
mance deficits at the 12-s delay condition, whilst control group
performed equally well across all delays. b Acute responses to oral
methylphenidate (MPH). Acute oral MPH had no effect, at either
dose, on performance accuracy under simultaneous test conditions.
Planned contrasts revealed that MPH 0.6 mg/kg (closed squares)
significantly enhanced performance accuracy across each of the
delay conditions when compared with placebo (closed triangles).
Indeed, task performance accuracy following MPH 0.6 mg/kg was
restored to those levels observed in healthy controls (open circles).
However, the AD-HKD group continued to show impaired func-
tioning across each of the delay conditions when administered ei-
ther placebo (closed triangles) or 0.3 mg/kg MPH (open triangles).
c Chronic responses to oral methylphenidate (MPH). Chronic ad-
ministration of MPH at 0.3 mg/kg (open triangles) and 0.6 mg/kg
(closed squares) enhanced accuracy of responding under both si-
multaneous and delay conditions when compared with placebo
(closed triangles). Although MPH continued to enhance visual
memory performance in the AD-HKD group when administered
chronically, this effect was smaller than that observed following
acute challenge. Performance was improved, but not normalised.
The AD-HKD group continued to display significant impairment in
functioning under delay conditions compared with controls (open




Delayed matching to sample. Chronic administration (Ta-
ble 5) of MPH at both doses enhanced accuracy of re-
sponding under both simultaneous (F2,114=9.8, P<0.001)
and delay (F2,116=15.4, P<0.001) conditions (Fig. 2c).
This effect was smaller than that observed following acute
challenge, with performance improved, but not normalised.
The AD-HKD group continued to display significant im-
pairment in functioning under delay conditions compar-
ed with controls, despite MPH 0.3 mg/kg (F1,135=10.4,
P<0.002) and 0.6 mg/kg (F1,132=6.2, P<0.01). Chronic
MPH treatment slowed response latencies for correct
choices at both 0.3 mg/kg (P<0.03) and 0.6 mg/kg
(P<0.01). However, a positive correlation between re-
sponse latencies and accuracy of responding was only
observed for children taking the 0.3-mg/kg dose at the 4-s
(r=0.344, P<0.004) and 12-s (r=0.347, P<0.005) delays.
More detailed evaluation of this relationship using linear
regression analysis revealed that the predictive association
was modest (4 s, r 2=0.119; 12 s, r2=0.120).
Spatial working memory. Chronic MPH did not affect
performance on the SWM task. There was no significant
effect of treatment group on BSE, although effects nar-
rowly failed to reach significance (F2,116=2.85, P=0.067).
There was a significant effect of difficulty level on BSE
(F3,174=279.6, P<0.001), but no significant task difficul-
ty  treatment group interaction revealing that treatment
groups performed similarly according to difficulty level.
Likewise, there was no significant effect of treatment
group on WSE, although this narrowly failed to reach
significance (F2,116=2.9, P=0.06), or on strategy score.
Pattern recognition. Chronic administration of MPH im-
proved accuracy of responding on the pattern-recogni-
tion task (F2,116=6.02, P<0.001) at both the 0.3-mg/kg
(P<0.02) and 0.6-mg/kg (P<0.003) doses relative to pla-
cebo. There were no significant effects of MPH on la-
tencies for correct or incorrect responding on the pattern-
recognition task.
Discussion
Stimulant-naive boys with AD-HKD showed profound
deficits in visual memory performance on a simultaneous
and DMtS task and on a pattern-recognition task both
known to be sensitive to temporal and amygdalo-hippo-
campal dysfunction, but on which patients with frontal
lobe excisions show relatively intact performance (Owen
et al. 1995). They also showed deficits on a SWM task
known to be associated with activations of the dorsolat-
eral and ventrolateral PFC and posterior parietal cortex,
in functional neuroimaging studies, in children (Nelson
et al. 2000). These performance deficits are not readi-
ly explained by existing neuropsychological models of
AD-HKD. Acute MPH administration restored the deficit
observed on the DMtS task but did not alter performance
on the pattern-recognition or SWM tasks. Chronic MPH
also improved, but did not normalise, performance on the
DMtS task, improved performance on the pattern-recog-
nition task but, again, did not alter performance on the
SWM task. A facilitatory effect of MPH on inhibitory
control does not explain the acute effects and can only
offer a partial explanation for the chronic effects. There
was evidence of a reduced effect of MPH on the DMtS
task with chronic administration, perhaps reflecting the
development of tolerance.
Limitations of the study
There are several limitations of the current study. The
present sample comprises a group of children and young
people meeting the rigorous ICD 10 criteria for HD. As
such, these results may not be generalisable to those with
DSM IV ADHD who fail to meet ICD 10 criteria. This
may explain some of the differences between the current
results and some previous studies and it will be important
for future studies to include a range of subjects so that
similarities and differences between the diagnostic sys-
tems can be fully explored. In order to include subjects
representative of those referred to UK clinical services,
we did not exclude subjects with co-morbid diagnoses. As
expected, oppositional defiant disorder and conduct dis-
order were the most common co-morbidities. There is a
debate in the literature as to whether or not these disorders
are themselves associated with deficits in neuropsycho-
logical functioning (Pennington and Ozonoff 1996; Mor-
gan and Lilienfeld 2000). Further studies are required to
investigate the moderating effects of co-morbidity on
baseline neuropsychological performance and the neu-
ropsychopharmacological effects of MPH. Finally, intel-
Table 5 Summary of findings: chronic responses
Measure Placebo mean (SD) 0.3 mg/kg mean (SD) 0.6 mg/kg mean (SD) F P
Delayed matching to sample
Simultaneous % correct 85.22 (18.03) 91.34 (13.58) 95.38 (9.2) 9.8 <0.001*
Delay % correct (0 s, 4 s, 12 s combined) 56.04 (19.21) 65.78 (21.23) 68.82 (16.29) 15.4 <0.001*
Spatial working memory
Total between-search errors (3, 4, 6, &
8 boxes combined)
39.0 (20.11) 37.09 (22.95) 35.08(19.83) 2.85 >0.05
Strategy score 35.04 (4.08) 33.96 (5.32) 34.22 (5.28) 1.09 >0.05
Pattern recognition
% correct 81.28 (14.41) 86.09 (12.79) 87.57 (12.42) 6.02 <0.001
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lectual functioning in the present study was measured
using the BPVS, a standardised measure of verbal abili-
ties, which in UK samples correlates highly with mea-
sures of general intelligence (Dunn et al. 1997), and
which was used as a covariate in the baseline analyses to
ensure that group differences were not a result of the
lower verbal abilities of the AD-HKD subjects. Unfortu-
nately measures of non-verbal or full-scale IQ were not
available for these subjects and no comment can be made
with respect to these aspects of functioning.
Neuropsychological performance of drug naive boys
with AD-HKD
Our results support extension of the range of neuropsy-
chological deficits ascribed to AD-HKD to include non-
executive visual memory functioning. The performance
deficits demonstrated on the SWM task were expected.
Similar deficits have been demonstrated in previous
studies (Nigg et al. 2002), two of which (Barnett et al.
2001; Kempton et al. 1999) used the same task as in the
present study. However, unlike these two studies, the
significant positive correlation between BSE and strategy
scores, in both the AD-HKD and control groups, suggests
that poor use of strategy may contribute to the poor task
performance. These differences may be explained by the
much larger sample size in the present study (n=15
Kempton et al. versus n=75 present study) and differences
in the diagnostic status of the samples (DSM IV in
Kempton et al. versus ICD 10 in present study).
With respect to the DMtS task, our results support, to
an extent, those reported in previous studies. Kempton et
al. (1999) used an identical task and reported delay-in-
dependent performance deficits in un-medicated ADHD
subjects. Chelonis et al. (2002), using a different DMtS
task, reported delay-dependent deficits in ADHD subjects
withdrawn from stimulants for at least 18 h. Our data
support and extend these findings to drug-naive subjects
with AD-HKD. The finding in both the present study and
that of Chelonis et al. (2002) of no deficit at a 0-s delay
suggests that these recognition memory deficits result
from difficulties in retention or recall rather than encod-
ing or attending to information at presentation. The def-
icits observed on the pattern-recognition task in the pres-
ent study were not predicted. Previous studies have re-
ported no group differences on this (Kempton et al. 1999)
and other recognition memory tasks (Douglas 1988). The
differences between the present and previous studies may
again be related to differences in sample size, rigor of
diagnostic assessment, diagnostic classificatory system
used and medication status of subjects.
Are these deficits in non-working recognition memory
adequately explained by current theories of AD-HKD?
Working memory deficits would not impact upon tasks
with no requirement to manipulate information on line.
Inhibition theories such as that described by Barkley
(1997) would predict that AD-HKD-related performance
deficits on these tasks should be associated with shorter
response latencies, with “impulsive” responding pre-empt-
ing accurate solution of the discrimination. Hence, incor-
rect response latencies should be the shortest. No such
association was found at the simultaneous condition of the
DMtS. Whilst incorrect response latencies were shorter at
the delay condition of the DMtS, this association was
delay independent, making it unlikely that the reduced
performance accuracy at longer delay intervals was at-
tributable to impulsive responding. Furthermore, regres-
sion analysis demonstrated that, for AD-HKD boys,
shorter response latencies made only a small contribution
to the total variance at the 0-s delay condition and did not
predict accuracy of responding at the 4-s or the 12-s delay
conditions. Similarly, the shorter incorrect response la-
tencies on the pattern-recognition task did not predict poor
performance on this task.
Further, our data do not support the proposition that
the performance deficits seen on the DMtS are due to
classically defined “delay aversion” (Sonuga-Barke et al.
1992). The simultaneous and DMtS task imposes a range
of fixed delays, presented in a pseudorandom order, such
that, within each trial, subjects do not know whether the
pattern to be remembered will disappear and, if so, for
how long. The “delay aversion” hypothesis would predict
that when children with AD-HKD have no control over
the inter-trial delay and cannot respond in a manner that
might reduce the subjective experience of delay, they
would show no impairment of performance. Sonuga-
Barke has recently argued that delay aversion can provide
a motivational route into cognitive deficits in as much as
it limits the opportunities to acquire the experience of
working under delay conditions and so developing the
necessary skills for effective performance (Sonuga-Barke
2002). It is not possible to conclusively discount this
explanation from the current data, and further studies
explicitly investigating the relationship between visual
memory performance and delay aversion are required.
Our data also suggest that the conceptualisation of AD-
HKD as a “frontal” disorder of monoaminergic neuro-
circuitry may be overly restrictive. Whilst performance on
this SWM task has been shown to be associated with
activations of the dorsolateral and ventrolateral PFC and
posterior parietal cortex, both the pattern-recognition and
DMtS tasks appear to have different neuroanatomical sub-
strates. Performance on this version of the pattern-rec-
ognition task has been demonstrated to be sensitive to
temporal and amygdalo-hippocampal damage, but not to
frontal lobe damage (Owen et al. 1995). Animal data
suggest that a comparable version of the DMtS task is also
particularly sensitive temporal and amygdalo-hippo-
campal damage (Mishkin 1982; Bachevalier and Mish-
kin 1986). Further, patients with frontal, temporal and
amygdalo-hippocampal excisions performed accurately
on the simultaneous condition of the DMtS task, whilst
temporal and amygdalo-hippocampal, but not frontal,
patients were impaired when a delay was introduced
(Owen et al. 1995). Similar patterns of delay-dependent
impairment on this DMtS task have previously been
described in patient groups with medial temporal lobe
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damage or disease notably senile dementia of Alzheimer’s
type (SDAT) (Sahakian et al. 1988), elderly depressives
(Abas et al. 1990) and healthy males exposed to the
muscarinic antagonist scopolamine (Robbins et al. 1997).
Other patient groups have shown delay-independent def-
icits on this task, for example, patients with Parkinson’s
disease (Sahakian et al. 1988). Our data suggest a po-
tential role for the temporal lobes, the amgydala and/or
hippocampus in AD-HKD. This supports recent magnetic
resonance imaging studies, one of which described re-
duced white and grey matter volumes in temporal, parietal
and occipital areas in addition to frontal areas (Castel-
lanos et al. 2002) and the other reported reduced brain
volume in the anterior temporal lobe and increased grey
matter in the posterior temporal lobe and inferior parietal
lobe (Sowell et al. 2003). Further, the striking similarities
between the delay-dependent DMtS deficits found in the
AD-HKD group and those reported for patients with
SDAT and healthy adult males following administration
of scopolamine raise the possibility of altered cholinergic
neurotransmission in children with AD-HKD. This is of
interest given that both nicotinic agonists (Wilens et al.
1999) and donepezil, an acetylcholinesterase inhibitor
which improves memory function in SDAT (Rogers et al.
1998), have been demonstrated to exert beneficial effects
in AD-HKD (Wilens et al. 2000).
Intriguingly, in addition to demonstrating a striking
delay-dependent deficit on the DMtS task, boys with AD-
HKD were also impaired at the simultaneous condition.
Such impairment has previously been reported in patients
with Parkinson’s disease (Sahakian et al. 1988). Patients
with frontal, temporal or amygdalo-hippocampal damage
(Owen et al. 1995), SDAT (Sahakian et al. 1988), elderly
depressives (Abas et al. 1990) and healthy males exposed
to scopolamine (Robbins et al. 1997) did not show such
impairment. A previous small study that reported delay-
independent impairment on the DMtS task in children with
ADHD found no impairment at the simultaneous condition
(Kempton et al. 1999). The performance deficit in AD-
HKD boys during the simultaneous matching component
of the task did not account for poor performance during
the delayed matching components. Hence, there may be
two discrete deficits that can be identified. Much less is
known about the mediating neural substrates of simulta-
neous matching components of this task. The Parkinson’s
disease-related deficits in simultaneous matching and the
chronic MPH amelioration of the AD-HKD-related deficit
may point towards a dopaminergic substrate and frontos-
triatal circuitry. Further studies will be required to address
these observations.
The effects of methylphenidate
on neuropsychological performance
It is currently hypothesised that the pharmacological ac-
tions of MPH are mediated by its ability to inhibit the
reuptake of dopamine and noradrenaline through block-
ade of the dopamine transporter (DAT). However, the
precise effects of MPH in any particular brain region
depends on the balance between tonic and phasic cate-
cholamine release at baseline, the distribution of DATs
and pre-synaptic autoreceptors within that region and the
interaction between catecholaminergic neurotransmission
and other neurotransmitter systems (Mehta et al. 2001).
Our findings that MPH did not alter performance on the
SWM task contrast strikingly with those of Kempton et al.
(1999) and Mehta et al. (2000a,2000b). It is again pos-
sible that these differences are related to methodological
differences. Both previous studies reported results on
much smaller samples diagnosed using DSM IV criteria,
and used less rigorous medication strategies than the
present study; this non-replication of previous findings
is important and raises the possibility of differential im-
pacts of MPH between differently diagnosed samples on
this important area of functioning. Interestingly, a re-
cent re-analysis of the influential Multimodal Treatment
of ADHD Study (MTA Cooperative Group 1999) has
found that diagnostic status (ICD-10 HD versus DSM
IV ADHD) is a moderator of treatment response (E.
Taylor, personal communication). Also principle differ-
ences in monoamine metabolism between mild and severe
forms of AD-HKD have been reported (Uzbekov and
Misionzhnik 2003).
Whilst we have some understanding of how MPH may
act on catecholamine systems in the prefrontal cortex and
striatum (Volkow et al. 2001a), there has been limited
study of the potential actions of MPH within other brain
structures. Our results raise the possibility that the ef-
fects of MPH on aspects of visual memory function in
AD-HKD may involve interaction between catecholamin-
ergic and cholinergic neurotransmission. Whilst a single
dose of MPH, at a dose of 0.6 mg/kg, did not affect
performance on the pattern-recognition task, it restored
performance accuracy on the DMtS delay conditions to
the levels observed in controls. These observations sup-
port and extend the work of Chelonis et al. (2002) who
also reported normalisation of DMtS performance fol-
lowing administration of stimulant medication. Chronic
MPH treatment resulted in less pronounced effects than
were observed after the acute challenge, with perfor-
mance being improved but not normalised. This suggests
the possibility that, at least with respect to this task, tol-
erance develops after chronic MPH administration. Whilst
acute tolerance has been demonstrated with clinical doses
of oral MPH (Swanson et al. 1999), the MPH literature to
date has suggested that long-term tolerance does not occur
in clinical cases (Greenhill et al. 2001). There are, how-
ever, some suggestions from the literature that long-term
tolerance may occur. For example, increases in the mean
daily MPH dose required to optimally control ADHD
symptoms were reported over the 14 months of the
Multimodal Treatment of ADHD study (Vitiello et al.
2001).
Unlike the study of Chelonis et al. (2002) enhanced
performance on DMtS in the current study following
acute 0.6 mg/kg MPH was not accompanied by signifi-
cant changes in latencies to make correct responses.
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Therefore, enhanced accuracy of responding in the AD-
HKD group in this condition was not a consequence of
either increased deliberation time or reduced impulsivity.
Chronic MPH treatment with either dose did not alter
response latencies for the pattern-recognition task but did
slow response latencies for correct choices on DMtS. This
observation supports a presumed therapeutic mechanism
of action whereby chronic MPH may enhance inhibitory
control (Barkley 1997). However, positive correlations
between response latencies and accuracy of responding
were only observed for children taking the lower dose and
only at the 4-s and 12-s delays. Linear regression analysis
revealed that this predictive association was modest,
suggesting that the therapeutic effects of MPH are, at
best, only partially attributable to an enhancement of in-
hibitory control.
The dissociation with respect to the impact of MPH on
the working memory and non-working memory tasks
suggests that, at least in those children with the more
refined ICD 10 HD phenotype, whilst treatment with
MPH may result in significant improvement in behav-
ioural symptoms and in some aspects of neuropsycho-
logical functioning, it does not normalise all aspects of
functioning in all patients.
Conclusions
Our data highlights the heterogeneity of AD-HKD, chal-
lenges single-cause theories of AD-HKD and supports a
multi-pathway model whereby AD-HKD is the pheno-
typic consequence of several endophenotypic risk factors
(Castellanos and Tannock 2002). We propose that deficits
in non-working visual memory may constitute a novel
independent endophenotype for AD-HKD. In contrast to
previous pathophysiological explanations of AD-HKD,
this impairment is consistent with medial temporal lobe,
but not frontal lobe dysfunction, and may implicate cho-
linergic neurotransmission. Further, we have demonstra-
ted that, whilst none of the observed deficits resulted from
previous exposure to stimulant medication, the deficit in
DMtS performance was restored by acute administration
of MPH and, on both DMtS and pattern recognition, was
improved by chronic administration.
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ABSTRACT
Background. Although children with hyperkinetic disorder and/or attention deﬁcit hyperactivity
disorder (ADHD) show disordered executive neuropsychological functioning, the nature of these
changes remains controversial. Additionally, impairments in non-executive neuropsychological
functioning have been relatively unexplored. Here, the authors describe the neuropsychological
functioning of a sample of stimulant drug-naive boys with hyperkinetic disorder on a battery of
neuropsychological tasks sensitive to impairments of both executive and non-executive functions.
Method. Seventy-ﬁve stimulant drug-naive boys meeting diagnostic criteria for ICD-10 hyper-
kinetic disorder were compared with 70 healthy developing controls matched for age but not IQ on
computerized tests of neuropsychological functioning from the Cambridge Neuropsychological
Test Automated Battery (CANTAB) and a Go/No-Go inhibition task.
Results. Boys with hyperkinetic disorder exhibited impairments on tasks with a prominent execu-
tive component – working memory, planning, strategy formation, attentional set-shifting and on a
reaction time task. However, they were also impaired on tasks without prominent executive com-
ponents – pattern and spatial recognition, spatial span, delayed matching to sample and paired
associates learning. Contrary to predictions, no impairment was observed on the Go/No-Go inhi-
bition task.
Conclusions. Medication-naive boys with hyperkinetic disorder displayed a broad range of neuro-
psychological impairments. Deﬁcits were demonstrated on tasks with and without prominent
executive components. Impairments were not conﬁned to tasks dependent upon frontostriatal
functioning, cannot wholly be explained by deﬁcits in inhibitory control, nor can they be attributed
to intelligence or previous exposure to stimulant medication.
INTRODUCTION
Hyperkinetic disorder (ICD-10; WHO, 1992)
and attention deﬁcit hyperactivity disorder
(DSM-IV; APA, 1994) are characterized by
pervasive impaired attention, hyperactivity and
impulsivity. These disorders are common, par-
ticularly in boys (Swanson et al. 1998), with 1
year combined prevalence rates in school-age
children of 1.7% for hyperkinetic disorder
(Meltzer et al. 2000) and between 5 and 10%
(Swanson et al. 1998) for ADHD. With con-
tinuing controversy with respect to nosology,
we have adopted the convention suggested by
Taylor (1994) and described by Schachar &
Tannock (2002) and refer to speciﬁc diagnostic
terms, such as hyperkinetic disorder (HD) or
attention deﬁcit hyperactivity disorder (ADHD)
when addressing a particular diagnostic entity
and set of criteria. However, we use the acronym
AD-HKD when referring to characteristics that
are shared by both ADHD and HD.
The impairments associated with AD-HKD
are considerable, and core symptoms and
associated social, interpersonal, and academic
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problems often persist into adulthood (Klein &
Mannuzza, 1991; Hechtman, 1992; Murphy &
Barkley, 1996; Barkley et al. 2004). Despite
considerable study and speculation, the patho-
physiology of AD-HKD remains poorly under-
stood (Solanto et al. 2001). Converging evidence
implicates dysregulation of frontostriatal neural
circuits (Castellanos et al. 1996b ; Giedd et al.
2001; Rubia et al. 2001b) and, more speciﬁcally,
reduced prefrontal dopamine (DA) trans-
mission (Castellanos et al. 1996a ; Pliszka et al.
1996; Ernst et al. 1998).
Executive neuropsychological functioning
(EF) has been used as an umbrella term to de-
scribe those functions that mediate ‘the ability
to maintain an appropriate problem-solving set
for attainment of a future goal ’ (Luria, 1996).
EF includes, for example, diverse processes such
as response inhibition, planning, working mem-
ory, and ﬂexibility of thinking or responding.
Performance deﬁcits on executive tasks of work-
ing memory have been observed in prefrontal
cortex (PFC)-lesioned animals (Goldman-
Rakic, 1996) and humans (Owen et al. 1990).
Similarly, inhibitory control, attentional set-
shifting and planning are impaired in pa-
tients with frontal lobe resections (Owen
et al. 1990, 1991; Braun et al. 1992). Hence,
executive dysfunction might reasonably be pre-
dicted in association with the altered fronto-
striatal functioning reported in AD/HKD.
However, no consensus has been derived within
the literature concerning EF impairments in
AD-HKD (Tannock, 1998; Kempton et al.
1999; Castellanos et al. 2000). Neuropsycho-
logical investigation has undoubtedly been
hampered by a lack of clearly deﬁned, speciﬁc,
sensitive and valid measures of EF other than
inhibition (Tannock, 1998) and persistent
failure to deploy task batteries sensitive to a
broad range of impairments. Other important
methodological limitations have included small
sample sizes (e.g. Kempton et al. 1999), the use
of rating scales rather than structured clinical
interviews for case deﬁnition (e.g. Scheres et al.
2001), and the inclusion of children who were
either taking, or had recently stopped taking
stimulant medication (e.g. Seidman et al. 1997;
Aman et al. 1998). These latter issues are
crucial since methylphenidate (MPH), the ﬁrst-
line pharmacological treatment for AD-HKD,
signiﬁcantly enhances various aspects of
neuropsychological functioning, including EF
(Kempton et al. 1999; Mehta et al. 2000).
One inﬂuential neuropsychological account
of AD-HKD emphasizes behavioural impul-
siveness and postulates a primary deﬁcit in in-
hibitory control leading to secondary deﬁcits in
other EF (Barkley, 1998). However, no empiri-
cal evidence has been provided to support the
primacy of inhibition. It is increasingly im-
plausible that AD-HKD could represent the
clinical manifestation of a single neuropsy-
chological or neurophysiological abnormality.
Recently developed models have, instead, pro-
posed (Castellanos & Tannock, 2002; Sonuga-
Barke, 2002) that AD-HKD be viewed as the
behavioural consequence of a combination of
several risk factors, present to varying degrees in
diﬀerent individuals, with heterogeneity of EF
deﬁcits (Pennington & Ozonoﬀ, 1996; Denney
& Rapport, 2001). It has further been suggested
that only a proportion of those with AD-HKD
may demonstrate neuropsychological deﬁcits
(Doyle et al. 2000; Sonuga-Barke, 2002; Nigg
et al. 2004). These views are supported by em-
pirical evidence regarding inhibitory function
(Rubia et al. 2001b) ; working memory and
attentional set-shifting (Kempton et al. 1999;
Tripp et al. 2002) and planning ability
(Kempton et al. 1999). In addition, children
with AD-HKD are impaired on tasks with low
executive demands, for example a spatial span
task (Kempton et al. 1999), and on tasks
traditionally associated with parietal rather than
frontal functioning, such as mental rotation (the
Turning task) and visuospatial processing
(Aman et al. 1998). Similarly, neuroimaging
studies in AD-HKD describe abnormalities in
several areas of the brain other than the PFC,
including the temporal and parietal lobes and
the cerebellum (Filipek et al. 1997; Castellanos
et al. 2002). Encouraging an integrative
approach that takes these observations in
account, Castellanos & Tannock (2002) have
proposed four candidate ‘endophenotypes ’ for
AD-HKD; delay aversion, deﬁcits in working
memory, deﬁcits in time estimation and
behavioural inhibition. Compelling empirical
evidence for each is awaited.
We have examined the neuropsychological
functioning of a large sample of stimulant-naive
boys with ICD-10 hyperkinetic disorder (who
also met criteria for a diagnosis of DSM-IV
1110 S. M. Rhodes et al.
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ADHD combined subtype), using tasks from
the CANTAB neuropsychological test battery
and a computerized Go/No-Go task. The
CANTAB battery (Fray & Robbins, 1996) has
been extensively validated in both child
(Luciana & Nelson, 1998; Hughes et al. 1999;
Williams et al. 2000; Curtis et al. 2002) and
adult populations (Robbins et al. 1994) and has
been shown to be diﬀerentially sensitive to
dysfunction in several brain regions, including
frontal, temporal and amygdalo-hippocampal
regions (Owen et al. 1995). We have previously
reported data from the same clinical group
on the Spatial Working Memory, Delayed
Matching to Sample and Pattern Recognition
tasks from the CANTAB battery (Rhodes et al.
2004). Having included these data in the corre-
lational and regression analyses that follow, the
results are brieﬂy summarized alongside those
that represent the present report.
METHOD
Participants
We tested two groups of boys aged between 7
and 15 years. One was an experimental cohort
of 75 stimulant-medication-naı¨ve participants
with ICD-10 HD, but who also met criteria for
DSM-IV ADHD combined subtype (AD-HKD
group, mean age 10.8 years). The other con-
tained 70 healthy control boys (Controls, mean
age 10.7 years).
AD-HKD group
Participants were recruited from consecutive
male out-patient referrals to the Tayside Child
and Adolescent psychiatric service using a two-
stage screening procedure. Potential partici-
pants were ﬁrst screened using the Child
Behaviour Checklist (Achenbach et al. 1991)
and the Conners’ Parent and Teaching Rating
Scales (Conners, 1997a, b). Subjects with a
T-score greater than 65 on all subscales of the 27
item Conners’ Parent Rating Scale–Revised (S)
(CPRS-48) and the Conners’ Teacher Rating
Scale–Revised (S) (CTRS-28) were interviewed
by an experienced child and adolescent psy-
chiatrist using the Kiddie-SADS Present and
Lifetime (K-SADS-PL) Version 1.0 semi-
structured interview (Kaufman et al. 1996,
1997). Each AD-HKD subject met diagnostic
criteria on K-SADS interview for both ICD-10
HD, and DSM-IV attention-deﬁcit/hyper-
activity disorder, combined type. Although
co-morbidity is not formally permitted within
the ICD-10 system, the presence of a range of
commonly occurring co-morbid conditions;
including oppositional deﬁant disorder, conduct
disorder, and anxiety disorder, did not result in
exclusion from the study (see Table 1). This was
to ensure recruitment representative of the
clinical populations seen in routine practice
within the UK National Health Service. All
co-morbid diagnoses were considered secondary
to the primary diagnosis of HD. Five children
met criteria for multiple co-morbid diagnoses.
Controls
Healthy developing boys were recruited from
local schools and screened as above. Symptom-
free (T-score<60 on all subscales of the CPRS-
48, CTRS-28 and CBCL subscale T-scores
<60), age-matched participants and their par-
ents were interviewed using the K-SADS-PL to
conﬁrm health. A previous or current history of
any psychiatric disorder led to exclusion, as did
a history of neurological impairment, learning
disability, chronic physical illness, sensory or
motor impairment, current or previous ex-
posure to prescribed stimulant medication, and
abuse of any illegal drugs. The British Picture
Vocabulary Scale, second edition (BPVS; Dunn
et al. 1997) was used to estimate general
intellectual ability. The BPVS assesses verbal
intelligence and was chosen for its ease of ad-
ministration and ability to be used with children
aged between 3 and 15 years (Dunn et al. 1997).
Informed written consent to participate in the
study was obtained from each child’s parent(s)/
guardian. The characteristics of both groups are
summarized in Table 2.
Table 1. Co-morbid diagnoses in AD-HKD
group
n % of sample
Pure hyperkinetic disorder 18 24
Co-morbid diagnoses
Oppositional deﬁant disorder (no CD) 31 41.3
Conduct disorder (CD) 21 28
Depressive disorder 3 4
Generalized anxiety disorder 2 2.7
Separation anxiety disorder 3 4
Tic disorder 2 2.7
Social phobia 1 1.3
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Neuropsychological assessment
A total of 10 tasks were used and each subject
performed all tasks in the same order. A com-
puter-based Go/No-Go task was used to assess
inhibitory control and nine tasks were selected
from the three batteries (working memory and
planning, visual memory, and attention) of
CANTAB (Morris et al. 1987). All tasks were
presented on a high-resolution colour monitor
with CANTAB tasks utilizing a touch-sensitive
screen. A scheduled break of approximately
10 minutes was taken midway through the
testing session and subjects were informed
that they could take further breaks as required.
In practice few subjects requested additional
breaks.
Go/No-Go
This task assessed the ability to detect and
respond to a target stimulus and to inhibit
responding to distractor stimuli. A random se-
quence of 18 letters and numbers (nine of each)
were rapidly presented in the centre of a colour
computer screen, one by one. Stimuli were
presented on screen for 300 ms, with an inter-
stimulus interval of 900 ms. Subjects were
instructed to respond to target stimuli (letters)
by pressing the space bar as quickly as possible,
but not to respond to distractors (numbers).
Response contingencies alternated between
numbers and letters with two ‘switching’ and
two ‘non-switching’ blocks. The dependent
measures are the mean number of errors
for distractors (false positive responses) and
reaction time to target stimuli across eight test
trials. This version of the Go/No-Go task has
not previously been used in the study of neuro-
psychiatric disorders or psychopharmacological
manipulations; however, the test parameters are
identical to those previously used, in several
studies, to demonstrate impaired inhibitory
control in AD-HKD subjects.
CANTAB
Task descriptions and order for presentation of
the CANTAB tasks are described in Table 3.
Statistical analysis
All analyses were conducted using SPSS for
Windows (v.10) (SPSS Inc., Chicago, IL, USA).
As AD-HKD boys tended to score lower on the
BPVS percentile rank scores and despite there
being no correlation between task performance
and BPVS scores on any task, the BPVS per-
centile rank scores were used as a covariate in
all parametric analyses. In addition, a separate
analysis of an age- and BPVS-matched sub-
sample was conducted. Data meeting assump-
tions of normality and homogeneity of variance
were analysed using analysis of covariance
(ANCOVA) and, thereafter, by determination
of simple eﬀects or interactions (Winer et al.
1991). All other data were compared using
appropriate non-parametric tests (e.g. Mann–
Whitney U test). To explore the potential
contribution of disordered impulse control on
task performance both accuracy measures and
reaction times are reported. For analysis of
Table 2. Demographic characteristics
AD-HKD boys (n=75) Control boys (n=70)
Mean (S.D.) Mean (S.D.) p
Age 10.85 (2.46) 10.74 (2.47) >0.05
BPVS percentile rank 35.43 (27.93) 58.94 (26.25) <0.001
Conners: parent (T-scores)
Oppositionality 75.57 (11.38) 45.25 (6.42) <0.001
Cognitive 72.94 (7.07) 44.16 (3.47) <0.001
Hyperactive 83.08 (8.88) 46.12 (3.43) <0.001
ADHD index 77.01 (6.09) 43.96 (3.37) <0.001
Conners: teachers (T-scores)
Oppositionality 65.05 (19.52) 49.15 (9.49) <0.001
Cognitive 62.77 (12.78) 47.66 (7.95) <0.001
Hyperactive 71.0 (14.34) 47.36 (7.42) <0.001
ADHD index 72.23 (14.93) 47.79 (8.12) <0.001
BPVS, British Picture Vocabulary Scale.
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performance on the Go/No-Go task, trials were
divided into two blocks: Block 1 represented the
‘switch’ blocks where the task changed from
letters to numbers (or vice versa) and Block 2
the ‘non-switch’ block. Blocks were entered into
a repeated-measures ANOVA for analysis.
Multiple regression analyses were conducted
using a backwards deletion entry method with a
probability of F for entry set at 0.05 and re-
moval at 0.10. As each of the neuropsychologi-
cal tasks is designed to measure a diﬀerent
aspect of functioning, and therefore can be seen
as representing a separate experiment, a levels
were not adjusted for the main comparative
analyses. For the correlational analyses a was
adjusted to 0.008 to reﬂect the multiple com-
parisons.
RESULTS
All subjects completed each of the tests. Mean
performance (raw scores and those adjusted for
covariate), statistical comparisons and eﬀect
sizes (d) for each task, for both groups, are
summarized in Table 4. As the Spatial Working
Memory, Pattern Recognition, and Delayed
Matching to Sample tasks been previously
reported (Rhodes et al. 2004), data are only
brieﬂy summarized here.
AD-HKD boys showed no impairments on
the Go/No-Go task. There was no diﬀerence
between groups for errors to distractors at either
the shift or non-shift block [F(1, 142)<1], or
in reaction times to targets [F(1, 142)=3.1,
p>0.05].








Spatial Span Span A test of spatial short-term memory
capacity based on the Corsi
block-tapping task.
Milner, 1971; Kempton et al.
1999
Spatial Working Memory Between-search errors,
Strategy score
A self-ordered search task that assesses
working memory for spatial stimuli
and requires a subject to use mnemonic
information to work towards a goal.
Petrides & Milner, 1982;
Kempton et al. 1999;
Rhodes et al. 2004
Stockings of Cambridge Problems solved in
minimum moves
Derived from the ‘Tower of Hanoi’ task,
measuring spatial planning, working
memory, and behavioural inhibition.
Shallice, 1982; Kempton et al.
1999
Visual memory battery
Pattern Recognition Percentage correct Tests the ability to recognize a previously
presented abstract pattern in a forced
choice procedure.
Kempton et al. 1999
Spatial Recognition Percentage correct Tests the ability to recognize the spatial
locations of target stimuli.
Kempton et al. 1999; Rhodes
et al. 2004
Delayed Matching to Sample Percentage correct Tests the ability to remember the visual
features of a complex, abstract, target
stimulus and to select from a choice of
four patterns after a variable delay.
Kempton et al. 1999; Rhodes
et al. 2004
Paired Associates Learning Stage reached, total
errors, Total trials
Tests the ability to learn the locations of a
progressively increasing number of
abstract stimuli. The main measures in
this task are the number of trials taken to
complete the task and the total number
of errors across all trials.




Stage reached Tests the ability to focus attention on
speciﬁc attributes of compound stimuli
(intradimensional stages) and to shift
attention when required to a previously
irrelevant stimulus dimension
(extradimensional stages).
Kempton et al. 1999
Reaction Time Reaction time,
Movement time
Tests reaction and movement times in
response to a stimulus under a simple
one-choice and a ﬁve-choice condition.
Sahakian & Owen, 1992
ID-ED, Intradimensional-extradimensional set-shifting.
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There was a signiﬁcant group diﬀerence in
performance on the Spatial Span task with AD-
HKD boys obtaining a lower Spatial Span score
than control boys [F(1, 142)=9.89, p<0.002,
d=0.6]. AD-HKD boys also made more be-
tween-search errors on the spatial working
memory task [F(1, 142)=18.8, p<0.001, d=
0.75]. There was a signiﬁcant interaction
between group and diﬃculty level and post hoc
tests revealed that AD-HKD boys made more
errors at the 8-box stage relative to the 3-, 4- or
6-box stages. AD-HKD boys also had higher
(impaired) strategy scores [F(2, 142)=16.52,
p<0.001, d=0.70] but there were no diﬀerences
in within-search errors [F(1, 142)=1.5, p>0.05].
AD-HKD boys solved fewer problems in the
minimum number of moves on the SoC task
[F(1, 142)=4.7, p<0.03, d=0.38] but there was
no signiﬁcant diﬀerence in the average moves
made [F(1, 141)=3.5, p>0.05] and no signiﬁ-
cant interaction between group and diﬃculty
level in average moves [F(2.3, 321)=1.6,
p>0.05]. There was no signiﬁcant overall
diﬀerence between the two groups with respect
to either initial [F(1, 141)=1.1, p>0.05] or sub-
sequent [F(1, 141)<1] thinking times but there
was a signiﬁcant interaction between group and
diﬃculty level [F(2.5, 349)=3.8, p<0.02] for
subsequent but not for initial [F(1.7, 236)<1]
thinking times. Planned contrasts revealed that
controls had longer subsequent thinking times
for 5-move problems relative to 3-move prob-
lems (p<0.01).
AD-HKD boys made fewer correct responses
on the Pattern Recognition task (z=x5.267,
p<0.001, d=0.89) but latencies for correct
responses did not diﬀer. AD-HKD boys had
shorter response latencies for incorrect choices.
Table 4. Summary of ﬁndings
Measure
AD-HKD Controls










Errors for Distractors (Block 1) 2.31 (1.5) 2.4 (1.42) 2.23 (1.35) 2.13 (1.56) N.S.
Errors for Distractors (Block 2) 2.21 (1.66) 2.27 (1.59) 1.94 (1.46) 1.88 (1.65) N.S.
Reaction time to Targets B1 (log10) 2.66 (0.09) 2.66 (0.08) 2.64 (0.08) 2.64 (0.09) N.S.
Reaction time to Targets B2 (log10) 2.67 (0.09) 2.66 (0.08) 2.64 (0.08) 2.64 (0.09) N.S.
Spatial Span
Span Score 5.08 (1.47) 5.08 (1.26) 5.93 (1.5) 5.94 (1.47) ** 0.57 0.6
Spatial Working Memory
Total between-search errors 50.71 (19.49) 50.84 (21.0) 35.13 (20.7) 34.99 (21.82) *** 0.77 0.75
Strategy score 36.31 (4.54) 36.32 (5.11) 32.74 (5.17) 32.73 (5.28) *** 0.73 0.70
Stockings of Cambridge
No. solved in minimum moves 7.13 (2.04) 7.2 (2.11) 8.07 (2.01) 7.99 (2.17) * 0.46 0.38
Pattern Recognition
% Correct 0.70 81.29 (11.71) 90.95 (8.37) 90.4 (12.12) *** 0.92 0.89
Spatial Recognition
% Correct 0.70 68.21 (13.9) 77.64 (13.68) 78.2 (13.8) *** 0.89 0.72
Delayed Matching to Sample
Simultaneous 90.93 (15.5) 90.77 (12.38) 97.14 (7.03) 97.32 (1.53) ** 0.53 0.52
Delay (0, 4+12) 59.38 (18.8) 59.52 (17.84) 75.81 (17.66) 75.66 (17.91) *** 0.91 0.90
Paired Associates Learning
Stage reached 7.96 (0.26) 7.96 (0.26) 7.97 (0.24) 7.97 (0.25) N.S.
Total errors 11.61 (11.5) 11.14 (9.71) 6.71 (7.1) 7.22 (10.39) ** 0.51 0.47
Total trials 12.76 (4.09) 12.61 (4.07) 10.7 (2.93) 10.86 (3.89) ** 0.57 0.58
ID-ED
Stage reached 7.55 (1.08) 7.5 (1.04) 7.94 (0.97) 7.99 (1.13) * 0.38 0.46
Reaction Time
Reaction time latency (5 choice) 2.61 (0.13) 2.62 (0.09) 2.58 (0.11) 2.57 (0.17) * 0.24 0.71
Movement time latency (5 choice) 2.61 (0.14) 2.63 (0.26) 2.55 (0.34) 2.53 (0.25) * 0.23 0.39
ID-ED, Intradimensional-extradimensional set-shifting.
* p<0.05, ** p<0.05, *** p<0.001.
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However, regression analysis revealed that the
latencies for incorrect responses did not
predict overall accuracy of responding for the
AD-HKD.
AD-HKD boys obtained a lower percentage
of correct responses on the Spatial Recognition
task [F(2, 142)=17.4, p<0.001, d=0.72]. There
was no signiﬁcant diﬀerence in latencies for
correct responses [F(1, 142)=1.07, p>0.05], but
AD-HKD boys had shorter latencies to respond
when making incorrect choices [F(1, 141)=13.9,
p<0.001]. Again, however, regression analysis
revealed that latencies for incorrect responses
did not predict overall accuracy of responding
for the AD-HKD boys [F(1, 72)<1].
AD-HKD boys demonstrated deﬁcits at both
the simultaneous and delay conditions of the
Delayed Matching to Sample task. There was
a signiﬁcant interaction between performance
accuracy and duration of task delay [F(2, 284)=
4.7, p<0.01] and AD-HKD boys made fewer
correct responses with increasing delay, whilst
control boys performed equally across all de-
lays. This performance deﬁcit was not explained
by diﬀerences in response latency on the task.
Groups did not diﬀer as to the Stage Reached
on the Paired Associates Learning task
[F(1, 142)<1]. AD-HKD boys, however, made
more errors [z=x2.9, p<0.003, d=0.47] and
required more trials [z=x3.7, p<0.001,
d=0.58].
AD-HKD boys achieved lower stage-reached
scores on the Intradimensional-Extradimen-
sional Set-Shifting (ID-ED) attentional set-
shifting task [F(1, 142)=7.0, p<0.009, d=0.46].
They made more errors prior to the ED shift
stage [F(1, 142)=10.17, p<0.002]. Fewer AD-
HKD boys completed the ED shift stage
[F(1, 142)=6.7, p<0.01], and examination of
errors made by boys who did reach the ED
Reversal stage (AD-HKD boys, n=26; control
boys, n=40), revealed that AD-HKD boys
made more errors at this stage [F(1, 63)=5.4,
p<0.02].
Groups diﬀered signiﬁcantly at the most
complex (5-choice) condition of the Reaction
Time task. AD-HKD boys were slower to re-
spond than controls both in terms of reaction
times [F(1, 133)=5.5, p<0.02, d=0.71] and
movement times [F(1, 133)=3.94, p<0.05, d=
0.39]. Groups did not diﬀer in reaction or move-
ment times at the simple condition (both F<1).
In view of the group diﬀerences in BPVS
scores a further analysis was conducted on a
subset of the sample comprising 47 AD-HKD
boys and 47 controls matched for age and
BPVS. This broadly conﬁrmed ﬁndings for the
total group analyses above. Some diﬀerences
narrowly failed to reach statistical signiﬁcance
[SoC number of problems solved in minimum
moves (F=3.66, p=0.059) ; total errors on the
Paired Associates Learning task (F=3.33,
p=0.07) ; and stage reached on the ID-ED task
(F=2.87, p=0.09) ; and movement time latency
on the 5-choice condition of the Reaction Time
task (F=3.81, p=0.054). It is likely that these
ﬁndings simply reﬂect reduced statistical power
due to smaller sample size.
Inter-relationships among tasks
To further examine the role of short-term
memory span, strategy, and spatial recognition
memory on spatial working memory perform-
ance, correlations were conducted between these
variables and total between-search errors (BSE)
on the Spatial Working Memory task. In view
of the multiple comparisons a was adjusted to
0.008. Spatial short-term memory span corre-
lated signiﬁcantly with BSE for AD-HKD boys
(r=x0.473, p<0.001) and control boys (r=
x0.533, p<0.001). Strategy score was signiﬁ-
cantly correlated with total BSE for both AD-
HKD boys (r=0.513, p<0.001) and control
boys (r=0.588, p<0.001). Accuracy on the
Spatial Recognition task was also correlated
with total BSE for the control (r=x0.351,
p<0.001) but not the AD-HKD (r=x0.253,
p<0.05) group.
In view of the signiﬁcant correlations between
several task measures and performance on the
Spatial Working Memory task, exploratory
multiple regression analyses were performed.
BSE score was the dependent variable and
short-term memory span, strategy score and
spatial recognition score were the predictors.
Separate analyses, using a backward deletion
entry method, were carried out for the AD-
HKD boys and the control boys. Spatial span
and strategy score were retained in the best ﬁt
equation for both groups. For AD-HKD boys
these two variables together accounted for
approximately 37% of the total variance
[r2=0.372, F(2, 72)=21.3, p<0.001]. For the
control boys, these two variables predicted for
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approximately 49% of the total variance
[r2=0.493, F(2, 68)=33.0, p<0.001]. Accuracy
on the spatial recognition task did not predict
performance on the Spatial Working Memory
task for either group. There was no evidence of
signiﬁcant multi-co-linearity and the similarities
of the values of r2 and the adjusted r2 suggest
that the models are generalizable. Part correla-
tions indicate that both span and strategy score
make independent contributions to BSE score
for both the AD-HKD (span r2=0.11, strategy
r2=0.15) and control (span r2=0.15, strategy
r2=0.21) groups.
DISCUSSION
These data conﬁrm and extend those published
previously (Rhodes et al. 2004). AD-HKD boys
showed profound impairments of EF in terms of
visual working memory, strategy formation,
planning, attentional set-shifting and were sig-
niﬁcantly slowed on a reaction time task.
Contrary to predictions, inhibitory performance
on a Go/No-Go task was unimpaired. Our data
suggest that EF impairments cannot be ex-
plained on the basis of inhibitory dysfunction.
Additionally, profound neuropsychological im-
pairment was evident in aspects of non-executive
neuropsychological functioning. AD-HKDboys
showed impairments in tasks assessing recog-
nition of patterns and spatial locations, spatial
short-term memory span, visual recognition
memory, and a spatial delayed response task.
Perhaps most importantly, these impairments in
executive and non-executive functioning cannot
be attributed to exposure to stimulant medica-
tions, nor can they be accounted for by diﬀer-
ences in verbal intelligence.
Several aspects of the present study design
may account for the important diﬀerences be-
tween these data and those from other studies.
Our sample was considerably larger than those
previously reported, hence the power to detect
diﬀerences between AD-HKD boys and healthy
boys was increased. One possible consequence
of this increased power would be to report
statistically signiﬁcant, but clinically irrelevant,
diﬀerences between the groups. However, we do
not believe this to be the case in the current
sample. The eﬀect sizes reported above were all
in the medium to strong range and are broadly
consistent with those reported in the existing
literature (Pennington & Ozonoﬀ, 1996). In
addition to meeting DSM-IV criteria for
ADHD, the boys in this study also met criteria
for the more rigorously deﬁned hyperkinetic
disorder as described in ICD-10. Previous
studies have, arguably, recruited more homo-
geneous populations by excluding subjects with
co-morbid conditions. Future studies will need
to compare neuropsychological functioning
across the phenotypic spectrum and to include
additional tasks which measure other important
processes such as delay aversion and time per-
ception (Castellanos & Tannock, 2002).
EF changes in AD-HKD boys encompass
working memory, strategy formation, planning,
attentional set-shifting abilities and reaction
times. The Spatial Working Memory deﬁcit has
previously been described (Rhodes et al. 2004).
This deﬁcit was negatively correlated with
Spatial Span; shorter spans were associated
with a greater number of Between Search
Errors. Kempton and co-workers (1999) re-
ported similar correlations between these tasks
and concluded that impairment was related to a
decreased ability to hold multiple elements of
spatial information in memory rather than an
inability to manipulate this information. Unlike
the Kempton study, however, we found impair-
ments in strategy use. Further, strategy use was
signiﬁcantly correlated with between-search
error score. Multiple regression analysis con-
ﬁrmed that both Spatial Span and strategy
score, alongwith performance on theGo/No-Go
task, correlated signiﬁcantly with Spatial
Working Memory total task variance for both
groups. However, in view of the lack of impair-
ments detected on the Go/No-Go task, it is
unlikely that inhibition deﬁcits contribute sig-
niﬁcantly. Thus, the Spatial Working Memory
impairment is more likely related to a deﬁcit in
spatial short-term memory span and/or strategy
formation. Interestingly, performance on the
Spatial Recognition task, considered to be an
intrinsic component of the Spatial Working
Memory task and thus a developmental pre-
requisite for accurate performance, was not
predictive of accuracy on Spatial Working
Memory. Thus, recognition impairment does
not appear to explain the working memory
impairments of the AD-HKD boys.
AD-HKD boys had slower reaction times and
were impaired in terms of planning ability and
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solved fewer problems in the minimum required
moves on the SoC task. SoC performance acti-
vates the PFC and connecting areas including
the anterior cingulate, striatum, thalamus, and
cerebellum (Morris et al. 1993; Baker et al.
1996; Elliott et al. 1997). AD-HKD boys also
had lower stage-reached scores on the ID-ED
attentional set-shifting task and evident diﬃ-
culty at the Extra-Dimensional stages. This
pattern supports suggestions that frontal lobe
functioning is impaired (Owen et al. 1991). In
particular, these data implicate the anterior
frontal lobe (Rogers et al. 2000) and support,
to an extent, existing dysexecutive models of
AD-HKD (Morton & Frith, 1995; Castellanos
& Tannock, 2002).
However, in marked contrast to previous
studies (e.g. Shue & Douglas, 1992; Iaboni
et al. 1995; Rubia et al. 1999a, b ; 2001a, b ;
Castellanos et al. 2000), AD-HKD boys per-
formed as well as controls on a Go/No-Go task.
One possible criticism of our Go/No-Go task is
the relatively high presentation rate of No-Go
stimuli (50%). Some positive studies have used
lower No-Go rates (e.g. Van der Meere et al.
1999, 20%; Rubia et al. 2001a, 30%) and it is,
therefore, possible that the task used in the
present study may have been less likely to tax
inhibitory processes. However, as several posi-
tive studies using a Go/No-Go task have used
the same 50%No-Go presentation rate (Shue &
Douglas, 1992; Iaboni et al. 1995; Castellanos
et al. 2000) it seems unlikely that diﬀerences in
this task parameter alone could account for our
data. There are, of course, several task para-
meters that inﬂuence performance. We utilized a
fast presentation rate with an inter-stimulus in-
terval of 900 ms – a rate which previous studies
have shown to be particularly sensitive in de-
tecting impairments in children with AD-HKD
(Van der Meere et al. 1999). It also seems
unlikely that the lack of impairment on the Go/
No-Go in our sample was due to sampling dif-
ferences. Our sample of AD-HKD boys were
diagnosed as meeting the more restrictive ICD-
10 criteria for HD and were stimulant-medi-
cation-naive – both of which factors would
probably predict a greater level of impairment.
Thus whilst it remains possible that this task is
not sensitive to the type of response inhibition
that is impaired in AD-HKD, we can see no
obvious simple explanations for the absence of
inhibitory impairments in our sample. The
design could be improved by including other
measures of inhibitory ability, such as the Stop
Signal Task, and further studies comparing
performance on CANTAB tasks with such
measures are indicated.
It has been suggested that impairments
observed in aspects of EF other than inhibition
in AD-HKD are, in fact, secondary to impaired
inhibitory responding (Barkley, 1998). Our
ﬁndings, whilst not ruling out inhibitory dys-
function as a component of AD-HKD, do sug-
gest that inhibitory deﬁcits cannot solely
account for the range of executive impairments
observed in these children.
Our data do not support earlier con-
ceptualizations of AD-HKD as a dysfunction in
a single aspect of EF. They do, however, sup-
port the growing literature suggesting impair-
ment across a range of EF (e.g. Kempton et al.
1999; Nigg et al. 2002; Tripp et al. 2002).
Development of future models, or reﬁnement of
existing models of EF must incorporate the
range and complexity of interacting systems
involved. Further, our data implicate non-
executive neuropsychological impairments as
important features of AD-HKD. We have
shown impairments on a range of tasks without
a prominent executive component. Whilst im-
pairment on the Spatial Recognition task may
mirror the performance of frontal lobe damaged
patients on this task (Owen et al. 1995), the in-
tact performance of lesion patients on Pattern
Recognition and Delayed Matching to Sample
(Owen et al. 1995) diﬀers from our AD-HKD
boys. In fact, the performance of AD-HKD
boys on these tasks more closely mirrors that of
patients with temporal lobe and amygdalo-
hippocampal damage. We have, as above, con-
sidered the possibility that these deﬁcits may
reﬂect inhibitory dysfunction. AD-HKD boys
were more impulsive when responding in-
correctly on both tasks. However, latencies for
incorrect responding did not predict accuracy of
responding on either task. Consequently, as
with the EF deﬁcits described above, these
impairments are unlikely to be solely ascribable
to impaired inhibitory responding.
These deﬁcits in executive and non-executive
functioning cannot be accounted for by diﬀer-
ences between the two groups with respect to
their levels of verbal intelligence. Despite there
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being a scheduled break at the mid-point of the
testing session and subjects being given the
opportunity to take further breaks if required
we cannot however rule out the possibility that a
proportion of the observed deﬁcit was related to
fatigue eﬀects in those tasks carried out later in
the testing session.
Our data suggest a potentially important role
for the temporal lobes, the amgydala and/or
hippocampus in the neuropsychological deﬁcits
found with AD-HKD. These are consistent
with a recent structural MRI study describing
reduced white and gray matter volumes in tem-
poral, parietal, and occipital areas in addition to
frontal areas (Castellanos et al. 2002). Hence,
neuropsychological and structural brain imag-
ing data suggest that AD-HKD is rather more
than a ‘frontostriatal ’ disorder of monoamin-
ergic neurocircuitry. Unfortunately, although
the current sample is considerably larger than
those previously reported in the AD-HKD lit-
erature, it is not suﬃciently large to conduct a
reliable exploratory factor analysis to search
for latent variables or fully to explore for het-
erogeneity. These analyses will be crucial in
furthering our understanding of the neuro-
psychological underpinnings of AD-HKD.
ACKNOWLEDGEMENTS
We thank M. Thrower, K. Antonson, A.
Brown, J. Esperon, K. Walker, and S. Trudu for
assistance.
DECLARATION OF INTEREST
This work was supported by a local trust
through a TENOVUS-Scotland initiative. D.C.
is on the speakers’ panel for, and has received
consultancy fees, sponsored conference attend-
ance and research funding from Celltech, Eli
Lilly and Janssen-Cilag, all of whom manufac-
ture medication for treating ADHD.
REFERENCES
Achenbach, T. M., Howell, C. T., Quay, H. C. & Conners, C. K.
(1991). National survey of problems and competencies among
four- to sixteen- year-olds : parents’ reports for normative and
clinical samples. Monographs of the Society for Research in Child
Development 56, 1–131.
Aman, C. J., Roberts, R. J., Jr & Pennington, B. F. (1998). A neuro-
psychological examination of the underlying deﬁcit in attention
deﬁcit hyperactivity disorder : frontal lobe versus right parietal
lobe theories. Developmental Psychology 34, 956–969.
APA (1994). Diagnostic and Statistical Manual of Mental Disorders
(4th edn) (DSM-IV). American Psychiatric Association : Wash-
ington, DC.
Baker, S. C., Rogers, R. D., Owen, A. M., Frith, C. D., Dolan, R. J.,
Frackowiak, R. S. & Robbins, T. W. (1996). Neural systems
engaged by planning: a PET study of the Tower of London task.
Neuropsychologia 34, 515–526.
Barkley, R. A. (1998). A theory of ADHD: inhibition, executive
functions, self-control, and time. In Attention-Deﬁcit Hyperactivity
Disorder: A Handbook for Diagnosis and Treatment (Anon), pp.
225–260. Guildford Press: New York.
Barkley, R. A., Fischer, M., Smallish, L. & Fletcher, K. (2004).
Young adult follow-up of hyperactive children: antisocial
activities and drug use. Journal of Child Psychology and Psychiatry
45, 195–211.
Braun, D., Weber, H., Mergner, T. & Schulte-Monting, J. (1992).
Saccadic reaction times in patients with frontal and parietal
lesions. Brain 115, 1359–1386.
Castellanos, F. X. & Tannock, R. (2002). Neuroscience of attention-
deﬁcit hyperactivity disorder: the search for endophenotypes.
Nature Reviews Neuroscience 3, 617–628.
Castellanos, F. X., Elia, J., Kruesi, M. J. P., Marsh, W. L., Gulotta,
C. S., Potter, W. Z., Ritchie, G. F., Hamburger, S. D., Rapoport,
J. L. & Kruesi, M. J. (1996a). Cerebrospinal homovanillic acid
predicts behavioral response to stimulants in 45 boys with atten-
tion-deﬁcit/hyperactivity disorder. Neuropsychopharmacology 14,
125–137.
Castellanos, F. X., Giedd, J. N., Marsh, W. L., Hamburger, S. D.,
Vaituzis, A. C., Dickstein, D. P., Sarfatti, S. E., Vauss, Y. C., Snell,
J. W., Lange, N., Kaysen, D., Krain, A. L., Ritchie, G. F.,
Rajapakse, J. C. & Rapoport, J. L. (1996b). Quantitative brain
magnetic resonance imaging in attention-deﬁcit/hyperactivity dis-
order. Archives of General Psychiatry 53, 607–616.
Castellanos, F. X., Lee, P. P., Sharp, W., Jeﬀries, N. O., Greenstein,
D. K., Clasen, L. S., Blumenthal, J. D., James, R. S., Ebens, C. L.,
Walter, J. M., Zijdenbos, A., Evans, A. C., Giedd, J. N. &
Rapoport, J. L. (2002). Developmental trajectories of brain vol-
ume abnormalities in children and adolescents with attention-
deﬁcit/hyperactivity disorder. Journal of the American Medical
Association 288, 1740–1748.
Castellanos, F. X., Marvasti, F. F., Ducharme, J. L., Walter, J. M.,
Israel, M. E., Krain, A. L., Pavlovsky, C. & Hommer, D. W. (2000).
Executive function oculomotor tasks in girls with ADHD. Journal
of the American Academy of Child and Adolescent Psychiatry 39,
644–650.
Conners, C. K. (1997a). Conners’ Rating Scales–Revised Technical
Manual. Multi-Health Systems, Inc. : North Tonawanda, NY.
Conners, C. K. (1997b). Conners’ Rating Scales–Revised User’s
Manual. Multi-Health Systems, Inc. : North Tonawanda, NY.
Curtis, W. J., Lindeke, L. L., Georgieﬀ, M. K. & Nelson, C. A.
(2002). Neurobehavioural functioning in neonatal intensive care
unit graduates in late childhood and early adolescence. Brain 125,
1646–1659.
Denney, C. B. & Rapport, M. D. (2001). Cognitive pharmacology of
stimulants in children with ADHD. In Stimulant Drugs and
ADHD: Basic and Clinical Neuroscience (ed. M. V. Solanto,
A. F. T. Arnsten and F. X. Castellanos), pp. 283–302. Oxford
University Press : New York.
Doyle, A. E., Biederman, J., Seidman, L. J., Weber, W. & Faraone,
S. V. (2000). Diagnostic eﬃciency of neuropsychological test
scores for discriminating boys with and without attention deﬁcit-
hyperactivity disorder. Journal of Consulting and Clinical
Psychology 68, 477–488.
Dunn, L., Dunn, L., Whetton, C. & Burley, J. (1997). British Picture
Vocabulary Scale (2nd edn). NFER-Nelson: London.
Elliott, R., Sahakian, B. J., Matthews, K., Bannerjea, A., Rimmer, J.
& Robbins, T. W. (1997). Eﬀects of methylphenidate on spatial
working memory and planning in healthy young adults. Psycho-
pharmacology (Berlin) 131, 196–206.
1118 S. M. Rhodes et al.
511
Ernst, M., Zametkin, A. J., Matochik, J. A., Jons, P. H. & Cohen,
R. M. (1998). DOPA decarboxylase activity in attention deﬁcit
hyperactivity disorder adults. A [ﬂuorine-18]ﬂuorodopa positron
emission tomographic study. Journal of Neuroscience 18, 5901–
5907.
Filipek, P. A., Semrud-Clikeman, M., Steingard, R. J., Renshaw,
P. F., Kennedy, D. N. & Biederman, J. (1997). Volumetric MRI
analysis comparing subjects having attention-deﬁcit hyperactivity
disorder and normal controls. Neurology 48, 589–601.
Fray, P. J. & Robbins, T. W. (1996). CANTAB battery: proposed
utility in neurotoxicology. Neurotoxicology and Teratology 18,
499–504.
Giedd, J. N., Blumenthal, J., Molloy, E. & Castellanos, F. X. (2001).
Brain imaging of attention deﬁcit/hyperactivity disorder. Annals of
the New York Academy of Sciences 931, 33–49.
Goldman-Rakic, P. S. (1996). The prefrontal landscape: implications
of functional architecture for understanding human mentation
and the central executive. Philosophical Transactions of the Royal
Society of London Series B – Biological Sciences 351, 1445–1453.
Hechtman, L. (1992). Long-term outcome in attention-deﬁcit hyper-
activity disorder. Child and Adolescent Psychiatric Clinics of North
America 1, 553–565.
Hughes, C., Plumet, M. H. & Leboyer, M. (1999). Towards a cogni-
tive phenotype for autism: increased prevalence of executive dys-
function and superior spatial span amongst siblings of children
with autism. Journal of Child Psychology and Psychiatry 40,
705–718.
Iaboni, F., Douglas, V. I. & Baker, A. G. (1995). Eﬀects of reward
and response costs on inhibition in ADHD children. Journal of
Abnormal Psychology 104, 232–240.
Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P.,
Williamson, D. & Ryan, N. (1997). Schedule for aﬀective disorders
and schizophrenia for school-age children – present and lifetime
version (K-SADS-PL) : initial reliability and validity data. Journal
of the American Academy of Child and Adolescent Psychiatry 36,
980–988.
Kaufman, J., Birmaher, B., Brent, D., Rao, U. & Ryan, N. (1996).
Diagnostic interview. Kiddie-SADS – present and lifetime version
(K-SADS-PL). Screen interview [Anonymous].
Kempton, S., Vance, A., Maruﬀ, P., Luk, E., Costin, J. & Pantelis, C.
(1999). Executive function and attention deﬁcit hyperactivity
disorder : stimulant medication and better executive function
performance in children. Psychological Medicine 29, 527–538.
Klein, R. G. & Mannuzza, S. (1991). Long-term outcome of hyper-
active children: a review. Journal of the American Academy of
Child and Adolescent Psychiatry 30, 383–387.
Luciana, M. & Nelson, C. A. (1998). The functional emergence of
prefrontally-guided working memory systems in four- to eight-
year-old children. Neuropsychologia 36, 273–293.
Luria, A. (1996). Human Brain and Psychological Processes. Harper
& Row: New York.
Mehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard,
J. D. & Robbins, T. W. (2000). Methylphenidate enhances working
memory by modulating discrete frontal and parietal lobe regions
in the human brain. Journal of Neuroscience 20 : RC65 (6), 1–6.
Meltzer, H., Goodman, R. & Ford, T. (2000). Mental health of
children and adolescents in Great Britian. HMSO: London.
Milner, B. (1971). Interhemispheric diﬀerences in the localization of
psychological processes in man. British Medical Bulletin 27,
272–277.
Morris, R. G., Ahmed, S., Syed, G. M. & Toone, B. K. (1993). Neural
correlates of planning ability: frontal lobe activation during the
Tower of London test. Neuropsychologia 31, 1367–1378.
Morris, R. C., Evendon, J. L., Sahakian, B. J. & Robbins, T. W.
(1987). Computer-aided assessment of dementia : comparative
studies of neuropsychological deﬁcits in Alzheimer-type dementia
and Parkinson’s disease. In Cognitive Neurochemistry (ed. S. M.
Stahl, S. D. Iversen and E. C. Goodman), pp. 21–36. Oxford
University Press : Oxford.
Morton, J. & Frith, U. (1995). Causal modeling: a structural
approach to developmental psychopathology. In Developmental
Psychopathology (ed. D. Cicchetti and D. J. Cohen), pp. 357–390.
John Wiley : New York.
Murphy, K. & Barkley, R. A. (1996). Attention deﬁcit hyperactivity
disorder adults : comorbidities and adaptive impairments. Com-
prehensive Psychiatry 37, 393–401.
Nigg, J. T., Blaskey, L. G., Huang-Pollock, C. L. & Rappley, M. D.
(2002). Neuropsychological executive functions and DSM-IV
ADHD subtypes. Journal of the American Academy of Child and
Adolescent Psychiatry 41, 59–66.
Nigg, J. T., Blaskey, L. G., Stawicki, J. & Sachek, J. (2004).
Evaluating the endophenotype model of ADHD neuropsy-
chological deﬁcit : results for parents and siblings of children with
DSM-IV ADHD combined and inattentive subtypes. Journal of
Abnormal Psychology 113, 614–625.
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E. &
Robbins, T. W. (1990). Planning and spatial working memory
following frontal lobe lesions in man. Neuropsychologia 28, 1021–
1034.
Owen, A. M., Roberts, A. C., Polkey, C. E., Sahakian, B. J.
& Robbins, T. W. (1991). Extra-dimensional versus intra-
dimensional set shifting performance following frontal lobe exci-
sions, temporal lobe excisions or amygdalo-hippocampectomy in
man. Neuropsychologia 29, 993–1006.
Owen, A. M., Sahakian, B. J., Semple, J., Polkey, C. E. & Robbins,
T. W. (1995). Visuo-spatial short-term recognition memory and
learning after temporal lobe excisions, frontal lobe excisions or
amygdalo-hippocampectomy in man. Neuropsychologia 33, 1–24.
Pennington, B. F. & Ozonoﬀ, S. (1996). Executive functions and
developmental psychopathology. Journal of Child Psychology and
Psychiatry and Allied Disciplines 37, 51–87.
Petrides, M. & Milner, B. (1982). Deﬁcits on subject-ordered tasks
after frontal- and temporal-lobe lesions in man. Neuropsychologia
20, 249–262.
Pliszka, S. R., McCracken, J. T. & Maas, J. W. (1996).
Catecholamines in attention-deﬁcit hyperactivity disorder: current
perspectives. Journal of the American Academy of Child and
Adolescent Psychiatry 35, 264–272.
Rhodes, S. M., Coghill, D. R. & Matthews, K. (2004).
Methylphenidate restores visual memory, but not working
memory function in attention deﬁcit – hyperkinetic disorder.
Psychopharmacology 175, 319–330.
Robbins, T. W., James, M., Owen, A. M., Sahakian, B. J., McInnes,
L. & Rabbitt, P. (1994). Cambridge Neuropsychological Test
Automated Battery (CANTAB): a factor analytic study of a large
sample of normal elderly volunteers. Dementia 5, 266–281.
Rogers, R. D., Andrews, T. C., Grasby, P. M., Brooks, D. J. &
Robbins, T. W. (2000). Contrasting cortical and subcortical
activations produced by attentional-set shifting and reversal
learning in humans. Journal of Cognitive Neuroscience 12, 142–
162.
Rubia, K., Overmeyer, S., Taylor, E., Brammer, M., Williams, S. C.,
Simmons, A. & Bullmore, E. T. (1999a). Hypofrontality in atten-
tion deﬁcit hyperactivity disorder during higher-order motor con-
trol : a study with functional MRI. American Journal of Psychiatry
156, 891–896.
Rubia, K., Russell, T., Overmeyer, S., Brammer, M. J., Bullmore,
E. T., Sharma, T., Simmons, A., Williams, S. C., Giampietro, V.,
Andrew, C. M. & Taylor, E. (2001a). Mapping motor inhibition:
conjunctive brain activations across diﬀerent versions of go/no-go
and stop tasks. Neuroimage 13, 250–261.
Rubia, K., Taylor, A., Taylor, E. & Sergeant, J. A. (1999b).
Synchronization, anticipation, and consistency in motor timing of
children with dimensionally deﬁned attention deﬁcit hyperactivity
behaviour. Perceptual and Motor Skills 89, 1237–1258.
Rubia, K., Taylor, E., Smith, A. B., Oksanen, H., Overmeyer, S.,
Newman, S. & Oksannen, H. (2001b). Neuropsychological analy-
ses of impulsiveness in childhood hyperactivity. British Journal of
Psychiatry 179, 138–143.
Sahakian, B. J. & Owen, A. M. (1992). Computerized assessment in
neuropsychiatry using CANTAB: discussion paper. Journal of the
Royal Society of Medicine 85, 399–402.
Neuropsychological functioning and hyperkinetic disorder 1119
512
Schachar, R. & Tannock, R. (2002). Syndromes of hyperactivity
and attention deﬁcit. In Child and Adolescent Psychiatry
(4th edn) (ed. M. Rutter and E. Taylor), pp. 399–418. Blackwell :
Oxford.
Scheres, A., Oosterlaan, J. & Sergeant, J. A. (2001). Response
inhibition in children with DSM-IV subtypes of AD/HD and
related disruptive disorders : the role of reward. Child Neuro-
psychology 7, 172–191.
Seidman, L. J., Biederman, J., Faraone, S. V., Weber, W. &
Ouellette, C. (1997). Toward deﬁning a neuropsychology of
attention deﬁcit-hyperactivity disorder : performance of children
and adolescents from a large clinically referred sample. Journal of
Consulting and Clinical Psychology 65, 150–160.
Shallice, T. (1982). Speciﬁc impairments of planning. Philosophical
Transactions of the Royal Society of London, B – Biological
Sciences 298 (1089), 199–209.
Shue, K. L. & Douglas, V. I. (1992). Attention deﬁcit hyperactivity
disorder and the frontal lobe syndrome. Brain and Cognition 20,
104–124.
Solanto, M. V., Arnsten, A. F. T. & Castellanos, F. X. (2001). The
neuroscience of stimulant drug action in ADHD. In Stimulant
Drugs and ADHD: Basic and Clinical Neuroscience (ed. M. V.
Solanto, A. F. T. Arnsten and F. X. Castellanos), pp. 355–379.
Oxford University Press : New York.
Sonuga-Barke, E. J. (2002). Psychological heterogeneity in AD/
HD – a dual pathway model of behaviour and cognition.
Behavioral Brain Research 130, 29–36.
Swanson, J. M., Sergeant, J. A., Taylor, E., Sonuga-Barke,
E. J., Jensen, P. S. & Cantwell, D. P. (1998). Attention-deﬁcit
hyperactivity disorder and hyperkinetic disorder. Lancet 351
(9100), 429–433.
Tannock, R. (1998). Attention deﬁcit hyperactivity disorder: ad-
vances in cognitive, neurobiological, and genetic research. Journal
of Child Psychology and Psychiatry and Allied Disciplines 39,
65–99.
Taylor, E. (1994). Syndromes of attention deﬁcit and overactivity. In
Child and Adolescent Psychiatry, Modern Approaches (3rd edn)
(ed. M. Rutter, L. Hersov and E. Taylor), pp. 285–307. Blackwell :
Oxford.
Tripp, G., Ryan, J. & Peace, K. (2002). Neuropsychological func-
tioning in children with DSM-IV combined type attention deﬁcit
hyperactivity disorder. Australian and New Zealand Journal of
Psychiatry 36, 771–779.
Van der Meere, J., Gunning, B. & Stemerdink, N. (1999). The eﬀect of
methylphenidate and clonidine on response inhibition and state
regulation in children with ADHD. Journal of Child Psychology
and Psychiatry and Allied Disciplines 40, 291–298.
WHO (1992). The ICD-10 Classiﬁcation of Mental and Behavioural
Disorders. Diagnostic Criteria for Research. World Health Organi-
zation: Geneva.
Williams, D., Stott, C. M., Goodyer, I. M. & Sahakian, B. J.
(2000). Speciﬁc language impairment with or without hyper-
activity : neuropsychological evidence for frontostriatal dys-
function. Developmental Medicine and Child Neurology 42, 368–
375.
Winer, B. J., Brown, D. R. & Michels, K. M. (1991). Statistical
Principles in Experimental Design (3rd edn). McGraw-Hill : New
York.







Acute neuropsychological effects of methylphenidate in stimulant 
drug-naive boys with ADHD II – broader executive and non-
executive domains 
Rhodes, Coghill, & Matthews (2006) Journal of Child Psychology 




Acute neuropsychological effects of
methylphenidate in stimulant drug-naı¨ve boys
with ADHD II – broader executive and
non-executive domains
Sine´ad M. Rhodes, David R. Coghill and Keith Matthews
Section of Psychiatry and Behavioural Sciences, Division of Pathology and Neuroscience, University of Dundee,
Ninewells Medical School, Dundee, UK
Background: Accumulating evidence supports methylphenidate-induced enhancement of neuro-
psychological functioning in attention deficit hyperactivity disorder (ADHD). The present study was
designed to investigate the acute effects of the psychostimulant drug, methylphenidate (MPH), on
neuropsychological performance in stimulant naı¨ve boys with ADHD. Methods: Seventy-three drug-
naı¨ve boys (age 7–15) with ADHD (combined type) completed neuropsychological tasks from the
CANTAB battery under randomised, placebo controlled, double-blind conditions following an acute
challenge with either placebo (n ¼ 24), .3 (n ¼ 25) or .6 (n ¼ 24) mg/kg oral MPH. Results: MPH did
not impair performance on any task. MPH (.6 mg/kg) lengthened response latencies on a task of Spatial
Recognition, shortened response times on a Reaction Time task and restored performance on a Delayed
Matching to Sample visual, non-working memory task. Contrary to predictions, MPH did not enhance
performance on tasks with a prominent executive component, including Go/NoGo, Spatial Working
Memory, Stockings of Cambridge and Attentional Set shifting tasks. Conclusions: Acute administra-
tion of MPH to drug-naı¨ve boys with ADHD did not impair neuropsychological performance. Acute MPH
enhanced performance on some aspects of non-executive functioning. MPH-induced slowing of
responding on a relatively complex Spatial Recognition memory task and quickened responding on a
reaction time task requiring less cognitive resources suggests that MPH may act by improving
self-regulatory ability. MPH may not exert its effects on neuropsychological functioning by enhancing
executive processes. Keywords: ADHD, stimulant, methylphenidate, cognition, executive functioning,
self-regulation. Abbreviations: BPVS: British Picture Vocabulary Scale; CANTAB: Cambridge Auto-
mated Neuropsychological Testing Automated Battery; DMtS: Delayed Matching to Sample; ID/ED:
Intradimensional/Extradimensional shifting; K-SADS-PL: Kiddie-SADS Present and Lifetime; MPH:
methylphenidate; PAL: Paired Associates Learning; SOC: Stockings of Cambridge; SWM: Spatial
Working Memory.
Attention deficit hyperactivity disorder (ADHD) com-
bined type (DSM-IV – American Psychiatric Associ-
ation, 1994) is characterised by pervasive
behavioural symptoms of inattention, hyperactivity
and impulsivity. Hyperkinetic disorder (ICD-10 –
WorldHealthOrganisation, 1992) is amore restrictive
definition requiring higher degrees of pervasiveness
and impairment and, as such, describes those with
severe ADHD. Current models of ADHD and hyper-
kinetic disorder (collectively referred to here as
ADHD) emphasise a causal pathway from genetic
variations generating functional abnormalities in
dopaminergic and noradrenergic neurotransmission
within fronto-striatal circuitry leading to deficits in
executive neuropsychological functioning and, ulti-
mately, to the behavioural manifestations of ADHD
(Castellanos & Tannock, 2002).
A range of executive functioning deficits, includ-
ing inhibition (Barkley, 1997), working memory
(Rhodes, Coghill, & Matthews, 2004; Kempton et
al., 1999) attentional set shifting and planning
(Kempton et al., 1999; Rhodes, Coghill, & Mat-
thews, 2005) have been described in ADHD. Studies
utilising broad neuropsychological testing, such as
the Cambridge Automated Neuropsychological
Testing Automated Battery (CANTAB) (Robbins et
al., 1994), suggest that ADHD is associated with
deficits in non-executive as well as executive func-
tioning. These include tasks such as spatial re-
cognition and spatial span in addition to tasks
upon which performance depends on intact tem-
poral or parietal lobe function – Delayed Matching
to Sample (DMtS) and Pattern Recognition (Kemp-
ton et al., 1999; Rhodes et al., 2004). Further,
deficits in cerebellar timing tasks (Toplak, Ruck-
lidge, Hetherington, John, & Tannock, 2003) and in
delay aversion tasks for which the neuroanatomical
substrates are unclear (Sonuga-Barke, 2003) have
been described.
Conflict of interest statement: Dr David Coghill is an advisory
board member for Eli Lilly, Janssen Cilag, Shire, Cephalon and
UCB and has research funding from Eli Lilly and Janssen Ci-
lag. Prof. Keith Matthews and Dr Sinead Rhodes have nothing
to disclose.
Journal of Child Psychology and Psychiatry 47:11 (2006), pp 1184–1194 doi:10.1111/j.1469-7610.2006.01633.x
 2006 The Authors
Journal compilation  2006 Association for Child and Adolescent Mental Health.
Published by Blackwell Publishing, 9600 Garsington Road, Oxford OX4 2DQ, UK and 350 Main Street, Malden, MA 02148, USA
515
Despite this evidence for broad neuropsycho-
logical dysfunction in ADHD, prevailing models
continue to emphasise an assumed primacy of in-
hibitory and working memory deficits (Barkley,
1997; but see Coghill, Nigg, Rothenberger, Sonuga-
Barke, & Tannock, 2005; Castellanos & Tannock,
2002).
Stimulant medication, of which methylphenidate
(MPH) is the most widely studied (Greenhill, Hal-
perin, & Abikoff, 1999), remains the cornerstone of
the pharmacological management of children with
ADHD (Safer & Malever, 2000). However, an under-
standing of the relationship between the pharmaco-
logical actions of MPH and its therapeutic effects
remains elusive. A generalised, simplistic explana-
tion suggests that, since oral MPH at therapeutic
doses increase the availability of extracellular do-
pamine (Volkow et al., 2001) and executive func-
tioning can be modified by even small manipulations
in catecholamine release (Mehta, Sahakian, & Rob-
bins, 2001), the therapeutic effects of MPH in ADHD
may arise from catecholamine-mediated improve-
ments in executive functioning (Volkow et al., 2001).
Indeed, it has been proposed that MPH may act rel-
atively selectively to enhance executive functioning
(Mehta et al., 2000; Elliott et al., 1997). If deficits in
inhibitory control and working memory reflect the
core psychopathology of ADHD, and MPH acts as
above, performance on inhibition and working
memory tasks should improve following adminis-
tration of MPH. Numerous studies support this
hypothesis, whereby MPH appears to enhance
inhibitory control, reducing impulsive and variable
responding and errors on tasks with prominent
inhibitory components (e.g. Berman, Douglas, &
Barr, 1999; Shue & Douglas, 1992; Trommer, Ho-
eppner, & Zecker, 1991; Scheres et al., 2003).
However, other studies have failed to demonstrate
enhanced inhibitory performance in medicated
children with ADHD (Ross, Hommer, Breiger, Varley,
& Radant, 1994; Van der Meere, Gunning, &
Stemerdink, 1999).
The CANTAB test battery is increasing utilised in
child and adolescent neuropsychopharmacological
studies because of its extensive validation (Luciana,
2003; Curtis, Lindeke, Georgieff, & Nelson, 2002), its
availability in parallel forms for repeated testing, and
its sensitivity to pharmacological manipulation.
A previous controlled study in healthy adults (Elliott
et al., 1997) and previous controlled (Bedard, Mar-
tinussen, Ickowicz, & Tannock, 2004; Mehta, Goo-
dyer, & Sahakian, 2004) and uncontrolled (Kempton
et al., 1999; Barnett et al., 2001) studies in children
with ADHD have reported that MPH enhanced per-
formance on the CANTAB Spatial Working Memory
task but have reported inconsistent effects on other
tasks. Each of the ADHD studies has significant
methodological limitations which limit their
interpretation. The two earliest studies were both
uncontrolled and non-randomised (Barnett et al.,
2001; Kempton et al., 1999). The studies of Kempton
and colleagues (1999) and Mehta et al. (2004)
reported on small samples with non-standard
clinical assessment procedures. Also, both of the
previously reported controlled studies included
non-medication-naı¨ve subjects (Mehta et al., 2004;
Bedard et al., 2004) and utilised a within-subjects
crossover design which permits practice effects in
addition to potential carryover and/or withdrawal
effects of MPH.
The aim of the present study was to address these
methodological limitations. We have used a rand-
omised, placebo-controlled, double-blind, parallel
design in a large sample of rigorously diagnosed
medication-naı¨ve boys with ADHD. We have exam-
ined their neuropsychological responses to the first
administration of MPH using a broad range of range
neuropsychological tasks from the CANTAB battery.
We predicted that MPH would enhance performance
on a range of tasks with (Go/NoGo, SWM; SOC, ID/
ED), and without (e.g. Spatial Span, DMtS), a signi-
ficant executive component. MPH enhancement of
performance was further predicted to be dose-
dependent.
We have previously reported the effects of acute
MPH on the SWM, DMtS and Pattern Recognition
tasks from the CANTAB battery (Rhodes et al., 2004).
In this paper we reported that acute MPH did not
affect performance on the SWM Task; MPH had no
significant effect on Between or Within Search Errors
or Strategy Score. Acute MPH also did not affect
performance on the Pattern Recognition Task or
performance accuracy under simultaneous test
conditions of the DMtS task. In contrast, acute MPH
at a .6 mg/kg dose restored performance accuracy
across each of the delay conditions of the DMtS task
to the levels observed in healthy controls (see Rhodes
et al., 2004) and this improvement was not associ-
ated with significant changes in response latencies.
Impaired functioning, however, continued to be seen
across each delay condition with placebo and MPH
.3 mg/kg. Here we report the effects of acute MPH on
performance of the previously unpublished tasks
from the CANTAB battery and the Go/NoGo task.
Method
This study was approved by the Tayside Committee
on Medical Research Ethics. All participants and
their parents/guardians provided written informed
consent.
Participants
Seventy-three stimulant medication-naive boys parti-
cipated in the study. Participants were selected from
consecutive male outpatient referrals to the Tayside
Child and Adolescent Psychiatric Service (Tayside, UK).
There was a two-stage screening procedure. Potential
participants were first screened using the Child Beha-
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viour Checklist (Achenbach, 1991) and the Conners’
Parent and Teaching Rating Scales (Conners, 1997).
Participants with a T-score greater than 65 on all sub-
scales of the parent and teacher Conners’ Rating Scales
entered the second stage of screening. Thereafter, par-
ticipants were assessed and screened by an experi-
enced child and adolescent psychiatrist using the
Kiddie-SADS Present and Lifetime (K-SADS-PL) Version
1.0 semi-structured interview (Kaufman, Birmher,
Brent, Rao, & Ryan, 1996). Standardised school reports
covering in-school behaviours, with particular empha-
sis on impairments related to attention, impulsivity and
overactivity, relationships with peers and teachers and
academic performance, were requested for all cases.
Teachers were interviewed only in cases where there
were discrepancies between this information and par-
ent report. All of the diagnostic information was re-
viewed by a senior child and adolescent psychiatrist
(DC). The K-SADS-PL interviews were videoed and a
selection (every fifth interview) was also reviewed by DC
for reliability. Symptom ratings, impairment, pervasiv-
ity and duration of illness were collated and compared
to the research versions of ICD-10 and DSM-IV. All
participants met diagnostic criteria for both DSM-IV
Attention-Deficit/Hyperactivity Disorder, Combined
Type, and ICD-10 Hyperkinetic Disorder. Our intention
was to ensure recruitment of a group of children rep-
resentative of those seen in typical clinical practice.
Hence, the presence of comorbid conditions did not
result in exclusion from the study (see Table 1). All boys
completed the British Picture Vocabulary Scale (BPVS)
(Dunn, Dunn, Whetton, & Burley, 1997) [2nd Edition],
providing an estimate of general intellectual ability. The
BPVS assesses verbal intelligence and was chosen for
its ease of administration and ability to be used with
children aged between 3 and 15 (Dunn et al., 1997). It is
an individually administered, norm-referenced wide-
range test of receptive vocabulary for Standard English
which has been demonstrated to be significantly
correlated with verbal IQ.
There were no significant differences between treat-
ment groups with respect to age [F < 1], socioeconomic
deprivation score [F < 1], verbal intelligence (BPVS
Percentile Rank) [F < 1], or baseline performance on
parent-rated and teacher-rated ADHD composite scores
(Conners’ Scale) [both with F < 1] (Table 1). There were
also no significant differences with respect to the pres-
ence of comorbid disorders other than separation
anxiety disorder [F ¼ 3.4, p < .04]. All three boys dia-
gnosed with this comorbid condition were in the treat-
ment group taking placebo. Separation anxiety disorder
is not considered to be associated with neuropsycho-
logical impairment.
Procedure
All participants were tested on two occasions: at base-
line (drug-naı¨ve) and two weeks later, following rand-
omisation by the trial pharmacist. The randomisation
code was developed using a computer random number
generator to select random permuted blocks (block
length 6). The trial pharmacist was not involved in
subject selection and all other researchers and subjects
were blind to the randomisation procedure and block
length. Subjects were randomised into three groups for
acute challenge with placebo (n ¼ 24), MPH .3 mg/kg
(n ¼ 25), or MPH .6 mg/kg (n ¼ 24). We have previously
described the wide range of executive and non-execut-
ive deficits at baseline (summarised in Table 2) (Rhodes
et al., 2004, 2005). Testing for all participants started at
10.00 a.m., 90 minutes after taking their first-ever dose
of MPH.
Computerised neuropsychological assess-
ment. Subjects performed a computer-based Go/
NoGo task at the beginning of each testing session. The
remaining tasks were selected from the CANTAB battery
(Robbins et al., 1994). CANTAB comprises a series of
computerised tests presented on a high-resolution
Table 1 Patient details for each treatment group as recorded at baseline testing
Placebo MPH.3 mg/kg MPH.6 mg/kg
Age (mean, s.d.) 11.08 (2.48) 10.40 (2.42) 10.92 (2.57)
BPVS percentile rank (mean, s.d.) 37 (30.42) 32.36 (25.22) 38.63 (28.96)
Social deprivation (DepCat score) 4.17 (1.85) 3.96 (1.40) 3.77 (1.85)
Conners: Parent (T scores)
Oppositionality 74.43 (9.78) 74.6 (13.73) 78.36 (9.01)
Cognitive 73.65 (5.6) 72 (8.26) 72.91 (7.41)
Hyperactive 81.48 (9.03) 82.16 (9.20) 85.18 (8.48)
ADHD index 77.09 (5.37) 76 (7.12) 77.5 (5.7)
Conners: Teachers (T scores)
Oppositionality 63 (20.12) 61.54 (21.41) 71.1 (16.37)
Cognitive 63.45 (11.27) 61.21 (16.34) 63.71 (9.91)
Hyperactive 76 (9.78) 66.08 (17.75) 71.14 (12.22)
ADHD index 71.95 (18.76) 71.13 (16.63) 73.76 (8.25)
Comorbid Conditions (N)
Oppositional defiant disorder (No CD) 11 12 8
Conduct disorder (CD) 7 6 7
Depressive disorder 1 1 1
Generalised anxiety disorder 2 0 1
Separation anxiety disorder 3 0 0
Tic disorder 1 1 1
Social phobia 0 1 1
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colour monitor with a touch-sensitive screen. Nine tests
taken from the three batteries, (1) working memory and
planning, (2) visual memory and (3) attention, were
used in this study.
Go/NoGo. This task is ameasure of the ability to detect
and respond to a target stimulus and to inhibit
responding to distractor stimuli, when all stimuli are
presented in a randomly changing order. A random se-
quence of eighteen letters andnumbers (nine of each) are
rapidly presented in the centre of the screen, one by one.
Stimuli are presented on screen for 300 ms, with an in-
ter-stimulus interval of 900 ms. Subjects are instructed
to respond to target stimuli by pressing the space bar as
quickly as possible but not to respond to distractors.
Trials were divided into two blocks: Block 1 represents
the ‘switch’ block where the task stimuli have changed
from letters to numbers (or vice versa) and Block 2 rep-
resents a ‘non-switch’ block. The principal dependent
measures in this taskwere themeannumber of errors for
distractors (false positive responses) and reaction time to
target stimuli across eight test trials.
CANTAB. Task descriptions and order of presentation
of the CANTAB tasks are provided in Table 3. The
standard battery was used to test all subjects at
the baseline session and the first parallel battery at the
acute session.
Data analysis
All analyses were conducted using SPSS for Windows
(v.10) (SPSS Inc. Chicago, Ill.)
Where necessary, data were subjected to square root
transformation [SQRT] or logarithmic transformation
[log10] to stabilise variance and to diminish skewness
depending on the relationship between the variance and
the group means (Tukey, 1977). Preliminary analysis
was conducted to check if data met the assumptions of
homogeneity of variance and normality assumptions. A
mixed design ANOVA with one between-subjects factor,
TREATMENT GROUP (placebo [PBO], MPH .3 mg/kg,
MPH .6 mg/kg) and with one within-subject factor,
SESSION (2 levels, baseline and acute), was used.
Measures with several levels of task difficulty [SOC







Mean (s.d.) F p
Go/NoGo
Errors for Distractors Block 1 (‘shift’ block) 2.31 (1.49) 2.24 (1.55) 2.38 (1.52) F < 1 N.S.
Errors for Distractors Block 2 1.97 (1.69) 2.21 (1.67) 2.46 (1.64) F < 1 N.S.
Reaction Time to targets Block 1 (log10) 2.64 (.09) 2.66 (.09) 2.66 (.07) F < 1 N.S.
Reaction Time to targets Block 2 (log10) 2.67 (.07) 2.65 (.09) 2.66 (.07) F < 1 N.S.
Spatial Span
Span Score 4.88 (1.3) 5.32 (1.18) 5.04 (1.31) F < 1 N.S.
Spatial Working Memory
Total Between Search Errors 54.84 (14.8) 49 (21.8) 48.28 (21.23) F < 1 N.S.
Strategy Score 36.92 (5.63) 35.84 (3.98) 36.16 (3.91) F < 1 N.S.
Stockings of Cambridge
No. Solved in Minimum Moves 7.08 (2.16) 7.20 (2.31) 7.12 (1.67) F < 1 N.S.
Average Moves (5 move problems) 7.2 (1.23) 7.99 (1.82) 7.54 (1.19) F ¼ 1.88 N.S.
Initial Thinking Times (5 move problems) (log10) 3.51 (.31) 3.67 (.38) 3.6 (.31) F < 1 N.S.
Pattern Recognition
% Correct 78.83 (16) 81.5 (11.35) 82 (11.7) F < 1 N.S.
Spatial Recognition
% Correct 65.6 (13.25) 66.8 (16.69) 73.8 (10.13) F ¼ 2.6 N.S.
Latency Correct (log10) 3.3 (.11) 3.32 (.16) 3.3 (.16) F < 1 N.S.
Latency Incorrect (log10) 3.26 (.15) 3.28 (.16) 3.27 (.13) F < 1 N.S.
Delayed Matching to Sample
% Correct
Simultaneous 89.6 (14.28) 91.2 (16.41) 92 (16.33) F < 1 N.S.
0 s delay 71.2 (25.87) 65.2 (29.31) 73.6 (21.39) F < 1 N.S.
4 s delay 58.33 (22.78) 53.66 (24.3) 66.4 (19.77) F ¼ 2.0 N.S.
12 s delay 45.6 (28.59) 51.2 (25.87) 56 (27.08) F < 1 N.S.
Paired Associates Learning
Stage Reached 8 (0) 8 (0) 8 (0) F < 1 N.S.
Total Errors 13.28 (12.51) 12.08 (12.57) 9.48 (9.36) F < 1 N.S.
Total Trials 13.84 (5.09) 12.44 (3.49) 12 (3.4) F ¼ 1.39 N.S.
ID/ED
Stage Reached Score 7.56 (.87) 7.36 (1.41) 7.72 (.89) F < 1 N.S.
Pre-ED Errors 9.64 (7.46) 9.64 (5.24) 8.72 (5.88) F < 1 N.S.
Errors at ED Shift 20. 4 (11.13) 20.33 (8.6) 19.68 (9.67) F < 1 N.S.
Reaction Time (all log10)
Reaction Time Latency: Simple 2.6 (.17) 2.57 (.13) 2.58 (.15) F < 1 N.S.
Movement Time Latency: Simple 2.62 (.16) 2.6 (.18) 2.6 (.14) F < 1 N.S.
Reaction Time Latency: 5 choice 2.61 (.11) 2.59 (.09) 2.62 (.18) F < 1 N.S.
Movement Time Latency: 5 Choice 2.61 (.15) 2.63 (.14) 2.6 (.15) F < 1 N.S.
N.S. indicates non-significant.
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(average moves, Initial and Subsequent Thinking
Times)] were analysed using repeated-measures ANO-
VA with an additional within-subject factor, TASK
DIFFICULTY.
Where ANOVA revealed significant effects or inter-
actions, planned comparisons comparing placebo to
the two doses of MPH were conducted. For repeated-
measures data with two within-subject factors, TASK
DIFFICULTY and SESSION, the most difficult level
(e.g., 5 moves SOC) was compared with all other
levels.
Results
Mean performance and statistical comparisons for
each of the treatment groups on each task are
summarised in Table 4. F and p values reported in
Table 4 represent SESSION · TREATMENT inter-
actions. Main effects of TREATMENT GROUP, TASK
DIFFICULTY and SESSION are reported only when
significant.
Go/NoGo
Whilst subjects showed a significant reduction in
Errors for Distractors from baseline to acute chal-
lenge, this improved performance was not due to
MPH which had no effect on either performance
accuracy or reaction times, at either dose, for either
of the blocks.
Spatial Span
MPH had no effect on spatial span score at either
dose.
Stockings of Cambridge
MPH did not influence performance on the SOC Task
either in terms of the number of problems Solved in
Minimum Number of Moves, average moves, or on
Initial and Subsequent Thinking times. There were
Table 3 Descriptions and order of presentation of CANTAB tasks
Task Main outcome measures Description
References for fuller
task description
Working Memory and Planning Battery
Spatial Span Span A test of spatial short-term memory
capacity based on the Corsi
block-tapping task.
Milner (1971)





A self-ordered search task that
assesses working memory for
spatial stimuli and requires a
subject to use mnemonic
information to work towards a goal.
Petrides & Milner (1982)
Kempton et al. (1999)






Derived from the ‘Tower of Hanoi’
task, measuring spatial planning,
working memory, and behavioural
inhibition.
Shallice (1982)
Kempton et al. (1999)
Visual Memory Battery
Pattern Recognition Percent correct Tests the ability to recognise a
previously presented abstract
pattern in a forced choice procedure.
Kempton et al. (1999)
Spatial Recognition Percent correct Tests the ability to recognise
the spatial locations of target stimuli.
Kempton et al. (1999)
Rhodes et al. (2004)
Delayed Matching to
Sample (DMtS)
Percent correct Tests the ability to remember
the visual features of a complex,
abstract, target stimulus and to
select from a choice of four patterns
after a variable delay.
Kempton et al. (1999)






Tests the ability to learn the spatial
locations of a progressively increasing
number of abstract stimuli. The main
measures in this task are the number of
trials taken to complete the task and
the total number of errors across all trials.







Stage reached Tests the ability to focus attention on
specific attributes of compound
stimuli (intradimensional stages)
and to shift attention when required
to a previously irrelevant stimulus
dimension (extradimensional stages).
Kempton et al. (1999)
Reaction Time Reaction time,
movement time
Tests reaction and movement times
in response to a stimulus under
both one choice and five choice conditions.
Sahakian & Owen (1992)
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significant effects of SESSION on each of these
measures. Overall, subjects showed improved per-
formance during the second test session. However,
as there were no significant SESSION · TREAT-
MENT interactions, these improvements cannot be
attributed to MPH. There was a significant effect of
TASK DIFFICULTY on average moves [F(3,207) ¼
944.6, p < .001], Initial [F(3,207) ¼ 68.8, p < .001],
and Subsequent Thinking [F(3,207) ¼ 79.7,
p < .001] times. There were no significant TASK
DIFFCULTY · TREATMENT GROUP interactions.
Spatial Recognition
MPH had no effect on accuracy but did increase the
time to respond on the Spatial Recognition Task.
Whilst accuracy was significantly improved at the
acute challenge session compared with baseline
[F(1,69) ¼ 12.0, p < .001], there was no significant
SESSION by TREATMENT GROUP interaction. MPH
(.6 mg/kg) slowed responding for both correct and
incorrect choices on the Spatial Recognition Task.
Although there was no significant effect of SESSION
on latency to make correct responses, there was a
significant SESSION · TREATMENT GROUP inter-
action [F(2,69) ¼ 3.36, p < .04]. Planned contrasts
showed that the MPH .6 mg/kg group showed longer
latencies when making correct responses at the
acute challenge session than did those taking pla-
cebo (t(45) ¼ )2.07, p < .04). There was also a sig-
nificant effect of TREATMENT GROUP [F(2,68) ¼
4.91, p < .01] on latencies to make incorrect re-
sponses, a significant effect of SESSION [F(1,68) ¼
25.8, p < .001] and a significant TREATMENT
GROUP by SESSION interaction [F(2,68) ¼ 7.27,
p < .001]. Planned contrasts revealed that the MPH
.6 mg/kg group showed longer latencies when
making incorrect responses at the acute challenge
session (t(45) ¼ )2.43, p < .003) compared with
placebo.
Paired Associates Learning
MPH did not affect performance on PAL. For stage
reached and mean error scores there was no effect of
TREATMENT GROUP, SESSION, nor an interaction
between the two. There was a significant effect of
TREATMENT GROUP [F(2,70) ¼ 3.5, p < .04] and of
SESSION [F(1,70) ¼ 170.8, p < .001] on total num-
ber of trials, but no interaction indicating an absence
of effect of MPH. The significant effect of TREATMENT
GROUP seems likely to reflect a non-statistic-
ally significant trend towards a smaller number of
trials taken by the .6 mg/kg MPH treatment group at
baseline in comparison to the placebo group.
ID/ED
MPH did not affect performance on the ID/ED at-
tentional set shifting task. There was no effect of
TREATMENT GROUP on Stage Reached, errors up to
and including ID reversal, errors at the ED shift or at
the ED reversal stages. There was a significant effect
of SESSION [F(1,70) ¼ 12.05, p < .001] on the pro-
portion successfully completing the Extra-Dimen-
sional Reversal stage (stage 9) but no significant
effects of TREATMENT GROUP [F(2,70) < 1] or sig-
nificant TREATMENT GROUP by SESSION interac-
tion.
Reaction time
There were no significant effects of MPH on reaction
time or movement time in the simple reaction test
condition. However, MPH .6 mg/kg shortened
latencies to respond during the 5-choice condition.
While there was no significant effect of TREATMENT
GROUP or SESSION on Reaction Time latencies,
there was a significant TREATMENT GROUP by
SESSION interaction [F(2,68) ¼ 3.30, p < .05].
Planned contrasts revealed that the MPH .6 mg/kg
group had shorter latencies during the acute chal-
lenge session (t(46) ¼ 2.13, p < .03). MPH did not
improve movement time latencies in the 5-choice
condition.
Discussion
The acute administration of oral MPH (.3 and .6 mg/
kg) under randomised, placebo-controlled, double-
blind conditions to a cohort of 73 medication-naı¨ve
boys with ADHD improved neuropsychological per-
formance on three tasks without a prominent ex-
ecutive component. Shortened response latencies
were reported on a complex reaction time task and
lengthened response latencies (which were not
associated with increased task accuracy) were found
on a Spatial Recognition memory task. As we previ-
ously reported (Rhodes et al., 2004), performance on
a Delayed Matching to Sample task was restored to
that described for healthy developing children.
Contrary to predictions, acute MPH failed to improve
performance on neuropsychological tasks with a
prominent executive component. This absence of
effect was observed on sensitive tests of inhibition,
working memory, strategy formation, planning, and
attentional set-shifting. These findings are striking
in that they contradict the existing literature. Spe-
cifically, the hypothesis that MPH selectively
enhances performance on neuropsychological tasks
with a prominent executive component was not
supported.
Whilst it was not appropriate to examine clinical
response to a single dose of medication, the results
presented do not support the hypothesis that the
therapeutic effects of MPH in children with ADHD
are mediated by improved executive neuropsycho-
logical performance. Further, the present study fails
to support the findings of two earlier studies which
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utilised the Go/NoGo task and demonstrated an
enhancement of inhibitory processes with acute
MPH (Trommer et al., 1991; Broyd et al., 2005).
However, Van der Meere and colleagues also con-
ducted a double-blind, placebo-controlled study of
strictly defined drug-naı¨ve children with ADHD (Van
der Meere et al., 1999) and found that stimulant
medication (chronically administered) failed to
enhance performance on a Go/NoGo task. It is also
possible that the differences between these studies
could be a consequence of the Go/NoGo tasks used.
The current study and that of Van der Meere used
tasks with visual targets whereas the Trommer and
Broyd studies used an auditory Go/NoGo task.
Further, the current study used a relatively fast
presentation rate with an inter-stimulus interval of
.9 whilst both the Trommer and the Broyd stud-
ies used a medium presentation rate with an inter-
stimulus interval of between 3 and 4 seconds. This
explanation seems less likely as Van der Meere and
colleagues investigated performance across several
inter-stimulus intervals (1, 4 and 8 secs) and found
no relationship between presentation rate and
medication effects.
The present findings also fail to fully replicate
those from previous comparable studies using the
CANTAB tasks (Bedard et al., 2004; Kempton et al.,
1999; Mehta et al., 2004; Barnett et al., 2001). Each
of these studies reported that MPH reduced BSE on
the SWM task, and both studies that included the
ID/ED task reported improvement with MPH
(Kempton et al., 1999; Mehta et al., 2004). However,
studies using the SOC planning task reported mixed
findings (Kempton et al., 1999; Bedard et al., 2004).
We found no effects on these three tasks. This may
relate to differences in study design. The two earliest
studies were both uncontrolled and non-randomised
(Barnett et al., 2001; Kempton et al., 1999). The
studies of Kempton and colleagues (1999) and Mehta
et al. (2004) reported on small samples with non-
standard clinical assessment procedures. Also, both
of the previously reported controlled studies in-
cluded non-medication-naı¨ve subjects (Mehta et al.,
2004; Bedard et al., 2004). Both also utilised a
within-subjects crossover design which permits
practice effects in addition to potential carryover
and/or withdrawal effects of MPH. We observed
improvements on several tasks between baseline and
acute challenge in the present study that cannot be
attributed to MPH. Finally, unlike these previous
studies, the statistical analyses for the present study
included unmedicated baseline performance when
estimating the significance of MPH effects.
Stimulant drug effects on tasks without a prom-
inent executive component are relatively under-
studied. Using an uncontrolled study design,
Kempton et al. (1999) suggested that MPH enhanced
performance on several tasks without a prominent
executive component: Spatial Span, Pattern Recog-
nition and Delayed Matching to Sample, but not on
others: Spatial Recognition and Paired Associates
Learning (PAL). Controlled studies have included
only small subsets of these tasks. MPH improved
performance on the Spatial Span task as reported by
Bedard, Ickowicz, and Tannock (2002) but did not
improve performance on the Spatial Recognition task
(Bedard et al., 2004; Mehta et al., 2004) or on the
Pattern Recognition task (Mehta et al., 2004). The
present study found that acute MPH (.6 mg/kg)
exerted significant effects on response latencies on
two such tasks. MPH .6 mg/kg lengthened latencies
for both correct and incorrect responses on the
Spatial Recognition task and shortened reaction
time latencies on the 5-choice condition of the
Reaction Time task. These findings support the
contention that MPH exerts therapeutic effects by
improving ‘regulatory ability’ – slowing performance
during the difficult conditions of tasks and shorten-
ing response times during easier stages (Douglas,
1999; Berman et al., 1999). These beneficial effects
may be dependent upon memory load. Berman et al.
(1999) demonstrated that at a low memory load,
improvement in performance accuracy occurred with
no cost to reaction time, irrespective of dose of MPH,
whereas at higher loads there was a dose-dependent
effect of MPH to slow reaction times. In support of
this model, we found that acute MPH did not uni-
formly slow or speed responding. MPH lengthened
responding on the Spatial Recognition task, but
shortened response times on the Reaction Time task.
While MPH has contrasting effects on reaction times
on these two tasks, both effects can be regarded as
enhancements of cognitive functioning. The Spatial
Recognition task is a relatively complex task in
comparison to the lighter cognitive processing bur-
den of the Reaction Time task; hence lengthened
responding in the former and shortened responding
in the latter can be regarded as an enhancement of
performance in both tasks. Whilst these results
support those found in other studies, it should be
noted that the reported p values for each of these
effects were in the .5 to .1 range. Considering the
number of tasks investigated, it remains possible
that these results represent Type 1 errors. Further
significant effects were found on another task with-
out a prominent executive component, the DMtS
task, which assesses the ability to hold information
in memory over a short delay (Rhodes et al., 2004).
The present study also supports the notion that
MPH selectively enhances discrete aspects of
neuropsychological functioning (Gao & Goldman-
Rakic, 2003) and that these effects extend beyond
baseline impairments (Rapport & Kelly, 1991).
Within the present sample, baseline assessments
revealed a wide range of deficits in neuropsycholo-
gical functioning (see Table 2) (Rhodes et al., 2005).
Acute MPH, however, failed to enhance performance
on many of these tasks. Indeed, apart from the
amelioration of deficits on the DMtS task and
the slowing of incorrect responses (but without
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improved accuracy) on Spatial Recognition, MPH-
related enhancements were restricted to aspects of
neuropsychological functioning in which boys
showed no impairment at baseline. Importantly,
despite there being no evidence for MPH-related
improvement on other aspects of neuropsychological
performance, there was no evidence of MPH-related
performance deficits. Specifically, there was no evid-
ence for MPH reducing cognitive flexibility (see
ID/ED results) as has previously been suggested
(Robbins & Sahakian, 1979; Dyme, Sahakian,
Golinko, & Rabe, 1982).
Several potential limitations of this study should
be addressed. The recruitment of participants
meeting criteria for both DSM-IV ADHD Combined
Type and ICD-10 Hyperkinetic Disorder may have
generated a more severely affected clinical sample
than previous studies. However, a recent re-analysis
of the Multimodal Treatment Study for ADHD (MTA)
data (E. Taylor, pers. comm.) suggests that such a
population is more, rather than less, likely to re-
spond to MPH. Presumably, this ought to increase
rather than decrease the chances of detecting clin-
ically meaningful changes. The inclusion of only
male subjects reduces the generalisability of the
findings to females with ADHD.
No attempt was made to measure clinical response
to the acute MPH challenge. However, in view of the
highly structured, controlled and relatively novel
environment required for neuropsychological test-
ing, it is unlikely that such ratings (even with relat-
ively objective measures such as from an actometer)
would accurately capture clinically relevant symp-
tom changes. Also, although participants were
randomised following baseline testing, it is possible
that the present findings are a consequence of latent
differences between the treatment groups in either
clinical or neuropsychological characteristics. How-
ever, there were no statistically significant differ-
ences between the three treatment groups on a wide
range of clinical variables: age, BPVS Percentile
Rank, the presence of a wide range of comorbid
conditions, or on neuropsychological functioning at
baseline. Whilst our sample size was modest, it
easily exceeds that of previous, comparable studies.
The use of a single session between-subjects rather
than multiple session within-subject design results
in a reduction in power; however, as detailed above,
such repeated measures designs also add potential
confounding factors. To evaluate the first-ever
neuropsychological response to MPH in drug-naı¨ve
subjects mandates a between-subjects design. The
F-ratios reported above are frequently <1, suggesting
that the loss of power of a between-subjects design is
unlikely to have been a major issue with respect to
the negative findings. It is also worth noting that the
consistently negative results across multiple neuro-
psychological domains reinforce the possibility that
MPH may not exert the previously anticipated ef-
fects.
One possible explanation for the absence of effects
of MPH on executive functioning is that we have only
studied the acute response to a first-ever dose and
chronic administration may have very different ef-
fects. Clinically, the positive impact of MPH on
behaviour within approximately an hour of admin-
istration has traditionally been interpreted as evid-
ence that its therapeutic effects are immediate and
are not mediated by long-term neurobiological
adaptation (Solanto, 1998). Perhaps this is incor-
rect? Previous controlled study designs, utilising
these same tasks, have considered the possibility
that the ‘enhanced’ performance seen with MPH may
be a consequence of neuropsychological rebound
secondary to acute medication withdrawal. Definit-
ive prospective studies comparing acute and chronic
responses in stimulant-naı¨ve subjects are awaited.
ADHD is associated with a wide range of neuro-
psychological deficits. While findings from this study
do not support the popular hypothesis that MPH
enhances performance on executive functioning
tasks, they do suggest selective enhancement of
several aspects of non-executive cognitive function-
ing which may reflect increased capacity for self-
regulation. As a majority of children with ADHD
demonstrate positive clinical responses to MPH, this
suggests that clinically important cognitive deficits
may not all be ‘executive’ in nature. Importantly,
MPH does not impair performance on any of the
tasks studied.
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The Neuropsychological Effects of Chronic
Methylphenidate on Drug-Naive Boys with
Attention-Deficit/Hyperactivity Disorder
David R. Coghill, Sinead M. Rhodes, and Keith Matthews
Background: The reported neuropsychological effects of methylphenidate (MPH) in attention-deficit/hyperactivity disorder (ADHD) are
inconsistent. The assumed relationships between these neuropsychological effects and clinical efficacy have not been substantiated. We
therefore investigated the effects of chronic MPH administration on neuropsychological functioning.
Methods: We conducted a 12-week, placebo-controlled, double-blinded, randomized, crossover trial (MPH .3 and .6 mg/kg/dose and
placebo). Participants were 75 boys aged 7–15 years with ADHD. Neuropsychological performance was assessed with tests taken from the
Cambridge Neuropsychological Test Automated Battery (CANTAB) battery and a GoNoGo task.
Results: ChronicMPH improvedperformance (p .001) onaspects of theGoNoGo task (p .02) andon threeCANTAB taskswhich together
contributed to a “recognitionmemory” component identified through principal components analysis (delayedmatching to sample [DMtS],
pattern and spatial recognition). There were no effects on other, high or low “executive demand” tasks (p  .05). GoNoGo performance
improvements were the only neuropsychopharmacological changes associated with clinical response. Poor performance on the DMtS task
was the sole baseline neuropsychological predictor of clinical response.
Conclusions: Chronic MPH predominantly enhanced neuropsychological functioning on “recognition memory” component tasks with
modest “executive” demands. Neuropsychological measures offer onlymodest contributions to the prediction of clinical responses toMPH
in ADHD.
Key Words: Attention deficit hyperactivity disorder, cognition, ex-
ecutive functioning,methylphenidate, randomized controlled trial,
stimulant
Conceptual models of attention deficit hyperactivity disor-der (DSM-IV)(American Psychiatric Association 1994) andhyperkinetic disorder (ICD-10) (World Health Organiza-
tion 1992), emphasize causal pathways by which genetic varia-
tion generates functional changes within frontostriatal dopamine
and noradrenaline neurotransmission. In turn, these alterations
mediate deficits in “executive” aspects of neuropsychological
functioning that are proposed to elicit the core phenotypic
manifestations of ADHD (Castellanos and Tannock 2002). Exec-
utive functioning deficits ascribed to ADHD include inhibition
(Barkley 1997), working memory (Kempton et al. 1999; Rhodes
et al. 2004) attentional set shifting and planning (Kempton et al.
1999; Rhodes et al. 2005). However, executive deficits are neither
necessary, nor sufficient, to account for all presentations of the
ADHD phenotype (Willcutt et al. 2005). Further, recent studies
have linked ADHD with deficits on neuropsychological tasks
with minimal ‘executive demands’ (spatial span and spatial
recognition memory, delayed matching to sample (DMtS) and
pattern recognition) (Kempton et al. 1999; Rhodes et al. 2004),
including tasks (e.g. DMtS, Pattern Recognition) previously as-
cribed as reliant upon intact temporal and parietal, rather than
frontal, lobe functioning (Owen et al. 1995). Similarly, consistent
performance deficits on cerebellar timing (Toplak et al. 2003)
and delay aversion tasks (for which the neural substrates remain
unclear (Sonuga-Barke 2003)), have been described. Hence, the
anatomical and neurochemical neural substrates mediating core
features of ADHD are likely to be complex and heterogeneous
(Coghill et al. 2005).
Stimulant medication, of which methylphenidate (MPH) is the
most commonly prescribed and studied (Greenhill et al. 1999),
remains the dominant, yet still controversial, pharmacological
contribution to the management of ADHD (Safer and Malever
2000) Several studies have demonstrated MPH-mediated en-
hancement of inhibitory control in ADHD, with reduced impul-
sive responding, response variability and errors (Berman et al.
1999; Scheres et al. 2003; Shue and Douglas 1992; Trommer et al.
1991). However, these findings are not robust (Ross et al. 1994;
Van der Meere et al. 1999) Thus, proposed mechanisms linking
the pharmacological actions of MPH to core neuropsychological
processes remain highly speculative (Elliott et al. 1997; Mehta et
al. 2000), and often fail to make any meaningful distinction
between acute and chronic pharmacological actions. We have
previously described acute responses on a range of neuropsy-
chological tasks in a large sample of rigorously diagnosed,
medication-naive boys with ADHD following their first ever
exposure to MPH in a randomized, placebo-controlled, double-
blind, parallel group design (Rhodes et al. 2004, 2006) In this
study, acute MPH failed to enhance performance on tasks with a
prominent executive component, but significantly enhanced
performance on three tasks without prominent executive de-
mands (a reaction time task, spatial recognition memory, and
DMtS). Other acute MPH administration studies (also using tasks
from the Cambridge Neuropsychological Test Automated Battery
(CANTAB) test system (Morris et al. 1987)) have described
enhanced Spatial Working Memory (SWM) performance in
healthy adults (Elliott et al. 1997) and in children with ADHD
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(Bedard et al. 2004; Mehta et al. 2004), enhanced strategy and
planning (Stockings of Cambridge (SOC) in healthy adults (Elliott
et al. 1997) (but not in ADHD subjects (Bedard et al. 2004; Mehta
et al. 2004)), and enhanced attentional flexibility/set-shifting
(ID/ED task) in ADHD subjects only (Mehta et al. 2004). Two
uncontrolled, acute MPH studies also reported improved SWM
(Barnett et al. 2001; Kempton et al. 1999), ID/ED and SOC task
performance (Kempton et al. 1999) in ADHD subjects.
Further detailed studies of the chronic effects of MPH on
executive neuropsychological functions in children with ADHD
are required because effective therapeutic use mandates chronic
administration. Chronic, but not acute, studies permit exploration
of the relationships between neuropsychological performance,
medication response and clinical status. Further, experimental
designs must accommodate potential withdrawal effects, as well
as manifestations of tolerance or sensitization. To date, there has
been only one such study. Using a randomized, placebo-con-
trolled design, Van der Meere and colleagues described impaired
performance of ADHD boys on a GoNoGo response inhibition
task (van der Meere et al. 1999) and the failure of chronic MPH
administration to improve performance. Thus, the reported
neuropsychological effects of MPH in ADHD are inconsistent.
Further, the assumed, intuitively attractive, relationship between
neuropsychological effects of MPH, dose and clinical efficacy has
not been substantiated.
We now describe neuropsychological performance in a clin-
ical sample of medication-naive boys with ADHD in response to
chronic MPH (.3 and .6 mg/kg twice daily) using a randomized,
placebo-controlled, double-blind, parallel group design. We
have previously reported elements of these data from the SWM,
DMtS and Pattern Recognition tasks (Rhodes et al. 2004). We
aimed to test the following hypotheses: 1) Chronic exposure to
MPH would enhance performance on tasks with a prominent
executive component; 2) neuropsychological responses to
chronic MPH would demonstrate dose-dependency; and 3) if, as
is proposed in several prominent causal theories of ADHD,
neuropsychological performance deficits contribute significantly
to the clinical presentation and impairments associated with
ADHD, then those study participants exhibiting the largest
neuropsychological responses to MPH would also demonstrate
the greatest clinical responses.
Methods andMaterials
This study was approved by the Tayside Committee on
Medical Research Ethics (NHS Tayside, Dundee, United King-
dom). All participants and parents/guardians provided written
informed consent.
Participants
Seventy-five boys were recruited from consecutive out-pa-
tient referrals (aged 7 to 15) to the Tayside Child and Adolescent
Psychiatric Service (Tayside, United Kingdom). Exclusion criteria
included history of neurological impairment, learning disability
(IQ 80), chronic physical illness, sensory or motor impairment,
current or previous exposure to stimulant medication, and abuse
of any illegal drugs. The presence of commonly comorbid
conditions; oppositional defiant disorder, conduct disorder, and
anxiety disorder, did not result in exclusion (see Table 1).
Eligible boys (scoring  1.5 standard deviations from the mean
on both Conners’ Parent Rating Scale short version (CPRS-26)
and Conners’ Teacher Rating Scale short version (CTRS-28)) were
interviewed by an experienced child and adolescent psychiatrist
using the Kiddie-Schedule for Affective Disorders and Schizo-
phrenia Present and Lifetime (K-SADS-PL) (Kaufman et al. 1996
unpublished data) interview schedule. Those meeting criteria for
hyperkinetic disorder (HD) (F90 ICD-10) and ADHD combined
subtype (DSM-IV) were invited to participate. The British Picture
Vocabulary Scale (BPVS) (Dunn et al. 1997) [2nd Edition] was
used to estimate general intellectual ability.
Design
Participants were randomized by an independent clinical
trials pharmacist (using a computer-generated random number
sequence with block design to ensure equal numbers in each
treatment arm) to receive placebo (n  25), .3mg/kg/dose MPH
(n  25), or .6mg/kg/dose MPH (n  25) (hereafter referred to
as; placebo, .3mg/kg and .6mg/kg) twice daily. These doses
were chosen to reflect low and high dose regimes respectively.
Neuropsychological performance was assessed prior to exposure
to MPH (Rhodes et al. 2004, 2005) {Rhodes, 2005 12848 /id}and
again two weeks after baseline testing, to minimize practice
effects, following the first dose of MPH (Rhodes et al. 2006)
Subsequently, MPH administration was continued for three
cross-over periods of 28 days under randomized, double-blinded
conditions. MPH was taken at 08:00 and midday (Figure 1).
Participants were tested 90 min after taking morning medication
at the end of each 28-day block. Clinical status was assessed by
interview conducted by an experienced, blinded child and
adolescent psychiatrist (Clinical Global Impressions - Improve-
ment scale (CGI-I) (National Institute of Mental Health 1985),
Parent and Teacher-rated 10-item Conners’ Global Index rating
scales (CGI-P and CGI-T) (Conners 1997)). Treatment adherence
was assessed by pill count and clinical enquiry.
Figure 1. Study design.
Table 1. Comorbid Diagnoses in ADHD Group
n %Of Sample
Pure ADHD 18 24
Comorbid Diagnoses
Oppositional Defiant Disorder (No CD) 31 41.3
Conduct Disorder (CD) 21 28
Depressive Disorder 3 4
Generalised Anxiety Disorder 2 2.7
Separation Anxiety Disorder 3 4
Tic Disorder 2 2.7
Social Phobia 1 1.3
ADHD, attention deficit hyperactivity disorder.




Participants performed each task in the same order on each
occasion. A GoNoGo task was followed by nine tasks (see Table 2
for descriptions) selected from the CANTAB (Morris et al. 1987).
All tasks were presented on a high-resolution color monitor with
touch sensitive screen. Where available, parallel versions of the
CANTAB tasks were used for repeat testing (pattern recognition,
spatial recognition, delayed matching to sample, paired associ-
ates learning and reaction time).
GoNoGo Task. The GoNoGo task required the detection and
response to target stimuli with inhibition of responding to
distractors. Stimuli were presented as 8 blocks of random 18
character sequences of letters and numbers (9 of each i.e. 50%
targets, 50% distractors) in the center of the screen for 300 msec,
with an interstimulus interval of 900 msec. Participants were
instructed to respond to target stimuli by pressing a computer
keyboard space bar. Response contingencies alternated between
numbers and letters every second block (i.e. l,l,n,n,l,l,n,n).
Dependent measures were mean number of errors for distractors
(ERD) and reaction times to target stimuli (RTT). For analysis,
trials were divided into those representing ‘switch’ blocks (1)
where task requirements shifted from detection of letters to
numbers (or vice-versa) and ‘nonswitch’ blocks (2).
Cambridge Neuropsychological Test Automated Battery
(CANTAB)
Task descriptions and presentation order are summarized in
Table 2.
Statistical Analysis
All analyses were conducted using SPSS (SPSS Inc., Chicago,
Illinois) for Windows (v.10). Where required, data were sub-
jected to square root transformation or logarithmic transforma-
tion to stabilize variance and diminish skewness. Where ORDER
effects were not detected, data were pooled (n 69 for placebo,
68 for .3mg/kg MPH and 65 for .6mg/kg MPH). A mixed design
analysis of variance (ANOVA) with one between-subject factor,
ORDER (treatment sequence), and with repeated-measures on
one within-subject factor, DOSE (placebo, .3mg/kg MPH, or
.6mg/kg MPH) was performed. Where ORDER effects were
evident, data were analysed by repeated-measures ANOVA with
two levels of the within-subjects factor SESSION (baseline and
session three scores only) and ORDER as a between-subjects factor.
Data failing to meet normality and homogeneity of variance as-
sumptions were analyzed using the nonparametric Wilcoxon Sign
test for repeated-measures. Posthoc analyses were conducted using
planned contrasts using data from subjects with complete datasets.
Clinical response was described as a continuous variable by
calculation of change scores between placebo and MPH dose. In
addition, ‘responder’ status was determined using the clinical
significance methods proposed by Jacobson and Truax (1991).
“Clinically significant change” was defined as movement from
the dysfunctional to the functional range ( 65) on the Conners’
Global Index total t-score. Reliable change scores were calcu-
lated (defined as reliable change index (RCI)  -1.96) and
“response” was defined as requiring both “clinically significant
change” and “reliable change”. Separate analyses were carried
out for each dose of MPH (see Jacobson and Truax 1991 for full
consideration of relevant theory and its application). Neuropsy-
chopharmacological response to MPH was defined as score
change on the primary measures from each task. Although both
parent and teacher ratings of clinical response were obtained,




References for Fuller Task
Description
Working Memory and Planning Battery
Spatial Span Span A test of spatial short-termmemory capacity based on the
Corsi block-tapping task
Milner (1971)
Kempton et al. (1999)
Spatial Working Memory (SWM) Between search errors,
strategy score
A self-ordered search task that assesses working memory for
spatial stimuli and requires a subject to use mnemonic
information to work towards a goal.
Petrides and Milner (1982)
Kempton et al. (1999)
Rhodes et al. (2004)
Stockings of Cambridge (SOC) Problems solved in
minimummoves
Derived from the ‘Tower of Hanoi’ task, measuring spatial
planning, working memory, and behavioral inhibition
Shallice (1982)
Kempton et al. (1999)
Visual Memory Battery
Pattern Recognition Percent correct A test of the ability to recognize a previously presented
abstract pattern in a forced choice procedure
Kempton et al. (1999)
Spatial Recognition Percent correct A test of the ability to recognize the spatial locations of
target stimuli
Kempton et al. (1999)
Rhodes et al. (2004)
Delayed Matching to Sample (DMtS) Percent correct A test of the ability to remember the visual features of a
complex, abstract, target stimulus and to select from a
choice of four patterns after a variable delay
Kempton et al. (1999)
Rhodes et al. (2004)
Paired Associates Learning (PAL) Stage reached, total
errors, total trials
A test of the ability to learn the locations of a progressively
increasing number of abstract stimuli. The main measures
in this task are the number of trials taken to complete the







Stage reached A test of the ability to focus attention on specific attributes
of compound stimuli (intradimensional stages) and to
shift attention when required to a previously irrelevant
stimulus dimension (extradimensional stages)
Kempton et al. (1999)
Reaction Time Reaction time
Movement time
A test of reaction and movement times in response to a
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only parent ratings of response were used in this analysis used
due to incomplete teacher data.
Prediction of Response. A principal components Analysis
was conducted on the z scores (adjusted for age and BPVS) for
the primary dependent measures derived from those neuropsy-
chological tasks for which statistically significant baseline differ-
ences were found between the present sample of ADHD boys
and healthy matched controls (spatial span, spatial working
memory, stockings of Cambridge, pattern and spatial recogni-
tion, delayed matching to sample, paired associates learning,
reaction time and ID/ED shift) (Rhodes et al. 2005) Correlations,
multiple regressions, ANOVAs and logistic regressions were used
to investigate socio-demographic, clinical, neuropsychological




There were no differences between groups at baseline with
respect to age [F 1], BPVS percentile rank [F 1], parent-rated,
or teacher-rated ADHD composite Conners’ scores [both F  1].
There were also no differences with respect to the incidence of
co-morbid disorders other than separation anxiety disorder [F 
3.4, p  .04]. Three boys with this diagnosis took placebo during
the first chronic session. Participant progress through the study is
described in the CONSORT diagram, which is available online as
supplemental information.
Clinical Response toMPH Treatment
Chronic treatment with MPH .3 and .6 mg/kg improved
functioning as measured by all subscales of the Conners’ scales and
by Clinical Global Impression-Improvement scale (see Table 3).
There were no differences between the two MPH doses, al-
though there was a nonsignificant trend for increased response
with increased MPH dose on teacher-rated Conners’ scores.
‘Responder’ status with MPH .3mg/kg was confirmed for 20 of 59
(33%) and with MPH 6mg/kg for 27 of 63 participants (43%).
Fifty-eight participants provided data on both doses of MPH; 24
(41%) were ‘nonresponders’, 8 (11%) ‘responded’ to .3, but not
.6mg/kg, 15 (26%) ‘responded’ to .6 but not .3mg/kg, and 11
(19%) ‘responded’ to both doses.
Effects of MPH on Neuropsychological Performance
Effects of Repeated Testing. Fourteen of the 22 measures
reported in Table 4 changed significantly between baseline and
chronic placebo testing, with all but one showing robust im-
provements (Cohen’s d up to 1.61). It is likely that these changes
represent the influence of practice and learning effects. One
notable exception was the measure of accuracy on the spatial
recognition memory task where performance worsened by .75
standard deviations from baseline to chronic placebo.
Chronic MPH Improved Accuracy and Speeded Performance
on a GoNoGo Task
MPH reduced mean errors for distractors (ERD) during both
Block 1 (the ‘shift’ block) [F (2,116)  4.1, p  .02] and Block 2
[F (2,116)  5.9, p  .005]. MPH .3mg/kg (p  03) reduced errors
during Block 2 and .6mg/kg during both Blocks (p  .01 and
p  004). There was also a significant overall effect of MPH to
shorten response latencies during Blocks 1 [F (2,116)  4.1, p 
.02] and 2 [F (2,116)  3.1, p  .049]. This was accounted for by
6mg/kg MPH shortening response latencies relative to placebo
(p  .005).
Spatial Span and Spatial Working Memory. There was no
effect of MPH on spatial span score (F (2,116)  1), nor on any
measures from the spatial working memory task (see Rhodes et
al. 2004).
Stockings of Cambridge. There was no effect of MPH on the
number of minimum move solutions [F (2,116)  1.9, p  .16],
but there was a significant effect of ORDER [F (2,58)  5.38, p 
.007] and a significant interaction between MPH and ORDER
[F (4,116)  3.3, p  .02]. Re-analysis with SESSION as a
within-subjects and GROUP as a between-subjects factor [n  24
per group] revealed no significant effect of GROUP [F (2,68) 
2.1, p  .13], although performance improved overall from
baseline to chronic challenge [F (1,68)  17.6, p  .001]. There
was a significant interaction between SESSION and GROUP
[F (2,68)  3.3, p  .04], but planned contrasts revealed no
significant differences between the groups (all p  .05). There
were no significant effects of MPH on initial (ITT) [F (2,116)  1]
or subsequent (STT)[F (2,116)  1.6, p  .21] thinking times.
There was a MPH and ORDER interaction for STT [F (4,116) 
3.1, p .02]; planned contrasts revealed that boys taking placebo
at the first chronic test session had longer STT than when taking
.3mg/kg (p  .049) or .6mg/kg (p  .043).
Pattern Recognition Memory. Chronic .3 mg/kg and .6
mg/kg MPH enhanced accuracy on this task but exerted no effect
on speed of response (see Rhodes et al. 2004).
Spatial Recognition Memory. MPH improved accuracy on
the spatial recognition task [F (2,116)  16.3, p  .001]. Planned
contrasts revealed improved performance when taking both
.3mg/kg (p  .001) and .6mg/kg (p  .001) MPH doses relative
to the performance deterioration observed with placebo. There
was a significant effect of MPH to slow responses when making
correct [F (2,116) 10.08, p .001] and incorrect [F (2,114) 3.8,
p  .03] responses, attributable to the differences between






mean (SD) F p
Effect Size
Pla vs. .3mg/kg Pla vs. .6mg/kg
Parent Conners’ Global Index
Restless/impulsive subscale (T score) 77.1 (1.9) 68.4 (13.8) 65.5 (13.6) 14.2 .001 70 .94
Emotional Lability subscale (T score) 71.6 (13.6) 65.2 (14.2) 65.6 (15.0) 4.0 .02 .46 42
Total subscale (T score) 77.2 (11.1) 67.2 (13.5) 67.0 (14.8) 12.2 .001 81 .78
Teachers Conners’ Global Index
Restless/impulsive subscale (T score) 71.8 (9.9) 63.7 (13.6) 57.7 (11.4) 17.4 .001 .68 1.32
Emotional lability subscale (T score) 69.0 (14.1) 62.6 (14.1) 57.8 (14.3) 7.5 .001 45 .79
Total subscale (T score) 73.0 (11.3) 65.0 (14.1) 58.5 (12.8) 15.3 .001 63 1.20
Clinical Global Impressions - Improvement 3.85 (.65) 2.99 (.81) 2.82 (1.06) 29.4 .001 1.17 1.17
D.R. Coghill et al. BIOL PSYCHIATRY 2007;62:954–962 957
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.6mg/kg MPH and placebo [correct (p  .001), incorrect (p 
.01]. There were no correlations between response latencies and
accuracy of responding.
DelayedMatching to Sample. Chronic .3mg/kg and .6mg/kg
MPH enhanced accuracy of performance of simultaneous match-
ing to sample without affecting speed of response. Chronic MPH
enhanced accuracy and slowed response latencies for correct
choices under the delay conditions of this task (see Rhodes et al.
2004).
Paired Associates Learning (PAL). All participants reached
the final stage with chronic MPH treatment. There was no effect
of MPH on total number of trials required to complete the task
[F (2,114)  2.1, p  .125], nor on total errors made [F (2,114) 
1.4, p .2]. There was a significant interaction between MPH and
ORDER for both total trials [F (4,114)  4.7, p  .002] and errors
[F (4,114)  5.6, p  .001]. Planned contrasts revealed that boys
who took placebo during the first chronic session required more
trials than when taking .3mg/kg (p .032) or .6mg/kg (p .002)
MPH. Re-analysis with SESSION and GROUP [n  24 in each
treatment group] revealed no significant effect of GROUP on total
trials [F (2,68)  1] nor total errors [F (2,68)  1]. There was a
significant effect of SESSION for both total trials [F (1,68) 196.1,
p  .001] and errors, but no significant interaction between
SESSION and GROUP (total trials [F (2,68)  1], total errors
[F (2,68)  1]), suggesting an improved performance that could
not be attributed to MPH.
Reaction Time. There was no effect of MPH on reaction time
latencies during simple [F (2,116)  2.3, p  .13] or 5-choice
[F (2,116)  2.9, p  .09] conditions.
Attentional Set-Shifting (ID/ED). There was no significant
effect of MPH on stage reached on the ID/ED task [F (2,116) 
1.78, p  .17]. There was no significant effect of MPH on errors
made prior to [F (1.7, 3.5)  2.72, p  .05], during [F (2,116) 
2.1, p  .13], or after [F (2,116)  1.1, p  .34] the extra-
dimensional shift stage.
Baseline Predictors of Clinical Response
Four components (Table 5) emerged from a principal com-
ponents analysis corresponding to “paired associates learning,”
“working memory and planning,” “recognition memory,” and
“mixed.” Baseline prediction of clinical response was assessed
separately for each dose level using several statistical methods.
Multiple regression analyses with neuropsychological perfor-
mance on each of these components, sociodemographic and
Table 4. Neuropsychological Response to Methylphenidate
Measure Baseline
Chronic Challenge






















Errors for Distractors b1 2.39 (1.47) 1.59 (1.5) 1.35 (1.4) 1.2 (1.4) NS .01 .27 .54
Errors for Distractors b2 2.27 (1.65) 1.62 (1.6) 1.27 (1.4) 1.14 (1.3) .03 .004 .33 .4
Reaction Time to Targets b1 (log10) 2.66 (.09) 2.70 (.07) 2.68 (.09) 2.67 (.09) NS .005 .37 .5
Reaction Time to Targets b2 (log10) 2.67 (.09) 2.69 (.07) 2.68 (.09) 2.69 (.08) .02 NS .12 .25
Spatial Span
Span Scorea 5.07 (1.47) 5.48 (1.7) 5.7 (1.6) 5.69 (1.5) NS NS .26
Spatial Working Memory
Total Between Search Errorsa 50.84 (21) 39.9 (20.6) 38.68 (23.0) 35.9 (19.8) NS NS .53
Strategy Scorea 36.32 (5.1) 35.15 (4.0) 34.4 (5.0) 34.4 (5.2) NS NS .26
Stockings of Cambridge
No. Solved in MinimumMoves 7.2 (2.1) 8.33 (1.9) 8.84 (2.2) 8.84 (2.1) NS NS .57
Initial Thinking 5 Move (log 10) 3.59 (.34) 3.54 (.40) 3.63 (.38) 3.64 (.35) NS NS .14
Subsequent Thinking 5 Move (log 10) 2.83 (.58) 1.88 (1.16) 2.08 (1.06) 2.28 (.97) NS NS 1.04
Pattern Recognition % Correcta 80.78 (13.1) 81.76 (13.3) 86.0 (12.9) 87.8 (12.5) .001 .001 .32 .47 .07
Spatial Recognition % Correcta 68.21 (13.9) 57.8 (14.0) 67.2 (14.4) 68.9 (13.4) .001 .001 .66 .81 .75
Latency Correct (log 10) 3.32 (.15) 3.27 (.16) 3.3 (.15) 3.37 (.15) NS .001 .64 .32
Latency Incorrect (log 10)a 3.27 (.14) 3.32 (.17) 3.34 (.2) 3.4 (.15) NS .01 .50 .32
Delayed Matching to Sample
Simultaneous % Correcta 90.93 (15.5) 85.20 (18.0) 91.34 (13.6) 95.38 (9.2) .001 .001 .38 .71 .34
Delay (0, 4 and 12 sec combined)a
% Correct 59.52 (17.8) 56.04 (19.2) 65.78 (21.23) 68.82 (16.29) .001 .001 .48 .72 .19
Paired Associates Learning
Stage Reached 7.96 (.26) 8 (0) 8 (0) 8 (0) NS NS Ceiling Effect
Total Errorsa 11.61 (11.5) 6.67 (6.6) 5.73 (5.74) 5.45 (5.6) NS NS .53
Total Trialsa 12.76 (4.1) 7.7 (2.2) 7.33 (2.03) 7.20 (1.9) NS NS 1.61
ID/ED Stage Reached Scorea 7.5 (1) 7.95 (.99) 8.16 (.95) 8.02 (.97) NS NS .45
Reaction Time
Reaction Time Latency: 5 Choice
(log 10) 2.62 (.09) 2.86 (1.1) 2.62 (.11) 2.62 (.11) NS NS .24
Movement Time Latency: 5 Choice
(log10) 2.63 (.26) 2.67 (.35) 2.63 (.12) 2.66 (.12) NS NS .13
ID/ED, Intradimensional-Extradimensional Set Shifting; ADHD, attention deficit hyperactivity disorder.
aMeasures on which ADHD boys demonstrated baseline performance deficits compared to healthy boys (Rhodes, Coghill, and Matthews 2004, and
submitted).
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baseline clinical variables as predictors and total change score
from placebo according to Conners’ Global Index—Parent
(CGI-P) was the outcome variable. These same predictor vari-
ables were entered into two separate ANOVAs with responder
status as independent variables.
For .3 mg/kg, only the “recognition memory” component
predicted response (multiple regression; r2 .19, F (1,43) 10.1,
p  .003, ANOVA F (1,57)  5.3, p  .025), poorer baseline
performance predicted superior response to medication. For
.6mg/kg, no variables predicted response to medication in the
multiple regression and only BPVS score differentiated between
the groups in the ANOVA [F (1,61)  6.7, p  .012] with
‘responders’ having higher BPVS scores than nonresponders.
Further regression analysis indicated that the baseline “recog-
nition memory” contribution at .3mg/kg was accounted for by
delayed matching to sample (DMtS) performance, with poorer
(DMtS) baseline performance predicting a better response to
medication. (For a fuller discussion of these findings see online
supplemental information.)
Neuropsychopharmacological Predictors of Clinical Response
For MPH .3mg/kg ‘responders’, GoNoGo Block 2 ERD and
RTT, spatial and pattern recognition (% correct) and DMtS (total
% correct, plus 0, 4 and 12 sec delays) change scores (placebo vs.
.3mg/kg) were entered as predictors within a correlational
regression analysis with CGI-P change score as the dependent
variable. Only Block 2 ERD performance improvement corre-
lated significantly with clinical response (p  .002) and was
retained in the best fit equation (r2  .17, F (1,44)  8.9, p 
.005). For .6 mg/kg ‘responders’ there were no significant
correlations. (For a fuller discussion of these findings see online
supplemental information.)
Discussion
With its short half-life and duration of action, MPH only exerts
clinically meaningful therapeutic effects when administered
chronically. Accordingly, acute effects may be of minor rele-
vance. The present study is the first to have evaluated the
neuropsychological effects of chronically administered MPH, in
stimulant naive subjects with ADHD, using a prospective, ran-
domized, controlled, crossover design These data, which confirm
and extend those published previously (Rhodes et al. 2004, 2005,
2006), are important for clinical and scientific reasons.
Consistent with the ‘acute response’ data that we have
previously reported (Rhodes et al. 2006), but contrary to predic-
tions based on existing literature, chronic MPH failed to enhance
performance on neuropsychological tasks with a prominent
‘executive’ component, with the exception of aspects of a
GoNoGo task. Intriguingly, MPH significantly enhanced perfor-
mance on two visual memory tasks without prominent exec-
utive demands (pattern and delayed matching to sample) and
reversed performance decline on a third (spatial recognition
memory). A detailed analysis of baseline, drug naive, neuro-
psychological and neuropsychopharmacological measures as
potential predictors of clinical response to MPH suggests that
each makes a statistically significant, but modest, predictive
contribution.
Study Limitations
Limitations which arise due to the cross-over, repeat-testing
design include loss of novelty and the emergence of practice,
learning and ceiling effects on neuropsychological performance.
Rabbitt (1997) and Lowe and Rabbitt (1998) highlighted the
vulnerabilities of tests of “executive functioning” to such factors.
It is, possible that the moderate to large practice effects for
aspects of spatial working memory, stockings of Cambridge,
GoNoGo, ID/ED shift and paired associates learning may have
diminished our ability to identify treatment effects on these tasks.
However, these factors cannot account for the differences in
findings between the current study and previous studies using
identical tasks with similar, but less robust, methods. Further
studies with large sample sizes and alternative trial designs will
be required to fully address these issues.
Interpretation of our data is also hindered by the absence of
reliable and valid measures of treatment adherence. Although
assigned to a specific treatment for a defined period of time, we
cannot be certain that the participant did indeed take medication
as prescribed, nor that other stimulant drugs were avoided. It is
also unfortunate that we were unable to use teacher ratings of
response. There was a suggestion that teachers and parents
differentially rated response to medication with a trend for
teachers to rate greater improvements with higher dose MPH. It
is therefore possible that an analysis of the predictors of teacher-
rated response would have produced different results to those
reported for parent-rated response.








Paired Associates Learning, Total Errors .972
Paired Associates Learning, Total Trials .972
5-Choice Reaction Time .737
ID/ED Shift, Total Trials .675
Spatial Span .533
Spatial Working Memory, Strategy Score .794
Spatial Working Memory, Between Search Errors .732
Stockings of Cambridge, Solved in MinimumMoves .701
Delayed Matching to Sample, Total Percent Correct .780
Pattern Recognition, Percent Correct .619
Spatial Recognition, Percent Correct .476
ID/ED, Intradimensional-Extradimensional Set Shifting. ExtractionMethod: Principal Components Analysis. RotationMethod:Obliminwith Kaiser Normal-
ization. Rotation converged in 20 iterations.
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What Does Chronic MPHDo?
Taken alongside our ‘acute response’ data (Rhodes et al. 2004,
2006) and those of other groups (Barnett et al. 2001; Bedard et al.
2004; Kempton et al. 1999; Mehta et al. 2004), the present results
support the contention that MPH selectively enhances discrete
aspects of neuropsychological functioning (Gao and Goldman-
Rakic 2003) However, the current findings are striking in that
they fail to substantiate; indeed they contradict, key aspects of
existing literature. Specifically, the hypothesis that MPH would
selectively enhance performance on neuropsychological tasks
with prominent executive demands was not supported. Baseline
assessments revealed a wide range of deficits in executive and
nonexecutive neuropsychological functioning in ADHD boys
compared with healthy controls (see Table 3) (Rhodes et al.
2005). MPH failed to restore function across many domains,
following both acute (Rhodes et al. 2006) and chronic adminis-
tration. Specifically, previously reported acute MPH performance
improvements on Spatial Working Memory (Barnett et al. 2001;
Bedard et al. 2004; Kempton et al. 1999; Mehta et al. 2004) ID/ED
(Kempton et al. 1999; Mehta et al. 2004) and Stockings of
Cambridge (Kempton et al. 1999) performance were not repli-
cated. These contradictory findings may relate to differences in
study methods, statistical analyses and/or the possible practice
effects noted above. Previous studies have made significant
design compromises including the use of nonrandomized and
uncontrolled protocols (Barnett et al. 2001; Kempton et al. 1999),
small samples with nonstandard assessment procedures (Kemp-
ton et al. 1999; Mehta et al. 2004), inclusion of previously
medicated subjects with the potential for withdrawal and car-
ryover effects of medication (Bedard et al. 2004; Mehta et al.
2004), and the use of only a single dose of MPH. It is also
possible that differences in study inclusion criteria may be
important. Previous studies’ inclusion criteria were based on
DSM-IV. We recruited participants meeting diagnostic criteria for
both DSM-IV ADHD combined type and ICD-10 hyperkinetic
disorder. The similarities and differences in neuropsychological
functioning and response to medication between children diag-
nosed under each of these systems are not well described and
merit further investigation. Our data support the contention that
the effects of MPH on neurocognitive functioning should not be
considered as a simple restoration of baseline impairments
(Rapport and Kelly 1991), particularly of psychological processes
with high ‘executive’ demands. Indeed, the only evidence of
improved performance on such a task in the present study was
that seen with the GoNoGo task. Even here, it is worth recalling
that, at baseline, no differences in performance were identified
between ADHD and control subjects (Rhodes et al. 2005).
Stimulant effects on tasks with relatively modest ‘executive’
demands have been relatively understudied. We have previously
reported that both acute and chronic MPH improved perfor-
mance on DMtS and pattern recognition tasks (Rhodes et al.
2004) We now report that, although performance improvements
were not seen on a spatial recognition memory task following
acute MPH (Rhodes et al. 2006), chronic exposure maintained
subjects’ performance on this task whereas deterioration in
performance was observed under placebo conditions. Interest-
ingly, these three tasks constituted the “recognition memory”
component identified through principal components analysis.
As previously reported for the effects of acute MPH on the
DMtS and pattern recognition memory tasks, there was again no
relationship between accuracy of responding and speed of
responding. This suggests that, whilst one effect of MPH may be
to improve “regulatory ability” (Berman et al. 1999; Douglas
1999), improvements in performance accuracy cannot be solely
attributable to these improvements (nor indeed to improved
‘behavioral inhibition’ as has been suggested (Barkley 1997)), but
may instead represent true improvements in nonworking mne-
monic functioning. Interestingly, the shortened response laten-
cies in a complex reaction time task which were observed
following acute MPH were not replicated with chronic MPH.
This, and the previously reported amelioration of medication
effects on the DMtS with chronic, as compared to acute, MPH
(Rhodes et al. 2004), suggests that, at least with respect to these
tasks, a form of behavioral tolerance to MPH may develop.
Conversely, the improvements in performance on the spatial
recognition and GoNoGo tasks seen after chronic, but not acute,
administration may reflect a form of behavioral sensitization.
These speculative possibilities require further investigation.
Prediction of Clinical Response
We are unaware of previous studies investigating neuropsy-
chological predictors of clinical response to MPH. Evaluation of
clinical and demographic predictors of response have yielded
conflicting results. For example, whilst both Taylor (1987) and
Buitelaar (1995) found younger age to be a positive predictor of
clinical response to MPH, Taylor observed greater pretreatment
attentional impairment, hyperactivity, and lower IQ scores in
‘responders’ Buitelaar, however, found the opposite pattern. In
the present study, greater hyperactivity at baseline and higher
BPVS scores predicted clinically and statistically significant re-
sponse to MPH (.6 mg/kg). However, these variables accounted
for a very small component of the overall variance and their
utility in predicting individual response seems negligible. Den-
ney and Rappoport (1999) recently applied a range of theoretical
and statistical models to assess predictors of teacher-rated re-
sponse to MPH. They identified numerous weaknesses in previ-
ous studies and failed to replicate many previously reported
findings. They concluded that a comprehensive model of MPH
response will be dependent upon a wide range of factors that
cannot reasonably be reduced down to any single measure. Our
data support this. Denney and Rappoport also pointed out that a
comprehensive model of MPH response needs to capture several
levels of analysis (including both biological and behavioral) as
well as the relationships between these levels.
The CANTAB battery is a potentially useful tool to develop
causal models as the neural substrates for some of the tasks have
been identified. For example, the finding that although MPH
improved performance on two tasks conventionally associated
with frontal lobe functioning (spatial recognition and GoNoGo)
it also improved performance on two visual memory tasks for
which the initial patterns of deficits in ADHD boys resembled
those seen following medial temporal rather than frontal lobe
damage (Owen et al. 1995) This, in addition to the finding that
baseline performance on the DMtS task contributed to the
prediction of clinical response to low dose MPH, supports the
hypothesis that nonworking memory dysfunction and aspects of
temporal lobe functioning may make an important contribution
to ADHD pathophysiology (Castellanos and Tannock 2002;
Rhodes et al. 2004) However, that clinical response to MPH was
only associated with neuropsychological response to MPH on a
single measure from a single task (GoNoGo), and that this task
did not itself discriminate between ADHD boys and healthy
controls at baseline (Rhodes et al. 2005), mandates caution.
Although there are measurable deficits on a range of neuropsy-
chological tasks, and whilst some of these deficits are, appar-
ently, ameliorated by MPH, we must consider the possibility that
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they may not be meaningfully related to the core functional
impairments in ADHD. On the other hand, it could be that had
we been able to utilize teacher ratings of response we would
have identified a greater number of predictors. Also, it remains
plausible that improvements in neuropsychological functioning
mediate improvements in overall functioning and thus reduce
overall behavioral impairment in a manner which is either more
subtle, or less easily observed. Further, the incomplete overlap
between those responding to high and low doses of MPH and the
differential weak predictors for low and higher dose medication
raises the possibility that MPH actions are mediated differently at
different doses.
In conclusion, the present study supports the contention that
MPH selectively enhances neuropsychological functioning in
ADHD, with the most prominent effects observed on three tasks
which invoke relatively modest ‘executive’ demands and which
were represented in a single component, “recognition memory”,
identified through principal components analysis. These neuropsy-
chological findings, paired with the positive clinical responses
observed in the same participants, strengthen the hypothesis that
clinically important ADHD-related neurocognitive deficits are di-
verse and that, even following clinical improvement with MPH,
there remain unaffected deficits. These may require additional, or
alternative, therapeutic interventions. These data may assist in the
identification of useful cognitive and behavioral endophenotypes
for further study. It is important to note that, contrary to previous
suggestions (Robbins and Sahakian 1979), MPH does not appear to
impair performance on any of the studied tasks.
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